PMC:7283670 / 54594-110505 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":52244,"end":52251},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T2","span":{"begin":52244,"end":52251},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":46713,"end":46716},"obj":"Body_part"},{"id":"T2","span":{"begin":46795,"end":46798},"obj":"Body_part"},{"id":"T3","span":{"begin":48505,"end":48510},"obj":"Body_part"},{"id":"T4","span":{"begin":49003,"end":49013},"obj":"Body_part"},{"id":"T5","span":{"begin":50242,"end":50247},"obj":"Body_part"},{"id":"T6","span":{"begin":51515,"end":51520},"obj":"Body_part"},{"id":"T7","span":{"begin":52244,"end":52251},"obj":"Body_part"},{"id":"T8","span":{"begin":52673,"end":52681},"obj":"Body_part"},{"id":"T9","span":{"begin":52710,"end":52718},"obj":"Body_part"},{"id":"T10","span":{"begin":52862,"end":52870},"obj":"Body_part"},{"id":"T11","span":{"begin":52907,"end":52915},"obj":"Body_part"},{"id":"T12","span":{"begin":52922,"end":52930},"obj":"Body_part"},{"id":"T13","span":{"begin":53035,"end":53039},"obj":"Body_part"},{"id":"T14","span":{"begin":53073,"end":53083},"obj":"Body_part"},{"id":"T15","span":{"begin":53112,"end":53117},"obj":"Body_part"},{"id":"T16","span":{"begin":53372,"end":53380},"obj":"Body_part"},{"id":"T17","span":{"begin":53531,"end":53539},"obj":"Body_part"},{"id":"T18","span":{"begin":53632,"end":53636},"obj":"Body_part"},{"id":"T19","span":{"begin":53819,"end":53831},"obj":"Body_part"},{"id":"T20","span":{"begin":54305,"end":54321},"obj":"Body_part"},{"id":"T21","span":{"begin":54317,"end":54321},"obj":"Body_part"},{"id":"T22","span":{"begin":54550,"end":54559},"obj":"Body_part"},{"id":"T23","span":{"begin":54560,"end":54564},"obj":"Body_part"},{"id":"T24","span":{"begin":54680,"end":54685},"obj":"Body_part"},{"id":"T25","span":{"begin":54919,"end":54924},"obj":"Body_part"},{"id":"T26","span":{"begin":55086,"end":55091},"obj":"Body_part"},{"id":"T201","span":{"begin":1358,"end":1363},"obj":"Body_part"},{"id":"T202","span":{"begin":1701,"end":1705},"obj":"Body_part"},{"id":"T203","span":{"begin":2131,"end":2135},"obj":"Body_part"},{"id":"T204","span":{"begin":2223,"end":2228},"obj":"Body_part"},{"id":"T205","span":{"begin":2312,"end":2317},"obj":"Body_part"},{"id":"T206","span":{"begin":2461,"end":2473},"obj":"Body_part"},{"id":"T207","span":{"begin":2503,"end":2510},"obj":"Body_part"},{"id":"T208","span":{"begin":3007,"end":3028},"obj":"Body_part"},{"id":"T209","span":{"begin":3182,"end":3189},"obj":"Body_part"},{"id":"T210","span":{"begin":3385,"end":3389},"obj":"Body_part"},{"id":"T211","span":{"begin":3487,"end":3491},"obj":"Body_part"},{"id":"T212","span":{"begin":3648,"end":3652},"obj":"Body_part"},{"id":"T213","span":{"begin":4329,"end":4333},"obj":"Body_part"},{"id":"T214","span":{"begin":4371,"end":4378},"obj":"Body_part"},{"id":"T215","span":{"begin":4476,"end":4479},"obj":"Body_part"},{"id":"T216","span":{"begin":5099,"end":5104},"obj":"Body_part"},{"id":"T217","span":{"begin":6089,"end":6095},"obj":"Body_part"},{"id":"T218","span":{"begin":6103,"end":6109},"obj":"Body_part"},{"id":"T219","span":{"begin":6114,"end":6137},"obj":"Body_part"},{"id":"T220","span":{"begin":6744,"end":6749},"obj":"Body_part"},{"id":"T221","span":{"begin":6835,"end":6840},"obj":"Body_part"},{"id":"T222","span":{"begin":10755,"end":10778},"obj":"Body_part"},{"id":"T223","span":{"begin":10835,"end":10858},"obj":"Body_part"},{"id":"T224","span":{"begin":11002,"end":11007},"obj":"Body_part"},{"id":"T225","span":{"begin":11015,"end":11019},"obj":"Body_part"},{"id":"T226","span":{"begin":11022,"end":11026},"obj":"Body_part"},{"id":"T227","span":{"begin":11081,"end":11089},"obj":"Body_part"},{"id":"T228","span":{"begin":11247,"end":11255},"obj":"Body_part"},{"id":"T229","span":{"begin":12485,"end":12508},"obj":"Body_part"},{"id":"T230","span":{"begin":12605,"end":12610},"obj":"Body_part"},{"id":"T231","span":{"begin":12618,"end":12622},"obj":"Body_part"},{"id":"T232","span":{"begin":12625,"end":12629},"obj":"Body_part"},{"id":"T233","span":{"begin":12684,"end":12692},"obj":"Body_part"},{"id":"T234","span":{"begin":13225,"end":13229},"obj":"Body_part"},{"id":"T235","span":{"begin":13987,"end":13991},"obj":"Body_part"},{"id":"T236","span":{"begin":14276,"end":14281},"obj":"Body_part"},{"id":"T237","span":{"begin":14291,"end":14296},"obj":"Body_part"},{"id":"T238","span":{"begin":14410,"end":14415},"obj":"Body_part"},{"id":"T239","span":{"begin":14565,"end":14572},"obj":"Body_part"},{"id":"T240","span":{"begin":14584,"end":14591},"obj":"Body_part"},{"id":"T241","span":{"begin":14593,"end":14607},"obj":"Body_part"},{"id":"T242","span":{"begin":14627,"end":14632},"obj":"Body_part"},{"id":"T243","span":{"begin":14661,"end":14666},"obj":"Body_part"},{"id":"T244","span":{"begin":14667,"end":14675},"obj":"Body_part"},{"id":"T245","span":{"begin":14677,"end":14681},"obj":"Body_part"},{"id":"T246","span":{"begin":15415,"end":15430},"obj":"Body_part"},{"id":"T247","span":{"begin":15431,"end":15453},"obj":"Body_part"},{"id":"T248","span":{"begin":15448,"end":15453},"obj":"Body_part"},{"id":"T249","span":{"begin":15504,"end":15514},"obj":"Body_part"},{"id":"T250","span":{"begin":15509,"end":15514},"obj":"Body_part"},{"id":"T251","span":{"begin":15634,"end":15640},"obj":"Body_part"},{"id":"T252","span":{"begin":15823,"end":15828},"obj":"Body_part"},{"id":"T253","span":{"begin":16623,"end":16645},"obj":"Body_part"},{"id":"T254","span":{"begin":16640,"end":16645},"obj":"Body_part"},{"id":"T255","span":{"begin":16752,"end":16757},"obj":"Body_part"},{"id":"T256","span":{"begin":16841,"end":16863},"obj":"Body_part"},{"id":"T257","span":{"begin":16858,"end":16863},"obj":"Body_part"},{"id":"T258","span":{"begin":16986,"end":16991},"obj":"Body_part"},{"id":"T259","span":{"begin":17205,"end":17210},"obj":"Body_part"},{"id":"T260","span":{"begin":17744,"end":17748},"obj":"Body_part"},{"id":"T261","span":{"begin":18458,"end":18464},"obj":"Body_part"},{"id":"T262","span":{"begin":21660,"end":21676},"obj":"Body_part"},{"id":"T263","span":{"begin":21672,"end":21676},"obj":"Body_part"},{"id":"T264","span":{"begin":21684,"end":21694},"obj":"Body_part"},{"id":"T265","span":{"begin":21703,"end":21711},"obj":"Body_part"},{"id":"T266","span":{"begin":21761,"end":21768},"obj":"Body_part"},{"id":"T267","span":{"begin":22047,"end":22057},"obj":"Body_part"},{"id":"T268","span":{"begin":22112,"end":22122},"obj":"Body_part"},{"id":"T269","span":{"begin":23096,"end":23100},"obj":"Body_part"},{"id":"T270","span":{"begin":23469,"end":23473},"obj":"Body_part"},{"id":"T271","span":{"begin":24765,"end":24769},"obj":"Body_part"},{"id":"T272","span":{"begin":26812,"end":26819},"obj":"Body_part"},{"id":"T273","span":{"begin":28678,"end":28691},"obj":"Body_part"},{"id":"T274","span":{"begin":28678,"end":28689},"obj":"Body_part"},{"id":"T275","span":{"begin":28699,"end":28709},"obj":"Body_part"},{"id":"T276","span":{"begin":28728,"end":28735},"obj":"Body_part"},{"id":"T277","span":{"begin":28955,"end":28960},"obj":"Body_part"},{"id":"T278","span":{"begin":29435,"end":29456},"obj":"Body_part"},{"id":"T279","span":{"begin":29452,"end":29456},"obj":"Body_part"},{"id":"T280","span":{"begin":29697,"end":29702},"obj":"Body_part"},{"id":"T281","span":{"begin":29706,"end":29710},"obj":"Body_part"},{"id":"T282","span":{"begin":29824,"end":29829},"obj":"Body_part"},{"id":"T283","span":{"begin":30058,"end":30062},"obj":"Body_part"},{"id":"T284","span":{"begin":30125,"end":30130},"obj":"Body_part"},{"id":"T285","span":{"begin":31067,"end":31077},"obj":"Body_part"},{"id":"T286","span":{"begin":31140,"end":31146},"obj":"Body_part"},{"id":"T287","span":{"begin":31218,"end":31224},"obj":"Body_part"},{"id":"T288","span":{"begin":31232,"end":31238},"obj":"Body_part"},{"id":"T289","span":{"begin":31300,"end":31306},"obj":"Body_part"},{"id":"T290","span":{"begin":31344,"end":31350},"obj":"Body_part"},{"id":"T291","span":{"begin":31367,"end":31373},"obj":"Body_part"},{"id":"T292","span":{"begin":31414,"end":31420},"obj":"Body_part"},{"id":"T293","span":{"begin":31514,"end":31520},"obj":"Body_part"},{"id":"T294","span":{"begin":33342,"end":33349},"obj":"Body_part"},{"id":"T295","span":{"begin":35487,"end":35491},"obj":"Body_part"},{"id":"T296","span":{"begin":35807,"end":35818},"obj":"Body_part"},{"id":"T297","span":{"begin":35819,"end":35841},"obj":"Body_part"},{"id":"T298","span":{"begin":35836,"end":35841},"obj":"Body_part"},{"id":"T299","span":{"begin":35855,"end":35866},"obj":"Body_part"},{"id":"T300","span":{"begin":35867,"end":35889},"obj":"Body_part"},{"id":"T301","span":{"begin":35884,"end":35889},"obj":"Body_part"},{"id":"T302","span":{"begin":35948,"end":35970},"obj":"Body_part"},{"id":"T303","span":{"begin":35965,"end":35970},"obj":"Body_part"},{"id":"T304","span":{"begin":36013,"end":36035},"obj":"Body_part"},{"id":"T305","span":{"begin":36030,"end":36035},"obj":"Body_part"},{"id":"T306","span":{"begin":36115,"end":36120},"obj":"Body_part"},{"id":"T307","span":{"begin":36146,"end":36150},"obj":"Body_part"},{"id":"T308","span":{"begin":36180,"end":36185},"obj":"Body_part"},{"id":"T309","span":{"begin":36224,"end":36229},"obj":"Body_part"},{"id":"T310","span":{"begin":41191,"end":41214},"obj":"Body_part"},{"id":"T311","span":{"begin":41270,"end":41293},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma67128"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma67128"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma67128"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma21185"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A201","pred":"fma_id","subj":"T201","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A202","pred":"fma_id","subj":"T202","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A203","pred":"fma_id","subj":"T203","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A204","pred":"fma_id","subj":"T204","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A205","pred":"fma_id","subj":"T205","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A206","pred":"fma_id","subj":"T206","obj":"http://purl.org/sig/ont/fma/fma62870"},{"id":"A207","pred":"fma_id","subj":"T207","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A208","pred":"fma_id","subj":"T208","obj":"http://purl.org/sig/ont/fma/fma81101"},{"id":"A209","pred":"fma_id","subj":"T209","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A210","pred":"fma_id","subj":"T210","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A211","pred":"fma_id","subj":"T211","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A212","pred":"fma_id","subj":"T212","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A216","pred":"fma_id","subj":"T216","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A217","pred":"fma_id","subj":"T217","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A218","pred":"fma_id","subj":"T218","obj":"http://purl.org/sig/ont/fma/fma312401"},{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma45662"},{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma49184"},{"id":"A221","pred":"fma_id","subj":"T221","obj":"http://purl.org/sig/ont/fma/fma49184"},{"id":"A222","pred":"fma_id","subj":"T222","obj":"http://purl.org/sig/ont/fma/fma45661"},{"id":"A223","pred":"fma_id","subj":"T223","obj":"http://purl.org/sig/ont/fma/fma45661"},{"id":"A224","pred":"fma_id","subj":"T224","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A225","pred":"fma_id","subj":"T225","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A226","pred":"fma_id","subj":"T226","obj":"http://purl.org/sig/ont/fma/fma84051"},{"id":"A227","pred":"fma_id","subj":"T227","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A228","pred":"fma_id","subj":"T228","obj":"http://purl.org/sig/ont/fma/fma12278"},{"id":"A229","pred":"fma_id","subj":"T229","obj":"http://purl.org/sig/ont/fma/fma45662"},{"id":"A230","pred":"fma_id","subj":"T230","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A231","pred":"fma_id","subj":"T231","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A232","pred":"fma_id","subj":"T232","obj":"http://purl.org/sig/ont/fma/fma84051"},{"id":"A233","pred":"fma_id","subj":"T233","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A234","pred":"fma_id","subj":"T234","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A235","pred":"fma_id","subj":"T235","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A236","pred":"fma_id","subj":"T236","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A237","pred":"fma_id","subj":"T237","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A238","pred":"fma_id","subj":"T238","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A239","pred":"fma_id","subj":"T239","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A240","pred":"fma_id","subj":"T240","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A241","pred":"fma_id","subj":"T241","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A242","pred":"fma_id","subj":"T242","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A243","pred":"fma_id","subj":"T243","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A244","pred":"fma_id","subj":"T244","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A245","pred":"fma_id","subj":"T245","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A246","pred":"fma_id","subj":"T246","obj":"http://purl.org/sig/ont/fma/fma323134"},{"id":"A247","pred":"fma_id","subj":"T247","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A248","pred":"fma_id","subj":"T248","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A249","pred":"fma_id","subj":"T249","obj":"http://purl.org/sig/ont/fma/fma63368"},{"id":"A250","pred":"fma_id","subj":"T250","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A251","pred":"fma_id","subj":"T251","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A252","pred":"fma_id","subj":"T252","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A256","pred":"fma_id","subj":"T256","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A257","pred":"fma_id","subj":"T257","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A258","pred":"fma_id","subj":"T258","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A259","pred":"fma_id","subj":"T259","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A260","pred":"fma_id","subj":"T260","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A261","pred":"fma_id","subj":"T261","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A262","pred":"fma_id","subj":"T262","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A263","pred":"fma_id","subj":"T263","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A264","pred":"fma_id","subj":"T264","obj":"http://purl.org/sig/ont/fma/fma62293"},{"id":"A265","pred":"fma_id","subj":"T265","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A266","pred":"fma_id","subj":"T266","obj":"http://purl.org/sig/ont/fma/fma82749"},{"id":"A267","pred":"fma_id","subj":"T267","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A268","pred":"fma_id","subj":"T268","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A269","pred":"fma_id","subj":"T269","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A270","pred":"fma_id","subj":"T270","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A271","pred":"fma_id","subj":"T271","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A272","pred":"fma_id","subj":"T272","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A273","pred":"fma_id","subj":"T273","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A274","pred":"fma_id","subj":"T274","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A275","pred":"fma_id","subj":"T275","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A276","pred":"fma_id","subj":"T276","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A277","pred":"fma_id","subj":"T277","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A278","pred":"fma_id","subj":"T278","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A279","pred":"fma_id","subj":"T279","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A280","pred":"fma_id","subj":"T280","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A281","pred":"fma_id","subj":"T281","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A282","pred":"fma_id","subj":"T282","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A283","pred":"fma_id","subj":"T283","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A284","pred":"fma_id","subj":"T284","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A285","pred":"fma_id","subj":"T285","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A286","pred":"fma_id","subj":"T286","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A287","pred":"fma_id","subj":"T287","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A288","pred":"fma_id","subj":"T288","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A289","pred":"fma_id","subj":"T289","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A290","pred":"fma_id","subj":"T290","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A291","pred":"fma_id","subj":"T291","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A292","pred":"fma_id","subj":"T292","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A293","pred":"fma_id","subj":"T293","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A294","pred":"fma_id","subj":"T294","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A295","pred":"fma_id","subj":"T295","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A296","pred":"fma_id","subj":"T296","obj":"http://purl.org/sig/ont/fma/fma55631"},{"id":"A297","pred":"fma_id","subj":"T297","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A298","pred":"fma_id","subj":"T298","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A299","pred":"fma_id","subj":"T299","obj":"http://purl.org/sig/ont/fma/fma55631"},{"id":"A300","pred":"fma_id","subj":"T300","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A301","pred":"fma_id","subj":"T301","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A302","pred":"fma_id","subj":"T302","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A303","pred":"fma_id","subj":"T303","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A304","pred":"fma_id","subj":"T304","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A305","pred":"fma_id","subj":"T305","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A306","pred":"fma_id","subj":"T306","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A307","pred":"fma_id","subj":"T307","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A308","pred":"fma_id","subj":"T308","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A309","pred":"fma_id","subj":"T309","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A310","pred":"fma_id","subj":"T310","obj":"http://purl.org/sig/ont/fma/fma45661"},{"id":"A311","pred":"fma_id","subj":"T311","obj":"http://purl.org/sig/ont/fma/fma45661"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T133","span":{"begin":1358,"end":1363},"obj":"Body_part"},{"id":"T134","span":{"begin":2223,"end":2228},"obj":"Body_part"},{"id":"T135","span":{"begin":2312,"end":2317},"obj":"Body_part"},{"id":"T136","span":{"begin":4329,"end":4333},"obj":"Body_part"},{"id":"T137","span":{"begin":5099,"end":5104},"obj":"Body_part"},{"id":"T138","span":{"begin":6089,"end":6095},"obj":"Body_part"},{"id":"T139","span":{"begin":6103,"end":6109},"obj":"Body_part"},{"id":"T140","span":{"begin":6114,"end":6137},"obj":"Body_part"},{"id":"T141","span":{"begin":6120,"end":6137},"obj":"Body_part"},{"id":"T142","span":{"begin":6744,"end":6749},"obj":"Body_part"},{"id":"T143","span":{"begin":6835,"end":6840},"obj":"Body_part"},{"id":"T144","span":{"begin":10755,"end":10778},"obj":"Body_part"},{"id":"T145","span":{"begin":10761,"end":10778},"obj":"Body_part"},{"id":"T146","span":{"begin":10835,"end":10858},"obj":"Body_part"},{"id":"T147","span":{"begin":10841,"end":10858},"obj":"Body_part"},{"id":"T148","span":{"begin":11002,"end":11007},"obj":"Body_part"},{"id":"T149","span":{"begin":12485,"end":12508},"obj":"Body_part"},{"id":"T150","span":{"begin":12491,"end":12508},"obj":"Body_part"},{"id":"T151","span":{"begin":12605,"end":12610},"obj":"Body_part"},{"id":"T152","span":{"begin":14276,"end":14281},"obj":"Body_part"},{"id":"T153","span":{"begin":14291,"end":14296},"obj":"Body_part"},{"id":"T154","span":{"begin":14410,"end":14415},"obj":"Body_part"},{"id":"T155","span":{"begin":14661,"end":14666},"obj":"Body_part"},{"id":"T156","span":{"begin":15634,"end":15640},"obj":"Body_part"},{"id":"T157","span":{"begin":15823,"end":15828},"obj":"Body_part"},{"id":"T158","span":{"begin":16752,"end":16757},"obj":"Body_part"},{"id":"T159","span":{"begin":17205,"end":17210},"obj":"Body_part"},{"id":"T160","span":{"begin":18458,"end":18464},"obj":"Body_part"},{"id":"T161","span":{"begin":19766,"end":19771},"obj":"Body_part"},{"id":"T162","span":{"begin":19897,"end":19902},"obj":"Body_part"},{"id":"T163","span":{"begin":19946,"end":19951},"obj":"Body_part"},{"id":"T164","span":{"begin":20030,"end":20035},"obj":"Body_part"},{"id":"T165","span":{"begin":21666,"end":21671},"obj":"Body_part"},{"id":"T166","span":{"begin":22242,"end":22246},"obj":"Body_part"},{"id":"T167","span":{"begin":22260,"end":22264},"obj":"Body_part"},{"id":"T168","span":{"begin":22455,"end":22459},"obj":"Body_part"},{"id":"T169","span":{"begin":22473,"end":22477},"obj":"Body_part"},{"id":"T170","span":{"begin":23248,"end":23253},"obj":"Body_part"},{"id":"T171","span":{"begin":23435,"end":23440},"obj":"Body_part"},{"id":"T172","span":{"begin":23469,"end":23473},"obj":"Body_part"},{"id":"T173","span":{"begin":24715,"end":24720},"obj":"Body_part"},{"id":"T174","span":{"begin":24765,"end":24769},"obj":"Body_part"},{"id":"T175","span":{"begin":25061,"end":25066},"obj":"Body_part"},{"id":"T176","span":{"begin":28955,"end":28960},"obj":"Body_part"},{"id":"T177","span":{"begin":30125,"end":30130},"obj":"Body_part"},{"id":"T178","span":{"begin":31140,"end":31146},"obj":"Body_part"},{"id":"T179","span":{"begin":31218,"end":31224},"obj":"Body_part"},{"id":"T180","span":{"begin":31232,"end":31238},"obj":"Body_part"},{"id":"T181","span":{"begin":31300,"end":31306},"obj":"Body_part"},{"id":"T182","span":{"begin":31344,"end":31350},"obj":"Body_part"},{"id":"T183","span":{"begin":31367,"end":31373},"obj":"Body_part"},{"id":"T184","span":{"begin":31414,"end":31420},"obj":"Body_part"},{"id":"T185","span":{"begin":31514,"end":31520},"obj":"Body_part"},{"id":"T186","span":{"begin":35487,"end":35491},"obj":"Body_part"},{"id":"T187","span":{"begin":35807,"end":35818},"obj":"Body_part"},{"id":"T188","span":{"begin":35855,"end":35866},"obj":"Body_part"},{"id":"T189","span":{"begin":36146,"end":36150},"obj":"Body_part"},{"id":"T190","span":{"begin":36180,"end":36185},"obj":"Body_part"},{"id":"T191","span":{"begin":36224,"end":36229},"obj":"Body_part"},{"id":"T192","span":{"begin":41191,"end":41214},"obj":"Body_part"},{"id":"T193","span":{"begin":41197,"end":41214},"obj":"Body_part"},{"id":"T194","span":{"begin":41270,"end":41293},"obj":"Body_part"},{"id":"T195","span":{"begin":41276,"end":41293},"obj":"Body_part"},{"id":"T196","span":{"begin":41558,"end":41563},"obj":"Body_part"},{"id":"T197","span":{"begin":46713,"end":46716},"obj":"Body_part"},{"id":"T198","span":{"begin":46795,"end":46798},"obj":"Body_part"},{"id":"T199","span":{"begin":48505,"end":48510},"obj":"Body_part"},{"id":"T200","span":{"begin":48583,"end":48588},"obj":"Body_part"},{"id":"T201","span":{"begin":50242,"end":50247},"obj":"Body_part"},{"id":"T202","span":{"begin":51515,"end":51520},"obj":"Body_part"},{"id":"T203","span":{"begin":53035,"end":53039},"obj":"Body_part"},{"id":"T204","span":{"begin":53112,"end":53117},"obj":"Body_part"},{"id":"T205","span":{"begin":53819,"end":53831},"obj":"Body_part"},{"id":"T206","span":{"begin":53827,"end":53831},"obj":"Body_part"},{"id":"T207","span":{"begin":54311,"end":54316},"obj":"Body_part"},{"id":"T208","span":{"begin":54919,"end":54924},"obj":"Body_part"},{"id":"T209","span":{"begin":55086,"end":55091},"obj":"Body_part"}],"attributes":[{"id":"A133","pred":"uberon_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A134","pred":"uberon_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A135","pred":"uberon_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A136","pred":"uberon_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A137","pred":"uberon_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A138","pred":"uberon_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A139","pred":"uberon_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"},{"id":"A140","pred":"uberon_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A141","pred":"uberon_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A142","pred":"uberon_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/UBERON_0000165"},{"id":"A143","pred":"uberon_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/UBERON_0000165"},{"id":"A144","pred":"uberon_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A145","pred":"uberon_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A146","pred":"uberon_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A147","pred":"uberon_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A148","pred":"uberon_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A149","pred":"uberon_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A150","pred":"uberon_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A151","pred":"uberon_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A152","pred":"uberon_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A153","pred":"uberon_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A154","pred":"uberon_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A155","pred":"uberon_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A156","pred":"uberon_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A157","pred":"uberon_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A158","pred":"uberon_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A159","pred":"uberon_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A160","pred":"uberon_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A161","pred":"uberon_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A162","pred":"uberon_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A163","pred":"uberon_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A164","pred":"uberon_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A165","pred":"uberon_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A166","pred":"uberon_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"A167","pred":"uberon_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"A168","pred":"uberon_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"A169","pred":"uberon_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"A170","pred":"uberon_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A171","pred":"uberon_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A172","pred":"uberon_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A173","pred":"uberon_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A174","pred":"uberon_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A175","pred":"uberon_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A176","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A177","pred":"uberon_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A178","pred":"uberon_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A179","pred":"uberon_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A180","pred":"uberon_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A181","pred":"uberon_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A182","pred":"uberon_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A183","pred":"uberon_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A184","pred":"uberon_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A185","pred":"uberon_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A186","pred":"uberon_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A187","pred":"uberon_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/UBERON_0001754"},{"id":"A188","pred":"uberon_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/UBERON_0001754"},{"id":"A189","pred":"uberon_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A190","pred":"uberon_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A191","pred":"uberon_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A192","pred":"uberon_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A193","pred":"uberon_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A194","pred":"uberon_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A195","pred":"uberon_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A196","pred":"uberon_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A197","pred":"uberon_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A198","pred":"uberon_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A199","pred":"uberon_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A200","pred":"uberon_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A201","pred":"uberon_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A202","pred":"uberon_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A203","pred":"uberon_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A204","pred":"uberon_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A205","pred":"uberon_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/UBERON_0001361"},{"id":"A206","pred":"uberon_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"A207","pred":"uberon_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A208","pred":"uberon_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A209","pred":"uberon_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T335","span":{"begin":29,"end":37},"obj":"Disease"},{"id":"T336","span":{"begin":41,"end":45},"obj":"Disease"},{"id":"T337","span":{"begin":258,"end":266},"obj":"Disease"},{"id":"T338","span":{"begin":290,"end":298},"obj":"Disease"},{"id":"T339","span":{"begin":894,"end":902},"obj":"Disease"},{"id":"T340","span":{"begin":935,"end":943},"obj":"Disease"},{"id":"T341","span":{"begin":1853,"end":1861},"obj":"Disease"},{"id":"T342","span":{"begin":1935,"end":1943},"obj":"Disease"},{"id":"T343","span":{"begin":2450,"end":2459},"obj":"Disease"},{"id":"T344","span":{"begin":2881,"end":2886},"obj":"Disease"},{"id":"T345","span":{"begin":3048,"end":3053},"obj":"Disease"},{"id":"T346","span":{"begin":3339,"end":3347},"obj":"Disease"},{"id":"T347","span":{"begin":3430,"end":3438},"obj":"Disease"},{"id":"T348","span":{"begin":3618,"end":3626},"obj":"Disease"},{"id":"T349","span":{"begin":3780,"end":3788},"obj":"Disease"},{"id":"T350","span":{"begin":3828,"end":3836},"obj":"Disease"},{"id":"T351","span":{"begin":3934,"end":3942},"obj":"Disease"},{"id":"T352","span":{"begin":3989,"end":3997},"obj":"Disease"},{"id":"T353","span":{"begin":4426,"end":4428},"obj":"Disease"},{"id":"T354","span":{"begin":4619,"end":4627},"obj":"Disease"},{"id":"T355","span":{"begin":4697,"end":4705},"obj":"Disease"},{"id":"T356","span":{"begin":4780,"end":4789},"obj":"Disease"},{"id":"T357","span":{"begin":4845,"end":4864},"obj":"Disease"},{"id":"T358","span":{"begin":5331,"end":5339},"obj":"Disease"},{"id":"T359","span":{"begin":5426,"end":5434},"obj":"Disease"},{"id":"T360","span":{"begin":6029,"end":6037},"obj":"Disease"},{"id":"T361","span":{"begin":6552,"end":6560},"obj":"Disease"},{"id":"T362","span":{"begin":6630,"end":6638},"obj":"Disease"},{"id":"T363","span":{"begin":7723,"end":7725},"obj":"Disease"},{"id":"T364","span":{"begin":7782,"end":7790},"obj":"Disease"},{"id":"T365","span":{"begin":7854,"end":7862},"obj":"Disease"},{"id":"T366","span":{"begin":8636,"end":8638},"obj":"Disease"},{"id":"T367","span":{"begin":8697,"end":8705},"obj":"Disease"},{"id":"T368","span":{"begin":9568,"end":9576},"obj":"Disease"},{"id":"T369","span":{"begin":9577,"end":9586},"obj":"Disease"},{"id":"T370","span":{"begin":9617,"end":9625},"obj":"Disease"},{"id":"T371","span":{"begin":9626,"end":9635},"obj":"Disease"},{"id":"T372","span":{"begin":10056,"end":10064},"obj":"Disease"},{"id":"T373","span":{"begin":10066,"end":10075},"obj":"Disease"},{"id":"T374","span":{"begin":10105,"end":10113},"obj":"Disease"},{"id":"T375","span":{"begin":11283,"end":11291},"obj":"Disease"},{"id":"T376","span":{"begin":11321,"end":11329},"obj":"Disease"},{"id":"T377","span":{"begin":11498,"end":11505},"obj":"Disease"},{"id":"T378","span":{"begin":11795,"end":11802},"obj":"Disease"},{"id":"T379","span":{"begin":12833,"end":12841},"obj":"Disease"},{"id":"T380","span":{"begin":12868,"end":12876},"obj":"Disease"},{"id":"T381","span":{"begin":13309,"end":13317},"obj":"Disease"},{"id":"T382","span":{"begin":13362,"end":13370},"obj":"Disease"},{"id":"T383","span":{"begin":13637,"end":13646},"obj":"Disease"},{"id":"T384","span":{"begin":13725,"end":13734},"obj":"Disease"},{"id":"T385","span":{"begin":13823,"end":13831},"obj":"Disease"},{"id":"T386","span":{"begin":14842,"end":14850},"obj":"Disease"},{"id":"T387","span":{"begin":14872,"end":14876},"obj":"Disease"},{"id":"T388","span":{"begin":14934,"end":14942},"obj":"Disease"},{"id":"T389","span":{"begin":15158,"end":15165},"obj":"Disease"},{"id":"T390","span":{"begin":15196,"end":15203},"obj":"Disease"},{"id":"T391","span":{"begin":15323,"end":15331},"obj":"Disease"},{"id":"T392","span":{"begin":15391,"end":15399},"obj":"Disease"},{"id":"T393","span":{"begin":15519,"end":15527},"obj":"Disease"},{"id":"T394","span":{"begin":16045,"end":16053},"obj":"Disease"},{"id":"T395","span":{"begin":16066,"end":16074},"obj":"Disease"},{"id":"T396","span":{"begin":16075,"end":16098},"obj":"Disease"},{"id":"T397","span":{"begin":16376,"end":16382},"obj":"Disease"},{"id":"T398","span":{"begin":16657,"end":16682},"obj":"Disease"},{"id":"T399","span":{"begin":16683,"end":16691},"obj":"Disease"},{"id":"T400","span":{"begin":16790,"end":16798},"obj":"Disease"},{"id":"T401","span":{"begin":17706,"end":17726},"obj":"Disease"},{"id":"T402","span":{"begin":17717,"end":17726},"obj":"Disease"},{"id":"T403","span":{"begin":17931,"end":17939},"obj":"Disease"},{"id":"T404","span":{"begin":18364,"end":18376},"obj":"Disease"},{"id":"T405","span":{"begin":18593,"end":18601},"obj":"Disease"},{"id":"T406","span":{"begin":18635,"end":18643},"obj":"Disease"},{"id":"T407","span":{"begin":19141,"end":19149},"obj":"Disease"},{"id":"T408","span":{"begin":19197,"end":19205},"obj":"Disease"},{"id":"T409","span":{"begin":21399,"end":21408},"obj":"Disease"},{"id":"T410","span":{"begin":21495,"end":21504},"obj":"Disease"},{"id":"T411","span":{"begin":21530,"end":21541},"obj":"Disease"},{"id":"T412","span":{"begin":21556,"end":21572},"obj":"Disease"},{"id":"T414","span":{"begin":21925,"end":21944},"obj":"Disease"},{"id":"T415","span":{"begin":21935,"end":21944},"obj":"Disease"},{"id":"T416","span":{"begin":22010,"end":22018},"obj":"Disease"},{"id":"T417","span":{"begin":22058,"end":22068},"obj":"Disease"},{"id":"T418","span":{"begin":22123,"end":22133},"obj":"Disease"},{"id":"T419","span":{"begin":22764,"end":22773},"obj":"Disease"},{"id":"T420","span":{"begin":22834,"end":22843},"obj":"Disease"},{"id":"T421","span":{"begin":23335,"end":23347},"obj":"Disease"},{"id":"T422","span":{"begin":23474,"end":23480},"obj":"Disease"},{"id":"T423","span":{"begin":23660,"end":23669},"obj":"Disease"},{"id":"T424","span":{"begin":23687,"end":23696},"obj":"Disease"},{"id":"T425","span":{"begin":23702,"end":23704},"obj":"Disease"},{"id":"T426","span":{"begin":23706,"end":23714},"obj":"Disease"},{"id":"T427","span":{"begin":23817,"end":23826},"obj":"Disease"},{"id":"T428","span":{"begin":23832,"end":23834},"obj":"Disease"},{"id":"T429","span":{"begin":23852,"end":23861},"obj":"Disease"},{"id":"T430","span":{"begin":24012,"end":24021},"obj":"Disease"},{"id":"T431","span":{"begin":24426,"end":24434},"obj":"Disease"},{"id":"T432","span":{"begin":24770,"end":24776},"obj":"Disease"},{"id":"T433","span":{"begin":25148,"end":25160},"obj":"Disease"},{"id":"T434","span":{"begin":25544,"end":25547},"obj":"Disease"},{"id":"T435","span":{"begin":25642,"end":25645},"obj":"Disease"},{"id":"T436","span":{"begin":25739,"end":25742},"obj":"Disease"},{"id":"T437","span":{"begin":26520,"end":26523},"obj":"Disease"},{"id":"T438","span":{"begin":26563,"end":26566},"obj":"Disease"},{"id":"T439","span":{"begin":27256,"end":27264},"obj":"Disease"},{"id":"T440","span":{"begin":27719,"end":27727},"obj":"Disease"},{"id":"T441","span":{"begin":27738,"end":27747},"obj":"Disease"},{"id":"T442","span":{"begin":27816,"end":27824},"obj":"Disease"},{"id":"T443","span":{"begin":27825,"end":27858},"obj":"Disease"},{"id":"T444","span":{"begin":28318,"end":28326},"obj":"Disease"},{"id":"T445","span":{"begin":28327,"end":28336},"obj":"Disease"},{"id":"T446","span":{"begin":28386,"end":28394},"obj":"Disease"},{"id":"T447","span":{"begin":28395,"end":28404},"obj":"Disease"},{"id":"T448","span":{"begin":29497,"end":29505},"obj":"Disease"},{"id":"T449","span":{"begin":29506,"end":29515},"obj":"Disease"},{"id":"T450","span":{"begin":29540,"end":29548},"obj":"Disease"},{"id":"T451","span":{"begin":29549,"end":29558},"obj":"Disease"},{"id":"T452","span":{"begin":30324,"end":30332},"obj":"Disease"},{"id":"T453","span":{"begin":30415,"end":30423},"obj":"Disease"},{"id":"T454","span":{"begin":30739,"end":30747},"obj":"Disease"},{"id":"T455","span":{"begin":31134,"end":31153},"obj":"Disease"},{"id":"T456","span":{"begin":31147,"end":31153},"obj":"Disease"},{"id":"T457","span":{"begin":31184,"end":31192},"obj":"Disease"},{"id":"T458","span":{"begin":31203,"end":31211},"obj":"Disease"},{"id":"T459","span":{"begin":31212,"end":31231},"obj":"Disease"},{"id":"T460","span":{"begin":31225,"end":31231},"obj":"Disease"},{"id":"T461","span":{"begin":31294,"end":31313},"obj":"Disease"},{"id":"T462","span":{"begin":31307,"end":31313},"obj":"Disease"},{"id":"T463","span":{"begin":31315,"end":31323},"obj":"Disease"},{"id":"T464","span":{"begin":31338,"end":31357},"obj":"Disease"},{"id":"T465","span":{"begin":31351,"end":31357},"obj":"Disease"},{"id":"T466","span":{"begin":31374,"end":31380},"obj":"Disease"},{"id":"T467","span":{"begin":31382,"end":31390},"obj":"Disease"},{"id":"T468","span":{"begin":31408,"end":31427},"obj":"Disease"},{"id":"T469","span":{"begin":31421,"end":31427},"obj":"Disease"},{"id":"T470","span":{"begin":31508,"end":31527},"obj":"Disease"},{"id":"T471","span":{"begin":31521,"end":31527},"obj":"Disease"},{"id":"T472","span":{"begin":31712,"end":31720},"obj":"Disease"},{"id":"T473","span":{"begin":31844,"end":31847},"obj":"Disease"},{"id":"T474","span":{"begin":31942,"end":31945},"obj":"Disease"},{"id":"T475","span":{"begin":32039,"end":32042},"obj":"Disease"},{"id":"T476","span":{"begin":32890,"end":32893},"obj":"Disease"},{"id":"T477","span":{"begin":32973,"end":32976},"obj":"Disease"},{"id":"T478","span":{"begin":33864,"end":33889},"obj":"Disease"},{"id":"T479","span":{"begin":33981,"end":33989},"obj":"Disease"},{"id":"T480","span":{"begin":35544,"end":35569},"obj":"Disease"},{"id":"T481","span":{"begin":35642,"end":35661},"obj":"Disease"},{"id":"T482","span":{"begin":35786,"end":35795},"obj":"Disease"},{"id":"T483","span":{"begin":35892,"end":35900},"obj":"Disease"},{"id":"T484","span":{"begin":36424,"end":36433},"obj":"Disease"},{"id":"T485","span":{"begin":36434,"end":36443},"obj":"Disease"},{"id":"T486","span":{"begin":36571,"end":36579},"obj":"Disease"},{"id":"T487","span":{"begin":36654,"end":36662},"obj":"Disease"},{"id":"T488","span":{"begin":36886,"end":36894},"obj":"Disease"},{"id":"T489","span":{"begin":37038,"end":37046},"obj":"Disease"},{"id":"T490","span":{"begin":37379,"end":37387},"obj":"Disease"},{"id":"T491","span":{"begin":37398,"end":37402},"obj":"Disease"},{"id":"T492","span":{"begin":37467,"end":37471},"obj":"Disease"},{"id":"T493","span":{"begin":37676,"end":37684},"obj":"Disease"},{"id":"T494","span":{"begin":37747,"end":37754},"obj":"Disease"},{"id":"T495","span":{"begin":38089,"end":38097},"obj":"Disease"},{"id":"T496","span":{"begin":38098,"end":38108},"obj":"Disease"},{"id":"T497","span":{"begin":38166,"end":38174},"obj":"Disease"},{"id":"T498","span":{"begin":38188,"end":38196},"obj":"Disease"},{"id":"T499","span":{"begin":38230,"end":38238},"obj":"Disease"},{"id":"T500","span":{"begin":38378,"end":38386},"obj":"Disease"},{"id":"T501","span":{"begin":39468,"end":39477},"obj":"Disease"},{"id":"T502","span":{"begin":40159,"end":40168},"obj":"Disease"},{"id":"T503","span":{"begin":40986,"end":40995},"obj":"Disease"},{"id":"T504","span":{"begin":41985,"end":41993},"obj":"Disease"},{"id":"T505","span":{"begin":42020,"end":42032},"obj":"Disease"},{"id":"T506","span":{"begin":42044,"end":42052},"obj":"Disease"},{"id":"T507","span":{"begin":42097,"end":42109},"obj":"Disease"},{"id":"T508","span":{"begin":42176,"end":42185},"obj":"Disease"},{"id":"T509","span":{"begin":42203,"end":42215},"obj":"Disease"},{"id":"T510","span":{"begin":42285,"end":42294},"obj":"Disease"},{"id":"T511","span":{"begin":42762,"end":42771},"obj":"Disease"},{"id":"T512","span":{"begin":42773,"end":42781},"obj":"Disease"},{"id":"T513","span":{"begin":42960,"end":42969},"obj":"Disease"},{"id":"T514","span":{"begin":43164,"end":43173},"obj":"Disease"},{"id":"T515","span":{"begin":43227,"end":43236},"obj":"Disease"},{"id":"T516","span":{"begin":43399,"end":43408},"obj":"Disease"},{"id":"T517","span":{"begin":43462,"end":43471},"obj":"Disease"},{"id":"T518","span":{"begin":43622,"end":43631},"obj":"Disease"},{"id":"T519","span":{"begin":43685,"end":43694},"obj":"Disease"},{"id":"T520","span":{"begin":43862,"end":43871},"obj":"Disease"},{"id":"T521","span":{"begin":43925,"end":43934},"obj":"Disease"},{"id":"T522","span":{"begin":44414,"end":44422},"obj":"Disease"},{"id":"T523","span":{"begin":44462,"end":44470},"obj":"Disease"},{"id":"T524","span":{"begin":44829,"end":44839},"obj":"Disease"},{"id":"T525","span":{"begin":44840,"end":44847},"obj":"Disease"},{"id":"T526","span":{"begin":44927,"end":44934},"obj":"Disease"},{"id":"T527","span":{"begin":45003,"end":45010},"obj":"Disease"},{"id":"T528","span":{"begin":45235,"end":45242},"obj":"Disease"},{"id":"T529","span":{"begin":45306,"end":45313},"obj":"Disease"},{"id":"T530","span":{"begin":45394,"end":45401},"obj":"Disease"},{"id":"T531","span":{"begin":45471,"end":45478},"obj":"Disease"},{"id":"T532","span":{"begin":45581,"end":45588},"obj":"Disease"},{"id":"T533","span":{"begin":45847,"end":45854},"obj":"Disease"},{"id":"T534","span":{"begin":46086,"end":46093},"obj":"Disease"},{"id":"T535","span":{"begin":46401,"end":46408},"obj":"Disease"},{"id":"T536","span":{"begin":46518,"end":46525},"obj":"Disease"},{"id":"T537","span":{"begin":46558,"end":46562},"obj":"Disease"},{"id":"T538","span":{"begin":46827,"end":46862},"obj":"Disease"},{"id":"T539","span":{"begin":46833,"end":46862},"obj":"Disease"},{"id":"T540","span":{"begin":46926,"end":46961},"obj":"Disease"},{"id":"T541","span":{"begin":46932,"end":46961},"obj":"Disease"},{"id":"T542","span":{"begin":47194,"end":47202},"obj":"Disease"},{"id":"T543","span":{"begin":47210,"end":47219},"obj":"Disease"},{"id":"T544","span":{"begin":49328,"end":49347},"obj":"Disease"},{"id":"T545","span":{"begin":49338,"end":49347},"obj":"Disease"},{"id":"T546","span":{"begin":49419,"end":49438},"obj":"Disease"},{"id":"T547","span":{"begin":49429,"end":49438},"obj":"Disease"},{"id":"T548","span":{"begin":49537,"end":49546},"obj":"Disease"},{"id":"T549","span":{"begin":49569,"end":49588},"obj":"Disease"},{"id":"T550","span":{"begin":49579,"end":49588},"obj":"Disease"},{"id":"T551","span":{"begin":49636,"end":49645},"obj":"Disease"},{"id":"T552","span":{"begin":49679,"end":49688},"obj":"Disease"},{"id":"T553","span":{"begin":49731,"end":49750},"obj":"Disease"},{"id":"T554","span":{"begin":49741,"end":49750},"obj":"Disease"},{"id":"T555","span":{"begin":50103,"end":50138},"obj":"Disease"},{"id":"T556","span":{"begin":50109,"end":50138},"obj":"Disease"},{"id":"T557","span":{"begin":50218,"end":50231},"obj":"Disease"},{"id":"T558","span":{"begin":50233,"end":50255},"obj":"Disease"},{"id":"T559","span":{"begin":50493,"end":50501},"obj":"Disease"},{"id":"T560","span":{"begin":50514,"end":50538},"obj":"Disease"},{"id":"T561","span":{"begin":50557,"end":50566},"obj":"Disease"},{"id":"T562","span":{"begin":52366,"end":52374},"obj":"Disease"},{"id":"T563","span":{"begin":53040,"end":53046},"obj":"Disease"},{"id":"T564","span":{"begin":53132,"end":53135},"obj":"Disease"},{"id":"T566","span":{"begin":53399,"end":53402},"obj":"Disease"},{"id":"T568","span":{"begin":53407,"end":53415},"obj":"Disease"},{"id":"T569","span":{"begin":53526,"end":53530},"obj":"Disease"},{"id":"T570","span":{"begin":54855,"end":54873},"obj":"Disease"},{"id":"T571","span":{"begin":55053,"end":55071},"obj":"Disease"},{"id":"T572","span":{"begin":55218,"end":55227},"obj":"Disease"},{"id":"T573","span":{"begin":55377,"end":55387},"obj":"Disease"},{"id":"T574","span":{"begin":55445,"end":55455},"obj":"Disease"},{"id":"T575","span":{"begin":55686,"end":55694},"obj":"Disease"}],"attributes":[{"id":"A335","pred":"mondo_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A336","pred":"mondo_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A337","pred":"mondo_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A338","pred":"mondo_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A339","pred":"mondo_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A340","pred":"mondo_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A341","pred":"mondo_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A342","pred":"mondo_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A343","pred":"mondo_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A344","pred":"mondo_id","subj":"T344","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A345","pred":"mondo_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A346","pred":"mondo_id","subj":"T346","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A347","pred":"mondo_id","subj":"T347","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A348","pred":"mondo_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A349","pred":"mondo_id","subj":"T349","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A350","pred":"mondo_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A351","pred":"mondo_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A352","pred":"mondo_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A353","pred":"mondo_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/MONDO_0017941"},{"id":"A354","pred":"mondo_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A355","pred":"mondo_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A356","pred":"mondo_id","subj":"T356","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A357","pred":"mondo_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A358","pred":"mondo_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A359","pred":"mondo_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A360","pred":"mondo_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A361","pred":"mondo_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A362","pred":"mondo_id","subj":"T362","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A363","pred":"mondo_id","subj":"T363","obj":"http://purl.obolibrary.org/obo/MONDO_0005773"},{"id":"A364","pred":"mondo_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A365","pred":"mondo_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A366","pred":"mondo_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/MONDO_0005773"},{"id":"A367","pred":"mondo_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A368","pred":"mondo_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A369","pred":"mondo_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A370","pred":"mondo_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A372","pred":"mondo_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A373","pred":"mondo_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A374","pred":"mondo_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A375","pred":"mondo_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A376","pred":"mondo_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A377","pred":"mondo_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"},{"id":"A378","pred":"mondo_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"},{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A380","pred":"mondo_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A383","pred":"mondo_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A384","pred":"mondo_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A385","pred":"mondo_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A386","pred":"mondo_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A387","pred":"mondo_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A388","pred":"mondo_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A389","pred":"mondo_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"},{"id":"A390","pred":"mondo_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/MONDO_0005047"},{"id":"A391","pred":"mondo_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A392","pred":"mondo_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A393","pred":"mondo_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A394","pred":"mondo_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A395","pred":"mondo_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A396","pred":"mondo_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A397","pred":"mondo_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A398","pred":"mondo_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A399","pred":"mondo_id","subj":"T399","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A400","pred":"mondo_id","subj":"T400","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A401","pred":"mondo_id","subj":"T401","obj":"http://purl.obolibrary.org/obo/MONDO_0043544"},{"id":"A402","pred":"mondo_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A403","pred":"mondo_id","subj":"T403","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A404","pred":"mondo_id","subj":"T404","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A405","pred":"mondo_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A406","pred":"mondo_id","subj":"T406","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A407","pred":"mondo_id","subj":"T407","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A408","pred":"mondo_id","subj":"T408","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A409","pred":"mondo_id","subj":"T409","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A410","pred":"mondo_id","subj":"T410","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A411","pred":"mondo_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A412","pred":"mondo_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/MONDO_0000605"},{"id":"A413","pred":"mondo_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"},{"id":"A414","pred":"mondo_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A415","pred":"mondo_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A416","pred":"mondo_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A417","pred":"mondo_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A418","pred":"mondo_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A419","pred":"mondo_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A420","pred":"mondo_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A421","pred":"mondo_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A422","pred":"mondo_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A423","pred":"mondo_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A424","pred":"mondo_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A425","pred":"mondo_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/MONDO_0005029"},{"id":"A426","pred":"mondo_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A427","pred":"mondo_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A428","pred":"mondo_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/MONDO_0005029"},{"id":"A429","pred":"mondo_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A431","pred":"mondo_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A432","pred":"mondo_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A433","pred":"mondo_id","subj":"T433","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A434","pred":"mondo_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A435","pred":"mondo_id","subj":"T435","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A436","pred":"mondo_id","subj":"T436","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A437","pred":"mondo_id","subj":"T437","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A438","pred":"mondo_id","subj":"T438","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A439","pred":"mondo_id","subj":"T439","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A440","pred":"mondo_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A441","pred":"mondo_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A442","pred":"mondo_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A443","pred":"mondo_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A444","pred":"mondo_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A445","pred":"mondo_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A446","pred":"mondo_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A447","pred":"mondo_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A448","pred":"mondo_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A449","pred":"mondo_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A450","pred":"mondo_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A451","pred":"mondo_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A452","pred":"mondo_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A453","pred":"mondo_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A454","pred":"mondo_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A455","pred":"mondo_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A456","pred":"mondo_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A457","pred":"mondo_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A458","pred":"mondo_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A459","pred":"mondo_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A460","pred":"mondo_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A461","pred":"mondo_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A462","pred":"mondo_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A463","pred":"mondo_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A464","pred":"mondo_id","subj":"T464","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A465","pred":"mondo_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A466","pred":"mondo_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A467","pred":"mondo_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A468","pred":"mondo_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A469","pred":"mondo_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A470","pred":"mondo_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/MONDO_0002492"},{"id":"A471","pred":"mondo_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A472","pred":"mondo_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A473","pred":"mondo_id","subj":"T473","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A474","pred":"mondo_id","subj":"T474","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A475","pred":"mondo_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A476","pred":"mondo_id","subj":"T476","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A477","pred":"mondo_id","subj":"T477","obj":"http://purl.obolibrary.org/obo/MONDO_0011194"},{"id":"A478","pred":"mondo_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A479","pred":"mondo_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A480","pred":"mondo_id","subj":"T480","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A481","pred":"mondo_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A482","pred":"mondo_id","subj":"T482","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A483","pred":"mondo_id","subj":"T483","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A484","pred":"mondo_id","subj":"T484","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A485","pred":"mondo_id","subj":"T485","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A486","pred":"mondo_id","subj":"T486","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A487","pred":"mondo_id","subj":"T487","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A488","pred":"mondo_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A489","pred":"mondo_id","subj":"T489","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A490","pred":"mondo_id","subj":"T490","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A491","pred":"mondo_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A492","pred":"mondo_id","subj":"T492","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A493","pred":"mondo_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A494","pred":"mondo_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A495","pred":"mondo_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A496","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A497","pred":"mondo_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A498","pred":"mondo_id","subj":"T498","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A499","pred":"mondo_id","subj":"T499","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A500","pred":"mondo_id","subj":"T500","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A501","pred":"mondo_id","subj":"T501","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A502","pred":"mondo_id","subj":"T502","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A503","pred":"mondo_id","subj":"T503","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A504","pred":"mondo_id","subj":"T504","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A505","pred":"mondo_id","subj":"T505","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A506","pred":"mondo_id","subj":"T506","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A507","pred":"mondo_id","subj":"T507","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A508","pred":"mondo_id","subj":"T508","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A509","pred":"mondo_id","subj":"T509","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A510","pred":"mondo_id","subj":"T510","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A511","pred":"mondo_id","subj":"T511","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A512","pred":"mondo_id","subj":"T512","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A513","pred":"mondo_id","subj":"T513","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A514","pred":"mondo_id","subj":"T514","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A515","pred":"mondo_id","subj":"T515","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A516","pred":"mondo_id","subj":"T516","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A517","pred":"mondo_id","subj":"T517","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A518","pred":"mondo_id","subj":"T518","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A519","pred":"mondo_id","subj":"T519","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A520","pred":"mondo_id","subj":"T520","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A521","pred":"mondo_id","subj":"T521","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A522","pred":"mondo_id","subj":"T522","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A523","pred":"mondo_id","subj":"T523","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A524","pred":"mondo_id","subj":"T524","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A525","pred":"mondo_id","subj":"T525","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A526","pred":"mondo_id","subj":"T526","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A527","pred":"mondo_id","subj":"T527","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A528","pred":"mondo_id","subj":"T528","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A529","pred":"mondo_id","subj":"T529","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A530","pred":"mondo_id","subj":"T530","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A531","pred":"mondo_id","subj":"T531","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A532","pred":"mondo_id","subj":"T532","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A533","pred":"mondo_id","subj":"T533","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A534","pred":"mondo_id","subj":"T534","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A535","pred":"mondo_id","subj":"T535","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A536","pred":"mondo_id","subj":"T536","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A537","pred":"mondo_id","subj":"T537","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A538","pred":"mondo_id","subj":"T538","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A539","pred":"mondo_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A541","pred":"mondo_id","subj":"T541","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A542","pred":"mondo_id","subj":"T542","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A543","pred":"mondo_id","subj":"T543","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A544","pred":"mondo_id","subj":"T544","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A545","pred":"mondo_id","subj":"T545","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A546","pred":"mondo_id","subj":"T546","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A547","pred":"mondo_id","subj":"T547","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A548","pred":"mondo_id","subj":"T548","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A549","pred":"mondo_id","subj":"T549","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A550","pred":"mondo_id","subj":"T550","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A551","pred":"mondo_id","subj":"T551","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A552","pred":"mondo_id","subj":"T552","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A553","pred":"mondo_id","subj":"T553","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A554","pred":"mondo_id","subj":"T554","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A555","pred":"mondo_id","subj":"T555","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A556","pred":"mondo_id","subj":"T556","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A557","pred":"mondo_id","subj":"T557","obj":"http://purl.obolibrary.org/obo/MONDO_0001106"},{"id":"A558","pred":"mondo_id","subj":"T558","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"},{"id":"A559","pred":"mondo_id","subj":"T559","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A560","pred":"mondo_id","subj":"T560","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A561","pred":"mondo_id","subj":"T561","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A562","pred":"mondo_id","subj":"T562","obj":"http://purl.obolibrary.org/obo/MONDO_0006022"},{"id":"A563","pred":"mondo_id","subj":"T563","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A564","pred":"mondo_id","subj":"T564","obj":"http://purl.obolibrary.org/obo/MONDO_0008296"},{"id":"A565","pred":"mondo_id","subj":"T564","obj":"http://purl.obolibrary.org/obo/MONDO_0015104"},{"id":"A566","pred":"mondo_id","subj":"T566","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A567","pred":"mondo_id","subj":"T566","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A568","pred":"mondo_id","subj":"T568","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A569","pred":"mondo_id","subj":"T569","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A570","pred":"mondo_id","subj":"T570","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A571","pred":"mondo_id","subj":"T571","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A572","pred":"mondo_id","subj":"T572","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A573","pred":"mondo_id","subj":"T573","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A574","pred":"mondo_id","subj":"T574","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A575","pred":"mondo_id","subj":"T575","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":45724,"end":45725},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":45761,"end":45762},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":46233,"end":46234},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":46270,"end":46271},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":46713,"end":46716},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T6","span":{"begin":46795,"end":46798},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T7","span":{"begin":47238,"end":47241},"obj":"http://purl.obolibrary.org/obo/CLO_0001046"},{"id":"T8","span":{"begin":47248,"end":47250},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T9","span":{"begin":47375,"end":47376},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":47454,"end":47456},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T11","span":{"begin":47674,"end":47675},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T12","span":{"begin":47705,"end":47706},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":48505,"end":48510},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T14","span":{"begin":48505,"end":48510},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T15","span":{"begin":48818,"end":48826},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T16","span":{"begin":49398,"end":49400},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T17","span":{"begin":50242,"end":50247},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T18","span":{"begin":50578,"end":50580},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T19","span":{"begin":50642,"end":50643},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T20","span":{"begin":51089,"end":51090},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T21","span":{"begin":51515,"end":51520},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T22","span":{"begin":52796,"end":52798},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T23","span":{"begin":52939,"end":52941},"obj":"http://purl.obolibrary.org/obo/CLO_0008954"},{"id":"T24","span":{"begin":53035,"end":53039},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T25","span":{"begin":53035,"end":53039},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T26","span":{"begin":53571,"end":53573},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T27","span":{"begin":53827,"end":53831},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T28","span":{"begin":53827,"end":53831},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T29","span":{"begin":53961,"end":53966},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T30","span":{"begin":54311,"end":54316},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T31","span":{"begin":54317,"end":54321},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T32","span":{"begin":54406,"end":54411},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T33","span":{"begin":54419,"end":54423},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T34","span":{"begin":54588,"end":54592},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T35","span":{"begin":54658,"end":54661},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T36","span":{"begin":54664,"end":54667},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T37","span":{"begin":54664,"end":54667},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T38","span":{"begin":54668,"end":54671},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T39","span":{"begin":54674,"end":54677},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T40","span":{"begin":54674,"end":54677},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T41","span":{"begin":54678,"end":54685},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T42","span":{"begin":54919,"end":54924},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T43","span":{"begin":54919,"end":54924},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T44","span":{"begin":55086,"end":55091},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T45","span":{"begin":55086,"end":55091},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T535","span":{"begin":310,"end":312},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T536","span":{"begin":955,"end":957},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T537","span":{"begin":1162,"end":1163},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T538","span":{"begin":1358,"end":1363},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T539","span":{"begin":1398,"end":1403},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T540","span":{"begin":1699,"end":1705},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T541","span":{"begin":1773,"end":1778},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T542","span":{"begin":1823,"end":1824},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T543","span":{"begin":1881,"end":1886},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T544","span":{"begin":1954,"end":1956},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T545","span":{"begin":2223,"end":2228},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T546","span":{"begin":2312,"end":2317},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T547","span":{"begin":2849,"end":2853},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T548","span":{"begin":2949,"end":2960},"obj":"http://purl.obolibrary.org/obo/PR_000012867"},{"id":"T549","span":{"begin":2961,"end":2970},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T550","span":{"begin":3383,"end":3389},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T551","span":{"begin":3450,"end":3452},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T552","span":{"begin":3485,"end":3491},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T553","span":{"begin":3565,"end":3566},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T554","span":{"begin":3646,"end":3652},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T555","span":{"begin":3726,"end":3727},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T556","span":{"begin":3903,"end":3904},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T557","span":{"begin":4008,"end":4010},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T558","span":{"begin":4329,"end":4333},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T559","span":{"begin":4329,"end":4333},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T560","span":{"begin":4435,"end":4437},"obj":"http://purl.obolibrary.org/obo/PR_000010213"},{"id":"T561","span":{"begin":4642,"end":4643},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T562","span":{"begin":4723,"end":4724},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T563","span":{"begin":4740,"end":4742},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T564","span":{"begin":4928,"end":4936},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T565","span":{"begin":5099,"end":5104},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T566","span":{"begin":5448,"end":5450},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T567","span":{"begin":5693,"end":5697},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T568","span":{"begin":5709,"end":5710},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T569","span":{"begin":5853,"end":5859},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T570","span":{"begin":6114,"end":6137},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"T571","span":{"begin":6744,"end":6749},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T572","span":{"begin":6777,"end":6783},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T573","span":{"begin":6835,"end":6840},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T574","span":{"begin":6979,"end":6983},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T575","span":{"begin":6996,"end":6998},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T576","span":{"begin":7042,"end":7046},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T577","span":{"begin":7059,"end":7061},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T578","span":{"begin":7568,"end":7572},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T579","span":{"begin":7699,"end":7707},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T580","span":{"begin":7874,"end":7876},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T581","span":{"begin":8073,"end":8077},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T582","span":{"begin":8248,"end":8252},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T583","span":{"begin":8612,"end":8620},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T584","span":{"begin":8820,"end":8822},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T585","span":{"begin":9013,"end":9017},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T586","span":{"begin":9189,"end":9193},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T587","span":{"begin":9218,"end":9224},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T588","span":{"begin":9647,"end":9649},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T589","span":{"begin":10137,"end":10139},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T590","span":{"begin":11022,"end":11026},"obj":"http://purl.obolibrary.org/obo/PR_000001379"},{"id":"T591","span":{"begin":11352,"end":11354},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T592","span":{"begin":11535,"end":11536},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T593","span":{"begin":11583,"end":11584},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T594","span":{"begin":11832,"end":11833},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T595","span":{"begin":11880,"end":11881},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T596","span":{"begin":12304,"end":12312},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T597","span":{"begin":12485,"end":12508},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"T598","span":{"begin":12625,"end":12629},"obj":"http://purl.obolibrary.org/obo/PR_000001379"},{"id":"T599","span":{"begin":12887,"end":12889},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T600","span":{"begin":13015,"end":13016},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T601","span":{"begin":13381,"end":13383},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T602","span":{"begin":13833,"end":13835},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T603","span":{"begin":13842,"end":13844},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T604","span":{"begin":14246,"end":14250},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T605","span":{"begin":14276,"end":14281},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T606","span":{"begin":14291,"end":14296},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T607","span":{"begin":14291,"end":14296},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T608","span":{"begin":14358,"end":14362},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T609","span":{"begin":14410,"end":14415},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T610","span":{"begin":14515,"end":14517},"obj":"http://purl.obolibrary.org/obo/CLO_0009141"},{"id":"T611","span":{"begin":14515,"end":14517},"obj":"http://purl.obolibrary.org/obo/CLO_0050980"},{"id":"T612","span":{"begin":14609,"end":14612},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T613","span":{"begin":14619,"end":14622},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T614","span":{"begin":14625,"end":14632},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T615","span":{"begin":14661,"end":14666},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T616","span":{"begin":14661,"end":14666},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T617","span":{"begin":14690,"end":14694},"obj":"http://purl.obolibrary.org/obo/CLO_0053704"},{"id":"T618","span":{"begin":14954,"end":14956},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T619","span":{"begin":15272,"end":15276},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T620","span":{"begin":15431,"end":15453},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T621","span":{"begin":15504,"end":15514},"obj":"http://purl.obolibrary.org/obo/CL_0000034"},{"id":"T622","span":{"begin":15547,"end":15549},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T623","span":{"begin":15817,"end":15822},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T624","span":{"begin":16110,"end":16112},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T625","span":{"begin":16623,"end":16645},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T626","span":{"begin":16664,"end":16669},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T627","span":{"begin":16746,"end":16751},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T628","span":{"begin":16809,"end":16811},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T629","span":{"begin":16841,"end":16863},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T630","span":{"begin":16986,"end":16991},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T631","span":{"begin":17199,"end":17204},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T632","span":{"begin":17737,"end":17740},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T633","span":{"begin":17742,"end":17748},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T634","span":{"begin":17803,"end":17807},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T635","span":{"begin":18066,"end":18068},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T636","span":{"begin":18138,"end":18144},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T637","span":{"begin":18655,"end":18657},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T638","span":{"begin":18931,"end":18936},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T639","span":{"begin":19217,"end":19219},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T640","span":{"begin":19638,"end":19640},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T641","span":{"begin":19669,"end":19671},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T642","span":{"begin":19748,"end":19751},"obj":"http://purl.obolibrary.org/obo/CLO_0001602"},{"id":"T643","span":{"begin":19748,"end":19751},"obj":"http://purl.obolibrary.org/obo/CLO_0001603"},{"id":"T644","span":{"begin":19748,"end":19751},"obj":"http://purl.obolibrary.org/obo/CLO_0050248"},{"id":"T645","span":{"begin":19748,"end":19751},"obj":"http://purl.obolibrary.org/obo/CLO_0052463"},{"id":"T646","span":{"begin":19855,"end":19857},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T647","span":{"begin":20078,"end":20080},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T648","span":{"begin":20168,"end":20170},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T649","span":{"begin":20268,"end":20270},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T650","span":{"begin":20344,"end":20346},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T651","span":{"begin":20447,"end":20449},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T652","span":{"begin":20848,"end":20850},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T653","span":{"begin":21666,"end":21671},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T654","span":{"begin":21672,"end":21676},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T655","span":{"begin":22047,"end":22057},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T656","span":{"begin":22047,"end":22057},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T657","span":{"begin":22112,"end":22122},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T658","span":{"begin":22112,"end":22122},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T659","span":{"begin":22242,"end":22246},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"T660","span":{"begin":22260,"end":22264},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"T661","span":{"begin":22455,"end":22459},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"T662","span":{"begin":22473,"end":22477},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"T663","span":{"begin":23094,"end":23100},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T664","span":{"begin":23469,"end":23473},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T665","span":{"begin":23469,"end":23473},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T666","span":{"begin":23750,"end":23752},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T667","span":{"begin":24765,"end":24769},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T668","span":{"begin":24765,"end":24769},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T669","span":{"begin":25458,"end":25460},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T670","span":{"begin":25556,"end":25558},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T671","span":{"begin":25634,"end":25638},"obj":"http://purl.obolibrary.org/obo/CLO_0053809"},{"id":"T672","span":{"begin":25654,"end":25656},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T673","span":{"begin":25751,"end":25753},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T674","span":{"begin":25872,"end":25876},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T675","span":{"begin":26000,"end":26006},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T676","span":{"begin":26153,"end":26157},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T677","span":{"begin":26233,"end":26237},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T678","span":{"begin":26368,"end":26372},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T679","span":{"begin":26476,"end":26480},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T680","span":{"begin":26720,"end":26724},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T681","span":{"begin":27110,"end":27111},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T682","span":{"begin":27180,"end":27184},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T683","span":{"begin":27322,"end":27326},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T684","span":{"begin":27468,"end":27472},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T685","span":{"begin":27870,"end":27872},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T686","span":{"begin":27887,"end":27893},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T687","span":{"begin":28227,"end":28230},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T688","span":{"begin":28539,"end":28540},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T689","span":{"begin":28678,"end":28691},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T690","span":{"begin":28955,"end":28960},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T691","span":{"begin":29435,"end":29456},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T692","span":{"begin":29568,"end":29570},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T693","span":{"begin":29697,"end":29702},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T694","span":{"begin":29824,"end":29829},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T695","span":{"begin":30042,"end":30045},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T696","span":{"begin":30051,"end":30054},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T697","span":{"begin":30056,"end":30062},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T698","span":{"begin":30087,"end":30091},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T699","span":{"begin":30125,"end":30130},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T700","span":{"begin":30125,"end":30130},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T701","span":{"begin":30156,"end":30160},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T702","span":{"begin":30289,"end":30290},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T703","span":{"begin":30436,"end":30438},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T704","span":{"begin":31140,"end":31146},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T705","span":{"begin":31140,"end":31146},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T706","span":{"begin":31140,"end":31146},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T707","span":{"begin":31218,"end":31224},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T708","span":{"begin":31218,"end":31224},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T709","span":{"begin":31218,"end":31224},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T710","span":{"begin":31232,"end":31238},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T711","span":{"begin":31232,"end":31238},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T712","span":{"begin":31232,"end":31238},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T713","span":{"begin":31259,"end":31261},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T714","span":{"begin":31300,"end":31306},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T715","span":{"begin":31300,"end":31306},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T716","span":{"begin":31300,"end":31306},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T717","span":{"begin":31344,"end":31350},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T718","span":{"begin":31344,"end":31350},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T719","span":{"begin":31344,"end":31350},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T720","span":{"begin":31367,"end":31373},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T766","span":{"begin":36146,"end":36150},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T721","span":{"begin":31367,"end":31373},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T722","span":{"begin":31367,"end":31373},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T723","span":{"begin":31414,"end":31420},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T724","span":{"begin":31414,"end":31420},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T725","span":{"begin":31414,"end":31420},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T726","span":{"begin":31514,"end":31520},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T727","span":{"begin":31514,"end":31520},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T728","span":{"begin":31514,"end":31520},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T729","span":{"begin":31732,"end":31734},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T730","span":{"begin":31856,"end":31858},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T731","span":{"begin":31934,"end":31938},"obj":"http://purl.obolibrary.org/obo/CLO_0053809"},{"id":"T732","span":{"begin":31954,"end":31956},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T733","span":{"begin":32051,"end":32053},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T734","span":{"begin":32190,"end":32196},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T735","span":{"begin":32399,"end":32403},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T736","span":{"begin":32524,"end":32528},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T737","span":{"begin":32620,"end":32624},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T738","span":{"begin":32728,"end":32732},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T739","span":{"begin":32808,"end":32812},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T740","span":{"begin":32921,"end":32925},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T741","span":{"begin":33004,"end":33008},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T742","span":{"begin":33209,"end":33213},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T743","span":{"begin":33288,"end":33292},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T744","span":{"begin":33380,"end":33384},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T745","span":{"begin":33473,"end":33477},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T746","span":{"begin":33871,"end":33876},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T747","span":{"begin":34001,"end":34003},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T748","span":{"begin":34132,"end":34133},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T749","span":{"begin":34192,"end":34193},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T750","span":{"begin":34309,"end":34312},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T751","span":{"begin":34657,"end":34663},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T752","span":{"begin":34736,"end":34737},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T753","span":{"begin":34796,"end":34797},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T754","span":{"begin":34881,"end":34887},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T755","span":{"begin":34936,"end":34939},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T756","span":{"begin":35402,"end":35406},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T757","span":{"begin":35487,"end":35491},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T758","span":{"begin":35487,"end":35491},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T759","span":{"begin":35551,"end":35556},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T760","span":{"begin":35819,"end":35841},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T761","span":{"begin":35867,"end":35889},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T762","span":{"begin":35911,"end":35913},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T763","span":{"begin":35948,"end":35970},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T764","span":{"begin":36013,"end":36035},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T765","span":{"begin":36115,"end":36120},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T767","span":{"begin":36146,"end":36150},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T768","span":{"begin":36180,"end":36185},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T769","span":{"begin":36224,"end":36229},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T770","span":{"begin":36224,"end":36229},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T771","span":{"begin":36590,"end":36592},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T772","span":{"begin":36841,"end":36847},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T773","span":{"begin":36935,"end":36936},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T774","span":{"begin":36957,"end":36958},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T775","span":{"begin":37435,"end":37437},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T776","span":{"begin":37868,"end":37869},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T777","span":{"begin":38796,"end":38798},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T778","span":{"begin":39072,"end":39074},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T779","span":{"begin":39311,"end":39312},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T780","span":{"begin":39342,"end":39343},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T781","span":{"begin":39976,"end":39977},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T782","span":{"begin":40007,"end":40008},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T783","span":{"begin":40239,"end":40245},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T784","span":{"begin":40663,"end":40664},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T785","span":{"begin":41556,"end":41557},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T786","span":{"begin":41924,"end":41930},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T787","span":{"begin":42062,"end":42064},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T788","span":{"begin":42880,"end":42885},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T789","span":{"begin":42899,"end":42900},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T790","span":{"begin":42990,"end":42992},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T791","span":{"begin":43028,"end":43029},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T792","span":{"begin":43320,"end":43325},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T793","span":{"begin":43339,"end":43340},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T794","span":{"begin":43492,"end":43498},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T795","span":{"begin":43517,"end":43518},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T796","span":{"begin":43784,"end":43789},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T797","span":{"begin":43803,"end":43804},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T798","span":{"begin":44767,"end":44768},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T799","span":{"begin":45184,"end":45185},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T800","span":{"begin":45221,"end":45222},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T34382","span":{"begin":236,"end":244},"obj":"Chemical"},{"id":"T9718","span":{"begin":341,"end":346},"obj":"Chemical"},{"id":"T25818","span":{"begin":437,"end":442},"obj":"Chemical"},{"id":"T79148","span":{"begin":462,"end":464},"obj":"Chemical"},{"id":"T1524","span":{"begin":575,"end":581},"obj":"Chemical"},{"id":"T65175","span":{"begin":848,"end":851},"obj":"Chemical"},{"id":"T42271","span":{"begin":910,"end":913},"obj":"Chemical"},{"id":"T66","span":{"begin":982,"end":987},"obj":"Chemical"},{"id":"T5227","span":{"begin":1000,"end":1003},"obj":"Chemical"},{"id":"T89603","span":{"begin":1016,"end":1024},"obj":"Chemical"},{"id":"T64472","span":{"begin":1081,"end":1096},"obj":"Chemical"},{"id":"T16097","span":{"begin":1081,"end":1090},"obj":"Chemical"},{"id":"T79085","span":{"begin":1091,"end":1096},"obj":"Chemical"},{"id":"T84596","span":{"begin":1113,"end":1116},"obj":"Chemical"},{"id":"T22462","span":{"begin":1177,"end":1182},"obj":"Chemical"},{"id":"T20379","span":{"begin":1192,"end":1200},"obj":"Chemical"},{"id":"T7585","span":{"begin":1258,"end":1273},"obj":"Chemical"},{"id":"T86024","span":{"begin":1258,"end":1267},"obj":"Chemical"},{"id":"T48066","span":{"begin":1268,"end":1273},"obj":"Chemical"},{"id":"T54548","span":{"begin":1404,"end":1411},"obj":"Chemical"},{"id":"T38531","span":{"begin":1779,"end":1790},"obj":"Chemical"},{"id":"T17203","span":{"begin":1887,"end":1898},"obj":"Chemical"},{"id":"T28054","span":{"begin":1985,"end":1990},"obj":"Chemical"},{"id":"T1929","span":{"begin":2009,"end":2011},"obj":"Chemical"},{"id":"T63564","span":{"begin":2056,"end":2061},"obj":"Chemical"},{"id":"T84","span":{"begin":2503,"end":2510},"obj":"Chemical"},{"id":"T17269","span":{"begin":2529,"end":2543},"obj":"Chemical"},{"id":"T19318","span":{"begin":2529,"end":2540},"obj":"Chemical"},{"id":"T89","span":{"begin":2541,"end":2543},"obj":"Chemical"},{"id":"T24232","span":{"begin":2549,"end":2551},"obj":"Chemical"},{"id":"T91","span":{"begin":2572,"end":2583},"obj":"Chemical"},{"id":"T80419","span":{"begin":2617,"end":2628},"obj":"Chemical"},{"id":"T30660","span":{"begin":2687,"end":2698},"obj":"Chemical"},{"id":"T95","span":{"begin":2718,"end":2729},"obj":"Chemical"},{"id":"T40933","span":{"begin":2767,"end":2778},"obj":"Chemical"},{"id":"T73661","span":{"begin":2825,"end":2827},"obj":"Chemical"},{"id":"T54173","span":{"begin":2849,"end":2851},"obj":"Chemical"},{"id":"T70837","span":{"begin":2917,"end":2919},"obj":"Chemical"},{"id":"T26545","span":{"begin":2971,"end":2980},"obj":"Chemical"},{"id":"T22043","span":{"begin":3112,"end":3143},"obj":"Chemical"},{"id":"T80881","span":{"begin":3171,"end":3181},"obj":"Chemical"},{"id":"T41839","span":{"begin":3182,"end":3189},"obj":"Chemical"},{"id":"T657","span":{"begin":3961,"end":3968},"obj":"Chemical"},{"id":"T36666","span":{"begin":4052,"end":4057},"obj":"Chemical"},{"id":"T59812","span":{"begin":4059,"end":4077},"obj":"Chemical"},{"id":"T48299","span":{"begin":4059,"end":4069},"obj":"Chemical"},{"id":"T80763","span":{"begin":4070,"end":4077},"obj":"Chemical"},{"id":"T56768","span":{"begin":4371,"end":4378},"obj":"Chemical"},{"id":"T36106","span":{"begin":5153,"end":5165},"obj":"Chemical"},{"id":"T79701","span":{"begin":5160,"end":5165},"obj":"Chemical"},{"id":"T36153","span":{"begin":5192,"end":5198},"obj":"Chemical"},{"id":"T54594","span":{"begin":5356,"end":5365},"obj":"Chemical"},{"id":"T97769","span":{"begin":5493,"end":5502},"obj":"Chemical"},{"id":"T20676","span":{"begin":5530,"end":5539},"obj":"Chemical"},{"id":"T92853","span":{"begin":5547,"end":5557},"obj":"Chemical"},{"id":"T46415","span":{"begin":5618,"end":5636},"obj":"Chemical"},{"id":"T20639","span":{"begin":5735,"end":5753},"obj":"Chemical"},{"id":"T47677","span":{"begin":6357,"end":6361},"obj":"Chemical"},{"id":"T34447","span":{"begin":6467,"end":6486},"obj":"Chemical"},{"id":"T27940","span":{"begin":6467,"end":6476},"obj":"Chemical"},{"id":"T20411","span":{"begin":6477,"end":6486},"obj":"Chemical"},{"id":"T71837","span":{"begin":6490,"end":6508},"obj":"Chemical"},{"id":"T131","span":{"begin":6569,"end":6588},"obj":"Chemical"},{"id":"T12779","span":{"begin":6569,"end":6578},"obj":"Chemical"},{"id":"T42223","span":{"begin":6579,"end":6588},"obj":"Chemical"},{"id":"T53502","span":{"begin":6596,"end":6614},"obj":"Chemical"},{"id":"T77554","span":{"begin":6615,"end":6622},"obj":"Chemical"},{"id":"T82580","span":{"begin":6697,"end":6716},"obj":"Chemical"},{"id":"T91739","span":{"begin":6697,"end":6706},"obj":"Chemical"},{"id":"T7801","span":{"begin":6707,"end":6716},"obj":"Chemical"},{"id":"T31954","span":{"begin":6796,"end":6814},"obj":"Chemical"},{"id":"T56995","span":{"begin":6897,"end":6916},"obj":"Chemical"},{"id":"T74129","span":{"begin":6897,"end":6906},"obj":"Chemical"},{"id":"T14779","span":{"begin":6907,"end":6916},"obj":"Chemical"},{"id":"T75588","span":{"begin":6921,"end":6939},"obj":"Chemical"},{"id":"T41134","span":{"begin":6941,"end":6943},"obj":"Chemical"},{"id":"T71387","span":{"begin":7164,"end":7170},"obj":"Chemical"},{"id":"T58068","span":{"begin":7416,"end":7435},"obj":"Chemical"},{"id":"T12331","span":{"begin":7416,"end":7425},"obj":"Chemical"},{"id":"T50748","span":{"begin":7426,"end":7435},"obj":"Chemical"},{"id":"T149","span":{"begin":7439,"end":7457},"obj":"Chemical"},{"id":"T150","span":{"begin":7518,"end":7537},"obj":"Chemical"},{"id":"T151","span":{"begin":7518,"end":7527},"obj":"Chemical"},{"id":"T152","span":{"begin":7528,"end":7537},"obj":"Chemical"},{"id":"T153","span":{"begin":7542,"end":7560},"obj":"Chemical"},{"id":"T154","span":{"begin":7606,"end":7614},"obj":"Chemical"},{"id":"T155","span":{"begin":7689,"end":7698},"obj":"Chemical"},{"id":"T156","span":{"begin":7711,"end":7721},"obj":"Chemical"},{"id":"T157","span":{"begin":7723,"end":7725},"obj":"Chemical"},{"id":"T158","span":{"begin":7799,"end":7809},"obj":"Chemical"},{"id":"T159","span":{"begin":8099,"end":8109},"obj":"Chemical"},{"id":"T160","span":{"begin":8350,"end":8356},"obj":"Chemical"},{"id":"T161","span":{"begin":8477,"end":8481},"obj":"Chemical"},{"id":"T162","span":{"begin":8602,"end":8611},"obj":"Chemical"},{"id":"T163","span":{"begin":8624,"end":8634},"obj":"Chemical"},{"id":"T164","span":{"begin":8636,"end":8638},"obj":"Chemical"},{"id":"T165","span":{"begin":8753,"end":8763},"obj":"Chemical"},{"id":"T166","span":{"begin":8865,"end":8875},"obj":"Chemical"},{"id":"T167","span":{"begin":9040,"end":9050},"obj":"Chemical"},{"id":"T168","span":{"begin":9461,"end":9465},"obj":"Chemical"},{"id":"T169","span":{"begin":9692,"end":9697},"obj":"Chemical"},{"id":"T170","span":{"begin":9725,"end":9729},"obj":"Chemical"},{"id":"T171","span":{"begin":9780,"end":9785},"obj":"Chemical"},{"id":"T172","span":{"begin":9989,"end":10000},"obj":"Chemical"},{"id":"T173","span":{"begin":10008,"end":10016},"obj":"Chemical"},{"id":"T174","span":{"begin":10083,"end":10094},"obj":"Chemical"},{"id":"T175","span":{"begin":10114,"end":10125},"obj":"Chemical"},{"id":"T176","span":{"begin":10196,"end":10201},"obj":"Chemical"},{"id":"T177","span":{"begin":10253,"end":10264},"obj":"Chemical"},{"id":"T178","span":{"begin":10265,"end":10270},"obj":"Chemical"},{"id":"T179","span":{"begin":10325,"end":10327},"obj":"Chemical"},{"id":"T180","span":{"begin":10683,"end":10689},"obj":"Chemical"},{"id":"T181","span":{"begin":11015,"end":11017},"obj":"Chemical"},{"id":"T183","span":{"begin":11022,"end":11024},"obj":"Chemical"},{"id":"T185","span":{"begin":11028,"end":11030},"obj":"Chemical"},{"id":"T187","span":{"begin":11034,"end":11036},"obj":"Chemical"},{"id":"T189","span":{"begin":11040,"end":11042},"obj":"Chemical"},{"id":"T191","span":{"begin":11212,"end":11223},"obj":"Chemical"},{"id":"T192","span":{"begin":11247,"end":11255},"obj":"Chemical"},{"id":"T193","span":{"begin":11302,"end":11306},"obj":"Chemical"},{"id":"T194","span":{"begin":11308,"end":11319},"obj":"Chemical"},{"id":"T195","span":{"begin":11330,"end":11341},"obj":"Chemical"},{"id":"T196","span":{"begin":11411,"end":11416},"obj":"Chemical"},{"id":"T197","span":{"begin":11419,"end":11429},"obj":"Chemical"},{"id":"T198","span":{"begin":11506,"end":11511},"obj":"Chemical"},{"id":"T199","span":{"begin":11602,"end":11620},"obj":"Chemical"},{"id":"T200","span":{"begin":11696,"end":11707},"obj":"Chemical"},{"id":"T201","span":{"begin":11708,"end":11713},"obj":"Chemical"},{"id":"T202","span":{"begin":11716,"end":11726},"obj":"Chemical"},{"id":"T203","span":{"begin":11803,"end":11808},"obj":"Chemical"},{"id":"T204","span":{"begin":11899,"end":11917},"obj":"Chemical"},{"id":"T205","span":{"begin":11944,"end":11955},"obj":"Chemical"},{"id":"T206","span":{"begin":11982,"end":11984},"obj":"Chemical"},{"id":"T207","span":{"begin":12592,"end":12596},"obj":"Chemical"},{"id":"T208","span":{"begin":12618,"end":12620},"obj":"Chemical"},{"id":"T210","span":{"begin":12625,"end":12627},"obj":"Chemical"},{"id":"T212","span":{"begin":12631,"end":12633},"obj":"Chemical"},{"id":"T214","span":{"begin":12637,"end":12639},"obj":"Chemical"},{"id":"T216","span":{"begin":12643,"end":12645},"obj":"Chemical"},{"id":"T218","span":{"begin":12788,"end":12799},"obj":"Chemical"},{"id":"T219","span":{"begin":12989,"end":13000},"obj":"Chemical"},{"id":"T220","span":{"begin":13007,"end":13009},"obj":"Chemical"},{"id":"T221","span":{"begin":13166,"end":13168},"obj":"Chemical"},{"id":"T222","span":{"begin":13423,"end":13428},"obj":"Chemical"},{"id":"T223","span":{"begin":13450,"end":13460},"obj":"Chemical"},{"id":"T224","span":{"begin":13471,"end":13476},"obj":"Chemical"},{"id":"T225","span":{"begin":13497,"end":13507},"obj":"Chemical"},{"id":"T226","span":{"begin":13579,"end":13584},"obj":"Chemical"},{"id":"T227","span":{"begin":13586,"end":13588},"obj":"Chemical"},{"id":"T228","span":{"begin":13892,"end":13897},"obj":"Chemical"},{"id":"T229","span":{"begin":14068,"end":14073},"obj":"Chemical"},{"id":"T230","span":{"begin":14297,"end":14303},"obj":"Chemical"},{"id":"T231","span":{"begin":14474,"end":14479},"obj":"Chemical"},{"id":"T232","span":{"begin":14515,"end":14517},"obj":"Chemical"},{"id":"T233","span":{"begin":14565,"end":14572},"obj":"Chemical"},{"id":"T234","span":{"begin":14584,"end":14591},"obj":"Chemical"},{"id":"T235","span":{"begin":14677,"end":14679},"obj":"Chemical"},{"id":"T237","span":{"begin":14684,"end":14686},"obj":"Chemical"},{"id":"T239","span":{"begin":14690,"end":14692},"obj":"Chemical"},{"id":"T241","span":{"begin":14695,"end":14697},"obj":"Chemical"},{"id":"T243","span":{"begin":14822,"end":14830},"obj":"Chemical"},{"id":"T244","span":{"begin":14909,"end":14917},"obj":"Chemical"},{"id":"T245","span":{"begin":14919,"end":14923},"obj":"Chemical"},{"id":"T246","span":{"begin":15018,"end":15026},"obj":"Chemical"},{"id":"T247","span":{"begin":15047,"end":15055},"obj":"Chemical"},{"id":"T248","span":{"begin":15286,"end":15288},"obj":"Chemical"},{"id":"T249","span":{"begin":15792,"end":15800},"obj":"Chemical"},{"id":"T250","span":{"begin":16153,"end":16158},"obj":"Chemical"},{"id":"T251","span":{"begin":16250,"end":16255},"obj":"Chemical"},{"id":"T252","span":{"begin":16657,"end":16663},"obj":"Chemical"},{"id":"T253","span":{"begin":16767,"end":16775},"obj":"Chemical"},{"id":"T254","span":{"begin":17220,"end":17228},"obj":"Chemical"},{"id":"T255","span":{"begin":17299,"end":17301},"obj":"Chemical"},{"id":"T256","span":{"begin":17412,"end":17417},"obj":"Chemical"},{"id":"T257","span":{"begin":17630,"end":17636},"obj":"Chemical"},{"id":"T258","span":{"begin":17959,"end":17963},"obj":"Chemical"},{"id":"T259","span":{"begin":17965,"end":17984},"obj":"Chemical"},{"id":"T260","span":{"begin":17965,"end":17974},"obj":"Chemical"},{"id":"T261","span":{"begin":17975,"end":17984},"obj":"Chemical"},{"id":"T262","span":{"begin":17996,"end":18003},"obj":"Chemical"},{"id":"T263","span":{"begin":18007,"end":18018},"obj":"Chemical"},{"id":"T264","span":{"begin":18019,"end":18028},"obj":"Chemical"},{"id":"T268","span":{"begin":18157,"end":18176},"obj":"Chemical"},{"id":"T269","span":{"begin":18157,"end":18166},"obj":"Chemical"},{"id":"T270","span":{"begin":18167,"end":18176},"obj":"Chemical"},{"id":"T271","span":{"begin":18180,"end":18187},"obj":"Chemical"},{"id":"T272","span":{"begin":18191,"end":18202},"obj":"Chemical"},{"id":"T273","span":{"begin":18203,"end":18212},"obj":"Chemical"},{"id":"T277","span":{"begin":18238,"end":18257},"obj":"Chemical"},{"id":"T278","span":{"begin":18238,"end":18247},"obj":"Chemical"},{"id":"T279","span":{"begin":18248,"end":18257},"obj":"Chemical"},{"id":"T280","span":{"begin":18269,"end":18276},"obj":"Chemical"},{"id":"T281","span":{"begin":18280,"end":18291},"obj":"Chemical"},{"id":"T282","span":{"begin":18292,"end":18301},"obj":"Chemical"},{"id":"T286","span":{"begin":18303,"end":18305},"obj":"Chemical"},{"id":"T287","span":{"begin":18574,"end":18589},"obj":"Chemical"},{"id":"T288","span":{"begin":18609,"end":18627},"obj":"Chemical"},{"id":"T289","span":{"begin":18705,"end":18710},"obj":"Chemical"},{"id":"T290","span":{"begin":18712,"end":18730},"obj":"Chemical"},{"id":"T291","span":{"begin":18781,"end":18786},"obj":"Chemical"},{"id":"T292","span":{"begin":19168,"end":19172},"obj":"Chemical"},{"id":"T293","span":{"begin":19303,"end":19305},"obj":"Chemical"},{"id":"T294","span":{"begin":19421,"end":19423},"obj":"Chemical"},{"id":"T295","span":{"begin":19524,"end":19526},"obj":"Chemical"},{"id":"T296","span":{"begin":19579,"end":19581},"obj":"Chemical"},{"id":"T297","span":{"begin":20207,"end":20209},"obj":"Chemical"},{"id":"T299","span":{"begin":20362,"end":20364},"obj":"Chemical"},{"id":"T301","span":{"begin":20686,"end":20692},"obj":"Chemical"},{"id":"T302","span":{"begin":20816,"end":20822},"obj":"Chemical"},{"id":"T303","span":{"begin":21684,"end":21694},"obj":"Chemical"},{"id":"T304","span":{"begin":21719,"end":21729},"obj":"Chemical"},{"id":"T305","span":{"begin":21744,"end":21753},"obj":"Chemical"},{"id":"T306","span":{"begin":21761,"end":21768},"obj":"Chemical"},{"id":"T307","span":{"begin":21793,"end":21802},"obj":"Chemical"},{"id":"T310","span":{"begin":22174,"end":22179},"obj":"Chemical"},{"id":"T311","span":{"begin":22334,"end":22339},"obj":"Chemical"},{"id":"T312","span":{"begin":23702,"end":23704},"obj":"Chemical"},{"id":"T313","span":{"begin":23832,"end":23834},"obj":"Chemical"},{"id":"T314","span":{"begin":24373,"end":24375},"obj":"Chemical"},{"id":"T315","span":{"begin":24397,"end":24404},"obj":"Chemical"},{"id":"T316","span":{"begin":24567,"end":24569},"obj":"Chemical"},{"id":"T317","span":{"begin":24660,"end":24662},"obj":"Chemical"},{"id":"T318","span":{"begin":25500,"end":25505},"obj":"Chemical"},{"id":"T319","span":{"begin":25598,"end":25603},"obj":"Chemical"},{"id":"T320","span":{"begin":25694,"end":25699},"obj":"Chemical"},{"id":"T321","span":{"begin":26812,"end":26819},"obj":"Chemical"},{"id":"T322","span":{"begin":27138,"end":27150},"obj":"Chemical"},{"id":"T323","span":{"begin":27146,"end":27150},"obj":"Chemical"},{"id":"T324","span":{"begin":27769,"end":27787},"obj":"Chemical"},{"id":"T325","span":{"begin":27789,"end":27793},"obj":"Chemical"},{"id":"T326","span":{"begin":28357,"end":28368},"obj":"Chemical"},{"id":"T327","span":{"begin":28597,"end":28599},"obj":"Chemical"},{"id":"T328","span":{"begin":28728,"end":28735},"obj":"Chemical"},{"id":"T329","span":{"begin":28797,"end":28803},"obj":"Chemical"},{"id":"T330","span":{"begin":28832,"end":28838},"obj":"Chemical"},{"id":"T331","span":{"begin":30001,"end":30013},"obj":"Chemical"},{"id":"T332","span":{"begin":30009,"end":30013},"obj":"Chemical"},{"id":"T333","span":{"begin":30131,"end":30137},"obj":"Chemical"},{"id":"T334","span":{"begin":30217,"end":30222},"obj":"Chemical"},{"id":"T335","span":{"begin":30295,"end":30304},"obj":"Chemical"},{"id":"T336","span":{"begin":30305,"end":30320},"obj":"Chemical"},{"id":"T337","span":{"begin":30358,"end":30362},"obj":"Chemical"},{"id":"T338","span":{"begin":30574,"end":30576},"obj":"Chemical"},{"id":"T339","span":{"begin":30660,"end":30668},"obj":"Chemical"},{"id":"T340","span":{"begin":30677,"end":30679},"obj":"Chemical"},{"id":"T341","span":{"begin":30977,"end":30985},"obj":"Chemical"},{"id":"T342","span":{"begin":31017,"end":31023},"obj":"Chemical"},{"id":"T343","span":{"begin":31800,"end":31805},"obj":"Chemical"},{"id":"T344","span":{"begin":31898,"end":31903},"obj":"Chemical"},{"id":"T345","span":{"begin":31994,"end":31999},"obj":"Chemical"},{"id":"T346","span":{"begin":33342,"end":33349},"obj":"Chemical"},{"id":"T347","span":{"begin":33832,"end":33843},"obj":"Chemical"},{"id":"T348","span":{"begin":33864,"end":33870},"obj":"Chemical"},{"id":"T349","span":{"begin":33897,"end":33908},"obj":"Chemical"},{"id":"T350","span":{"begin":33923,"end":33934},"obj":"Chemical"},{"id":"T351","span":{"begin":33936,"end":33940},"obj":"Chemical"},{"id":"T352","span":{"begin":33942,"end":33953},"obj":"Chemical"},{"id":"T353","span":{"begin":33955,"end":33959},"obj":"Chemical"},{"id":"T354","span":{"begin":33961,"end":33972},"obj":"Chemical"},{"id":"T355","span":{"begin":34033,"end":34044},"obj":"Chemical"},{"id":"T356","span":{"begin":34059,"end":34070},"obj":"Chemical"},{"id":"T357","span":{"begin":34071,"end":34076},"obj":"Chemical"},{"id":"T358","span":{"begin":34389,"end":34400},"obj":"Chemical"},{"id":"T359","span":{"begin":34676,"end":34687},"obj":"Chemical"},{"id":"T360","span":{"begin":34688,"end":34693},"obj":"Chemical"},{"id":"T361","span":{"begin":34900,"end":34911},"obj":"Chemical"},{"id":"T362","span":{"begin":34912,"end":34917},"obj":"Chemical"},{"id":"T363","span":{"begin":35016,"end":35027},"obj":"Chemical"},{"id":"T364","span":{"begin":35372,"end":35380},"obj":"Chemical"},{"id":"T365","span":{"begin":35389,"end":35401},"obj":"Chemical"},{"id":"T366","span":{"begin":35397,"end":35401},"obj":"Chemical"},{"id":"T367","span":{"begin":35544,"end":35550},"obj":"Chemical"},{"id":"T368","span":{"begin":36230,"end":36236},"obj":"Chemical"},{"id":"T369","span":{"begin":36472,"end":36491},"obj":"Chemical"},{"id":"T370","span":{"begin":36472,"end":36481},"obj":"Chemical"},{"id":"T371","span":{"begin":36482,"end":36491},"obj":"Chemical"},{"id":"T372","span":{"begin":36534,"end":36538},"obj":"Chemical"},{"id":"T373","span":{"begin":36540,"end":36559},"obj":"Chemical"},{"id":"T374","span":{"begin":36540,"end":36549},"obj":"Chemical"},{"id":"T375","span":{"begin":36550,"end":36559},"obj":"Chemical"},{"id":"T376","span":{"begin":36636,"end":36641},"obj":"Chemical"},{"id":"T377","span":{"begin":36756,"end":36765},"obj":"Chemical"},{"id":"T378","span":{"begin":36776,"end":36785},"obj":"Chemical"},{"id":"T379","span":{"begin":36795,"end":36800},"obj":"Chemical"},{"id":"T380","span":{"begin":36801,"end":36811},"obj":"Chemical"},{"id":"T381","span":{"begin":36868,"end":36873},"obj":"Chemical"},{"id":"T382","span":{"begin":36896,"end":36905},"obj":"Chemical"},{"id":"T383","span":{"begin":36906,"end":36915},"obj":"Chemical"},{"id":"T384","span":{"begin":36965,"end":36970},"obj":"Chemical"},{"id":"T385","span":{"begin":36971,"end":36981},"obj":"Chemical"},{"id":"T386","span":{"begin":37022,"end":37027},"obj":"Chemical"},{"id":"T387","span":{"begin":37140,"end":37149},"obj":"Chemical"},{"id":"T388","span":{"begin":37160,"end":37169},"obj":"Chemical"},{"id":"T389","span":{"begin":37179,"end":37184},"obj":"Chemical"},{"id":"T390","span":{"begin":37185,"end":37195},"obj":"Chemical"},{"id":"T391","span":{"begin":37629,"end":37640},"obj":"Chemical"},{"id":"T392","span":{"begin":37719,"end":37730},"obj":"Chemical"},{"id":"T393","span":{"begin":37732,"end":37736},"obj":"Chemical"},{"id":"T394","span":{"begin":37855,"end":37866},"obj":"Chemical"},{"id":"T395","span":{"begin":37892,"end":37896},"obj":"Chemical"},{"id":"T396","span":{"begin":37933,"end":37944},"obj":"Chemical"},{"id":"T397","span":{"begin":37945,"end":37959},"obj":"Chemical"},{"id":"T398","span":{"begin":37945,"end":37954},"obj":"Chemical"},{"id":"T402","span":{"begin":37955,"end":37959},"obj":"Chemical"},{"id":"T404","span":{"begin":38388,"end":38391},"obj":"Chemical"},{"id":"T405","span":{"begin":38633,"end":38637},"obj":"Chemical"},{"id":"T406","span":{"begin":38689,"end":38697},"obj":"Chemical"},{"id":"T407","span":{"begin":38733,"end":38741},"obj":"Chemical"},{"id":"T408","span":{"begin":38776,"end":38784},"obj":"Chemical"},{"id":"T409","span":{"begin":38867,"end":38872},"obj":"Chemical"},{"id":"T410","span":{"begin":38903,"end":38911},"obj":"Chemical"},{"id":"T411","span":{"begin":39090,"end":39098},"obj":"Chemical"},{"id":"T412","span":{"begin":39385,"end":39393},"obj":"Chemical"},{"id":"T413","span":{"begin":39601,"end":39606},"obj":"Chemical"},{"id":"T414","span":{"begin":39637,"end":39645},"obj":"Chemical"},{"id":"T415","span":{"begin":40050,"end":40058},"obj":"Chemical"},{"id":"T416","span":{"begin":40086,"end":40094},"obj":"Chemical"},{"id":"T417","span":{"begin":40289,"end":40297},"obj":"Chemical"},{"id":"T418","span":{"begin":40298,"end":40303},"obj":"Chemical"},{"id":"T419","span":{"begin":40334,"end":40342},"obj":"Chemical"},{"id":"T420","span":{"begin":40389,"end":40397},"obj":"Chemical"},{"id":"T421","span":{"begin":40470,"end":40478},"obj":"Chemical"},{"id":"T422","span":{"begin":40601,"end":40609},"obj":"Chemical"},{"id":"T423","span":{"begin":40696,"end":40704},"obj":"Chemical"},{"id":"T424","span":{"begin":40760,"end":40768},"obj":"Chemical"},{"id":"T425","span":{"begin":40877,"end":40885},"obj":"Chemical"},{"id":"T426","span":{"begin":40913,"end":40921},"obj":"Chemical"},{"id":"T427","span":{"begin":41067,"end":41069},"obj":"Chemical"},{"id":"T428","span":{"begin":41705,"end":41711},"obj":"Chemical"},{"id":"T429","span":{"begin":42623,"end":42647},"obj":"Chemical"},{"id":"T430","span":{"begin":42623,"end":42633},"obj":"Chemical"},{"id":"T431","span":{"begin":42634,"end":42647},"obj":"Chemical"},{"id":"T432","span":{"begin":42790,"end":42814},"obj":"Chemical"},{"id":"T433","span":{"begin":42790,"end":42800},"obj":"Chemical"},{"id":"T434","span":{"begin":42801,"end":42814},"obj":"Chemical"},{"id":"T435","span":{"begin":42824,"end":42828},"obj":"Chemical"},{"id":"T436","span":{"begin":42830,"end":42837},"obj":"Chemical"},{"id":"T437","span":{"begin":42838,"end":42851},"obj":"Chemical"},{"id":"T438","span":{"begin":42862,"end":42866},"obj":"Chemical"},{"id":"T439","span":{"begin":42886,"end":42896},"obj":"Chemical"},{"id":"T440","span":{"begin":42908,"end":42912},"obj":"Chemical"},{"id":"T441","span":{"begin":42914,"end":42925},"obj":"Chemical"},{"id":"T442","span":{"begin":43022,"end":43027},"obj":"Chemical"},{"id":"T443","span":{"begin":43040,"end":43045},"obj":"Chemical"},{"id":"T444","span":{"begin":43047,"end":43071},"obj":"Chemical"},{"id":"T445","span":{"begin":43058,"end":43071},"obj":"Chemical"},{"id":"T446","span":{"begin":43081,"end":43088},"obj":"Chemical"},{"id":"T447","span":{"begin":43089,"end":43102},"obj":"Chemical"},{"id":"T448","span":{"begin":43246,"end":43259},"obj":"Chemical"},{"id":"T449","span":{"begin":43326,"end":43336},"obj":"Chemical"},{"id":"T450","span":{"begin":43511,"end":43516},"obj":"Chemical"},{"id":"T451","span":{"begin":43527,"end":43532},"obj":"Chemical"},{"id":"T452","span":{"begin":43540,"end":43547},"obj":"Chemical"},{"id":"T453","span":{"begin":43548,"end":43561},"obj":"Chemical"},{"id":"T454","span":{"begin":43696,"end":43703},"obj":"Chemical"},{"id":"T455","span":{"begin":43704,"end":43717},"obj":"Chemical"},{"id":"T456","span":{"begin":43790,"end":43800},"obj":"Chemical"},{"id":"T457","span":{"begin":44343,"end":44349},"obj":"Chemical"},{"id":"T458","span":{"begin":44423,"end":44435},"obj":"Chemical"},{"id":"T459","span":{"begin":44431,"end":44435},"obj":"Chemical"},{"id":"T460","span":{"begin":44471,"end":44483},"obj":"Chemical"},{"id":"T461","span":{"begin":44479,"end":44483},"obj":"Chemical"},{"id":"T462","span":{"begin":44679,"end":44698},"obj":"Chemical"},{"id":"T464","span":{"begin":44688,"end":44698},"obj":"Chemical"},{"id":"T465","span":{"begin":44700,"end":44711},"obj":"Chemical"},{"id":"T466","span":{"begin":44713,"end":44724},"obj":"Chemical"},{"id":"T467","span":{"begin":44891,"end":44902},"obj":"Chemical"},{"id":"T468","span":{"begin":44935,"end":44946},"obj":"Chemical"},{"id":"T469","span":{"begin":45025,"end":45048},"obj":"Chemical"},{"id":"T470","span":{"begin":45025,"end":45034},"obj":"Chemical"},{"id":"T471","span":{"begin":45039,"end":45048},"obj":"Chemical"},{"id":"T472","span":{"begin":45054,"end":45065},"obj":"Chemical"},{"id":"T473","span":{"begin":45066,"end":45075},"obj":"Chemical"},{"id":"T474","span":{"begin":45089,"end":45098},"obj":"Chemical"},{"id":"T475","span":{"begin":45114,"end":45125},"obj":"Chemical"},{"id":"T476","span":{"begin":45257,"end":45280},"obj":"Chemical"},{"id":"T477","span":{"begin":45257,"end":45266},"obj":"Chemical"},{"id":"T478","span":{"begin":45271,"end":45280},"obj":"Chemical"},{"id":"T479","span":{"begin":45286,"end":45297},"obj":"Chemical"},{"id":"T31308","span":{"begin":45339,"end":45348},"obj":"Chemical"},{"id":"T26014","span":{"begin":45364,"end":45375},"obj":"Chemical"},{"id":"T28790","span":{"begin":45416,"end":45439},"obj":"Chemical"},{"id":"T43391","span":{"begin":45416,"end":45425},"obj":"Chemical"},{"id":"T42713","span":{"begin":45430,"end":45439},"obj":"Chemical"},{"id":"T89000","span":{"begin":45440,"end":45451},"obj":"Chemical"},{"id":"T36554","span":{"begin":45504,"end":45513},"obj":"Chemical"},{"id":"T16660","span":{"begin":45529,"end":45540},"obj":"Chemical"},{"id":"T77346","span":{"begin":45603,"end":45614},"obj":"Chemical"},{"id":"T18123","span":{"begin":45615,"end":45634},"obj":"Chemical"},{"id":"T7264","span":{"begin":45615,"end":45624},"obj":"Chemical"},{"id":"T88178","span":{"begin":45625,"end":45634},"obj":"Chemical"},{"id":"T33676","span":{"begin":45654,"end":45665},"obj":"Chemical"},{"id":"T63088","span":{"begin":45797,"end":45806},"obj":"Chemical"},{"id":"T27488","span":{"begin":45869,"end":45878},"obj":"Chemical"},{"id":"T45665","span":{"begin":45879,"end":45888},"obj":"Chemical"},{"id":"T78808","span":{"begin":45889,"end":45900},"obj":"Chemical"},{"id":"T99588","span":{"begin":45901,"end":45912},"obj":"Chemical"},{"id":"T5598","span":{"begin":45939,"end":45948},"obj":"Chemical"},{"id":"T87739","span":{"begin":45967,"end":45976},"obj":"Chemical"},{"id":"T81794","span":{"begin":46002,"end":46013},"obj":"Chemical"},{"id":"T65434","span":{"begin":46029,"end":46040},"obj":"Chemical"},{"id":"T38243","span":{"begin":46108,"end":46117},"obj":"Chemical"},{"id":"T52708","span":{"begin":46118,"end":46127},"obj":"Chemical"},{"id":"T13256","span":{"begin":46128,"end":46139},"obj":"Chemical"},{"id":"T90329","span":{"begin":46140,"end":46151},"obj":"Chemical"},{"id":"T83414","span":{"begin":46281,"end":46290},"obj":"Chemical"},{"id":"T8543","span":{"begin":46309,"end":46318},"obj":"Chemical"},{"id":"T86432","span":{"begin":46319,"end":46328},"obj":"Chemical"},{"id":"T81415","span":{"begin":46344,"end":46355},"obj":"Chemical"},{"id":"T48024","span":{"begin":47110,"end":47114},"obj":"Chemical"},{"id":"T82843","span":{"begin":47228,"end":47236},"obj":"Chemical"},{"id":"T97531","span":{"begin":47315,"end":47320},"obj":"Chemical"},{"id":"T34","span":{"begin":47472,"end":47480},"obj":"Chemical"},{"id":"T46725","span":{"begin":47981,"end":47986},"obj":"Chemical"},{"id":"T44374","span":{"begin":48399,"end":48401},"obj":"Chemical"},{"id":"T54831","span":{"begin":48511,"end":48517},"obj":"Chemical"},{"id":"T35025","span":{"begin":48703,"end":48709},"obj":"Chemical"},{"id":"T46910","span":{"begin":48870,"end":48876},"obj":"Chemical"},{"id":"T51952","span":{"begin":49209,"end":49213},"obj":"Chemical"},{"id":"T53408","span":{"begin":49439,"end":49444},"obj":"Chemical"},{"id":"T76646","span":{"begin":49589,"end":49594},"obj":"Chemical"},{"id":"T95398","span":{"begin":49603,"end":49608},"obj":"Chemical"},{"id":"T7063","span":{"begin":49751,"end":49756},"obj":"Chemical"},{"id":"T59274","span":{"begin":49787,"end":49792},"obj":"Chemical"},{"id":"T67786","span":{"begin":50436,"end":50442},"obj":"Chemical"},{"id":"T51571","span":{"begin":50628,"end":50633},"obj":"Chemical"},{"id":"T6125","span":{"begin":50675,"end":50689},"obj":"Chemical"},{"id":"T40279","span":{"begin":50675,"end":50684},"obj":"Chemical"},{"id":"T78450","span":{"begin":50685,"end":50689},"obj":"Chemical"},{"id":"T70786","span":{"begin":50708,"end":50714},"obj":"Chemical"},{"id":"T85333","span":{"begin":50800,"end":50805},"obj":"Chemical"},{"id":"T23407","span":{"begin":51025,"end":51030},"obj":"Chemical"},{"id":"T89303","span":{"begin":51065,"end":51070},"obj":"Chemical"},{"id":"T51321","span":{"begin":51122,"end":51136},"obj":"Chemical"},{"id":"T61015","span":{"begin":51122,"end":51131},"obj":"Chemical"},{"id":"T62050","span":{"begin":51132,"end":51136},"obj":"Chemical"},{"id":"T94802","span":{"begin":51155,"end":51161},"obj":"Chemical"},{"id":"T11085","span":{"begin":51279,"end":51285},"obj":"Chemical"},{"id":"T42076","span":{"begin":51378,"end":51384},"obj":"Chemical"},{"id":"T29380","span":{"begin":52244,"end":52251},"obj":"Chemical"},{"id":"T94147","span":{"begin":52253,"end":52267},"obj":"Chemical"},{"id":"T44009","span":{"begin":52446,"end":52452},"obj":"Chemical"},{"id":"T5062","span":{"begin":52486,"end":52492},"obj":"Chemical"},{"id":"T18722","span":{"begin":52525,"end":52531},"obj":"Chemical"},{"id":"T30228","span":{"begin":52659,"end":52661},"obj":"Chemical"},{"id":"T82071","span":{"begin":52704,"end":52708},"obj":"Chemical"},{"id":"T76124","span":{"begin":52780,"end":52782},"obj":"Chemical"},{"id":"T5320","span":{"begin":52841,"end":52843},"obj":"Chemical"},{"id":"T71040","span":{"begin":52846,"end":52851},"obj":"Chemical"},{"id":"T42282","span":{"begin":52857,"end":52859},"obj":"Chemical"},{"id":"T9670","span":{"begin":52880,"end":52882},"obj":"Chemical"},{"id":"T65756","span":{"begin":52916,"end":52921},"obj":"Chemical"},{"id":"T67187","span":{"begin":52990,"end":52995},"obj":"Chemical"},{"id":"T22212","span":{"begin":53013,"end":53015},"obj":"Chemical"},{"id":"T36692","span":{"begin":53140,"end":53142},"obj":"Chemical"},{"id":"T72462","span":{"begin":53423,"end":53434},"obj":"Chemical"},{"id":"T7025","span":{"begin":53684,"end":53692},"obj":"Chemical"},{"id":"T65846","span":{"begin":53961,"end":53966},"obj":"Chemical"},{"id":"T33991","span":{"begin":54135,"end":54141},"obj":"Chemical"},{"id":"T19624","span":{"begin":54399,"end":54405},"obj":"Chemical"},{"id":"T15741","span":{"begin":54560,"end":54562},"obj":"Chemical"},{"id":"T28024","span":{"begin":54567,"end":54569},"obj":"Chemical"},{"id":"T87","span":{"begin":54582,"end":54584},"obj":"Chemical"},{"id":"T26286","span":{"begin":54588,"end":54590},"obj":"Chemical"}],"attributes":[{"id":"A30352","pred":"chebi_id","subj":"T34382","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A40244","pred":"chebi_id","subj":"T9718","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A86185","pred":"chebi_id","subj":"T25818","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A18780","pred":"chebi_id","subj":"T79148","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A36720","pred":"chebi_id","subj":"T1524","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A69419","pred":"chebi_id","subj":"T65175","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A51503","pred":"chebi_id","subj":"T42271","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A42427","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A72432","pred":"chebi_id","subj":"T5227","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A83391","pred":"chebi_id","subj":"T89603","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A74762","pred":"chebi_id","subj":"T64472","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A30881","pred":"chebi_id","subj":"T16097","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A41384","pred":"chebi_id","subj":"T79085","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27764","pred":"chebi_id","subj":"T84596","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A49896","pred":"chebi_id","subj":"T22462","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A81107","pred":"chebi_id","subj":"T20379","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27789","pred":"chebi_id","subj":"T7585","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A96916","pred":"chebi_id","subj":"T86024","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A13695","pred":"chebi_id","subj":"T48066","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A80547","pred":"chebi_id","subj":"T54548","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A11733","pred":"chebi_id","subj":"T38531","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A42372","pred":"chebi_id","subj":"T17203","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A71151","pred":"chebi_id","subj":"T28054","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A53925","pred":"chebi_id","subj":"T1929","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A19036","pred":"chebi_id","subj":"T63564","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A76763","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A28792","pred":"chebi_id","subj":"T17269","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A71457","pred":"chebi_id","subj":"T17269","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A24972","pred":"chebi_id","subj":"T17269","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A10074","pred":"chebi_id","subj":"T19318","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A40133","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A52808","pred":"chebi_id","subj":"T24232","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A664","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A43577","pred":"chebi_id","subj":"T80419","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A27224","pred":"chebi_id","subj":"T30660","obj":"http://purl.obolibrary.org/obo/CHEBI_27584"},{"id":"A19463","pred":"chebi_id","subj":"T30660","obj":"http://purl.obolibrary.org/obo/CHEBI_30834"},{"id":"A66770","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A69015","pred":"chebi_id","subj":"T40933","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A1311","pred":"chebi_id","subj":"T73661","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A22271","pred":"chebi_id","subj":"T73661","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A13447","pred":"chebi_id","subj":"T54173","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A37791","pred":"chebi_id","subj":"T54173","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A13519","pred":"chebi_id","subj":"T70837","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A76574","pred":"chebi_id","subj":"T26545","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A23699","pred":"chebi_id","subj":"T22043","obj":"http://purl.obolibrary.org/obo/CHEBI_84123"},{"id":"A83744","pred":"chebi_id","subj":"T80881","obj":"http://purl.obolibrary.org/obo/CHEBI_35195"},{"id":"A66775","pred":"chebi_id","subj":"T41839","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A61051","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_133748"},{"id":"A18394","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_16947"},{"id":"A30512","pred":"chebi_id","subj":"T657","obj":"http://purl.obolibrary.org/obo/CHEBI_50744"},{"id":"A89545","pred":"chebi_id","subj":"T36666","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A63006","pred":"chebi_id","subj":"T59812","obj":"http://purl.obolibrary.org/obo/CHEBI_58987"},{"id":"A42763","pred":"chebi_id","subj":"T48299","obj":"http://purl.obolibrary.org/obo/CHEBI_9139"},{"id":"A46542","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_133748"},{"id":"A9226","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_16947"},{"id":"A98792","pred":"chebi_id","subj":"T80763","obj":"http://purl.obolibrary.org/obo/CHEBI_50744"},{"id":"A54910","pred":"chebi_id","subj":"T56768","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A42275","pred":"chebi_id","subj":"T36106","obj":"http://purl.obolibrary.org/obo/CHEBI_16480"},{"id":"A43987","pred":"chebi_id","subj":"T79701","obj":"http://purl.obolibrary.org/obo/CHEBI_25741"},{"id":"A13259","pred":"chebi_id","subj":"T79701","obj":"http://purl.obolibrary.org/obo/CHEBI_29356"},{"id":"A19196","pred":"chebi_id","subj":"T36153","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A10109","pred":"chebi_id","subj":"T54594","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A13376","pred":"chebi_id","subj":"T97769","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A84865","pred":"chebi_id","subj":"T20676","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A6712","pred":"chebi_id","subj":"T92853","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A3545","pred":"chebi_id","subj":"T46415","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A89179","pred":"chebi_id","subj":"T20639","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A41889","pred":"chebi_id","subj":"T47677","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A95585","pred":"chebi_id","subj":"T34447","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A91040","pred":"chebi_id","subj":"T27940","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A55626","pred":"chebi_id","subj":"T20411","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A94635","pred":"chebi_id","subj":"T71837","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A45465","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A80783","pred":"chebi_id","subj":"T12779","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A16005","pred":"chebi_id","subj":"T42223","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A7815","pred":"chebi_id","subj":"T53502","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A91479","pred":"chebi_id","subj":"T77554","obj":"http://purl.obolibrary.org/obo/CHEBI_16189"},{"id":"A51223","pred":"chebi_id","subj":"T82580","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A10452","pred":"chebi_id","subj":"T91739","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A58238","pred":"chebi_id","subj":"T7801","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A46920","pred":"chebi_id","subj":"T31954","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A84541","pred":"chebi_id","subj":"T56995","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A93651","pred":"chebi_id","subj":"T74129","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A90992","pred":"chebi_id","subj":"T14779","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A51026","pred":"chebi_id","subj":"T75588","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A22134","pred":"chebi_id","subj":"T41134","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A38777","pred":"chebi_id","subj":"T71387","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A20970","pred":"chebi_id","subj":"T58068","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A27687","pred":"chebi_id","subj":"T12331","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A95323","pred":"chebi_id","subj":"T50748","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_73516"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A164","pred":"chebi_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/CHEBI_73516"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A167","pred":"chebi_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A168","pred":"chebi_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A169","pred":"chebi_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A170","pred":"chebi_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A172","pred":"chebi_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A173","pred":"chebi_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"},{"id":"A174","pred":"chebi_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A175","pred":"chebi_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A176","pred":"chebi_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A177","pred":"chebi_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A178","pred":"chebi_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A179","pred":"chebi_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A180","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A181","pred":"chebi_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A182","pred":"chebi_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A184","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A186","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A188","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A190","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A191","pred":"chebi_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_24621"},{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A197","pred":"chebi_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A199","pred":"chebi_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A200","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A201","pred":"chebi_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A202","pred":"chebi_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A208","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A209","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A211","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A213","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A215","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A217","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A218","pred":"chebi_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/CHEBI_49"},{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_49"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_50853"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_63115"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_63115"},{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_141393"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A235","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A236","pred":"chebi_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A237","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A238","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A240","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A241","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A242","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A246","pred":"chebi_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A247","pred":"chebi_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A248","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A249","pred":"chebi_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A251","pred":"chebi_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A252","pred":"chebi_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A257","pred":"chebi_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A258","pred":"chebi_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A259","pred":"chebi_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A260","pred":"chebi_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A261","pred":"chebi_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A262","pred":"chebi_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A263","pred":"chebi_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A264","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A265","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A266","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A267","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A268","pred":"chebi_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A269","pred":"chebi_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A270","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A271","pred":"chebi_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A272","pred":"chebi_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A273","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A274","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A275","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A276","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A277","pred":"chebi_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A278","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A279","pred":"chebi_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A280","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A281","pred":"chebi_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A283","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A284","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A285","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A286","pred":"chebi_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A287","pred":"chebi_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A288","pred":"chebi_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A289","pred":"chebi_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A291","pred":"chebi_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A293","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A294","pred":"chebi_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A295","pred":"chebi_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A296","pred":"chebi_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A297","pred":"chebi_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A298","pred":"chebi_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A299","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A300","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A301","pred":"chebi_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A302","pred":"chebi_id","subj":"T302","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A303","pred":"chebi_id","subj":"T303","obj":"http://purl.obolibrary.org/obo/CHEBI_35143"},{"id":"A304","pred":"chebi_id","subj":"T304","obj":"http://purl.obolibrary.org/obo/CHEBI_16737"},{"id":"A305","pred":"chebi_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_16449"},{"id":"A307","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A308","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A309","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"},{"id":"A310","pred":"chebi_id","subj":"T310","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A311","pred":"chebi_id","subj":"T311","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A312","pred":"chebi_id","subj":"T312","obj":"http://purl.obolibrary.org/obo/CHEBI_73510"},{"id":"A313","pred":"chebi_id","subj":"T313","obj":"http://purl.obolibrary.org/obo/CHEBI_73510"},{"id":"A314","pred":"chebi_id","subj":"T314","obj":"http://purl.obolibrary.org/obo/CHEBI_73579"},{"id":"A315","pred":"chebi_id","subj":"T315","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A316","pred":"chebi_id","subj":"T316","obj":"http://purl.obolibrary.org/obo/CHEBI_73579"},{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A322","pred":"chebi_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A323","pred":"chebi_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A334","pred":"chebi_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A335","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A336","pred":"chebi_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/CHEBI_50846"},{"id":"A337","pred":"chebi_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A338","pred":"chebi_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A339","pred":"chebi_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A340","pred":"chebi_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A341","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_137431"},{"id":"A342","pred":"chebi_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A343","pred":"chebi_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A344","pred":"chebi_id","subj":"T344","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A345","pred":"chebi_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A346","pred":"chebi_id","subj":"T346","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A347","pred":"chebi_id","subj":"T347","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A348","pred":"chebi_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"},{"id":"A349","pred":"chebi_id","subj":"T349","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A350","pred":"chebi_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A351","pred":"chebi_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A352","pred":"chebi_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A353","pred":"chebi_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A354","pred":"chebi_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A355","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A356","pred":"chebi_id","subj":"T356","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A357","pred":"chebi_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A358","pred":"chebi_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A359","pred":"chebi_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A360","pred":"chebi_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A361","pred":"chebi_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A362","pred":"chebi_id","subj":"T362","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A363","pred":"chebi_id","subj":"T363","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A364","pred":"chebi_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A365","pred":"chebi_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A366","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A367","pred":"chebi_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"},{"id":"A368","pred":"chebi_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A372","pred":"chebi_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A373","pred":"chebi_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A374","pred":"chebi_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A375","pred":"chebi_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A380","pred":"chebi_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A381","pred":"chebi_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A382","pred":"chebi_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A383","pred":"chebi_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A384","pred":"chebi_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A385","pred":"chebi_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A386","pred":"chebi_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A387","pred":"chebi_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A388","pred":"chebi_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A389","pred":"chebi_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A390","pred":"chebi_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A391","pred":"chebi_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A392","pred":"chebi_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A393","pred":"chebi_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A394","pred":"chebi_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A395","pred":"chebi_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/CHEBI_22695"},{"id":"A396","pred":"chebi_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A397","pred":"chebi_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/CHEBI_37853"},{"id":"A398","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A399","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A400","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A401","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A402","pred":"chebi_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/CHEBI_24866"},{"id":"A403","pred":"chebi_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A404","pred":"chebi_id","subj":"T404","obj":"http://purl.obolibrary.org/obo/CHEBI_35640"},{"id":"A405","pred":"chebi_id","subj":"T405","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A406","pred":"chebi_id","subj":"T406","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A407","pred":"chebi_id","subj":"T407","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A408","pred":"chebi_id","subj":"T408","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A409","pred":"chebi_id","subj":"T409","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A410","pred":"chebi_id","subj":"T410","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A411","pred":"chebi_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A412","pred":"chebi_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A413","pred":"chebi_id","subj":"T413","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A414","pred":"chebi_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A415","pred":"chebi_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A416","pred":"chebi_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A417","pred":"chebi_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A418","pred":"chebi_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A419","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A420","pred":"chebi_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A421","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A422","pred":"chebi_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A423","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A424","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A425","pred":"chebi_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A426","pred":"chebi_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A427","pred":"chebi_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A428","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A429","pred":"chebi_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/CHEBI_31303"},{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_77032"},{"id":"A431","pred":"chebi_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A432","pred":"chebi_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/CHEBI_31303"},{"id":"A433","pred":"chebi_id","subj":"T433","obj":"http://purl.obolibrary.org/obo/CHEBI_77032"},{"id":"A434","pred":"chebi_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A435","pred":"chebi_id","subj":"T435","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A436","pred":"chebi_id","subj":"T436","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A437","pred":"chebi_id","subj":"T437","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A438","pred":"chebi_id","subj":"T438","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A439","pred":"chebi_id","subj":"T439","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A440","pred":"chebi_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A441","pred":"chebi_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A442","pred":"chebi_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A443","pred":"chebi_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A444","pred":"chebi_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/CHEBI_31303"},{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A446","pred":"chebi_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A448","pred":"chebi_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A449","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A450","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A451","pred":"chebi_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A452","pred":"chebi_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A453","pred":"chebi_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A454","pred":"chebi_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A455","pred":"chebi_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/CHEBI_36807"},{"id":"A456","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A457","pred":"chebi_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A458","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A459","pred":"chebi_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A460","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A461","pred":"chebi_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A463","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A464","pred":"chebi_id","subj":"T464","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A465","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A466","pred":"chebi_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A468","pred":"chebi_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A469","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A470","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A471","pred":"chebi_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A472","pred":"chebi_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A473","pred":"chebi_id","subj":"T473","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A474","pred":"chebi_id","subj":"T474","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A475","pred":"chebi_id","subj":"T475","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A476","pred":"chebi_id","subj":"T476","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A477","pred":"chebi_id","subj":"T477","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A478","pred":"chebi_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A479","pred":"chebi_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A93999","pred":"chebi_id","subj":"T31308","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A83107","pred":"chebi_id","subj":"T26014","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A85602","pred":"chebi_id","subj":"T28790","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A69535","pred":"chebi_id","subj":"T43391","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A80149","pred":"chebi_id","subj":"T42713","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A32528","pred":"chebi_id","subj":"T89000","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A57945","pred":"chebi_id","subj":"T36554","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A28391","pred":"chebi_id","subj":"T16660","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A16134","pred":"chebi_id","subj":"T77346","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A8312","pred":"chebi_id","subj":"T18123","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A61384","pred":"chebi_id","subj":"T7264","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A76988","pred":"chebi_id","subj":"T88178","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A51928","pred":"chebi_id","subj":"T33676","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A12511","pred":"chebi_id","subj":"T63088","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A63076","pred":"chebi_id","subj":"T27488","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A78515","pred":"chebi_id","subj":"T45665","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A2535","pred":"chebi_id","subj":"T78808","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A9068","pred":"chebi_id","subj":"T99588","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A33969","pred":"chebi_id","subj":"T5598","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A27405","pred":"chebi_id","subj":"T87739","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A57391","pred":"chebi_id","subj":"T81794","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A32059","pred":"chebi_id","subj":"T65434","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A36327","pred":"chebi_id","subj":"T38243","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A68996","pred":"chebi_id","subj":"T52708","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A72141","pred":"chebi_id","subj":"T13256","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A96867","pred":"chebi_id","subj":"T90329","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A43581","pred":"chebi_id","subj":"T83414","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A98850","pred":"chebi_id","subj":"T8543","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A71807","pred":"chebi_id","subj":"T86432","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A71838","pred":"chebi_id","subj":"T81415","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A15174","pred":"chebi_id","subj":"T48024","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A84916","pred":"chebi_id","subj":"T82843","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27866","pred":"chebi_id","subj":"T97531","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A11464","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A82627","pred":"chebi_id","subj":"T46725","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A72421","pred":"chebi_id","subj":"T44374","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A59078","pred":"chebi_id","subj":"T54831","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A37148","pred":"chebi_id","subj":"T35025","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A66525","pred":"chebi_id","subj":"T46910","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A74944","pred":"chebi_id","subj":"T51952","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A54911","pred":"chebi_id","subj":"T53408","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A82974","pred":"chebi_id","subj":"T76646","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A59740","pred":"chebi_id","subj":"T95398","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A25146","pred":"chebi_id","subj":"T7063","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A59057","pred":"chebi_id","subj":"T59274","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A43462","pred":"chebi_id","subj":"T67786","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A41831","pred":"chebi_id","subj":"T51571","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A42079","pred":"chebi_id","subj":"T6125","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A54312","pred":"chebi_id","subj":"T40279","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A42643","pred":"chebi_id","subj":"T78450","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A67689","pred":"chebi_id","subj":"T70786","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A82044","pred":"chebi_id","subj":"T85333","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A22673","pred":"chebi_id","subj":"T23407","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A59398","pred":"chebi_id","subj":"T89303","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A58810","pred":"chebi_id","subj":"T51321","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A7785","pred":"chebi_id","subj":"T61015","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A97216","pred":"chebi_id","subj":"T62050","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A74093","pred":"chebi_id","subj":"T94802","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A82712","pred":"chebi_id","subj":"T11085","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A70889","pred":"chebi_id","subj":"T42076","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A84009","pred":"chebi_id","subj":"T29380","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A15944","pred":"chebi_id","subj":"T94147","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"},{"id":"A62978","pred":"chebi_id","subj":"T44009","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A4341","pred":"chebi_id","subj":"T5062","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A28129","pred":"chebi_id","subj":"T18722","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A66048","pred":"chebi_id","subj":"T30228","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A36718","pred":"chebi_id","subj":"T82071","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A59947","pred":"chebi_id","subj":"T76124","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A17449","pred":"chebi_id","subj":"T5320","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A5860","pred":"chebi_id","subj":"T71040","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A65351","pred":"chebi_id","subj":"T42282","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A83729","pred":"chebi_id","subj":"T9670","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A10914","pred":"chebi_id","subj":"T65756","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A21136","pred":"chebi_id","subj":"T67187","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A96130","pred":"chebi_id","subj":"T22212","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A8637","pred":"chebi_id","subj":"T36692","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A69530","pred":"chebi_id","subj":"T36692","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A91289","pred":"chebi_id","subj":"T72462","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A85121","pred":"chebi_id","subj":"T7025","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A53798","pred":"chebi_id","subj":"T65846","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A92500","pred":"chebi_id","subj":"T33991","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A85142","pred":"chebi_id","subj":"T19624","obj":"http://purl.obolibrary.org/obo/CHEBI_37409"},{"id":"A75184","pred":"chebi_id","subj":"T15741","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A55525","pred":"chebi_id","subj":"T15741","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A91342","pred":"chebi_id","subj":"T28024","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A7907","pred":"chebi_id","subj":"T28024","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A63351","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A8496","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A70323","pred":"chebi_id","subj":"T26286","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A86569","pred":"chebi_id","subj":"T26286","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T35","span":{"begin":2887,"end":2895},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T36","span":{"begin":2887,"end":2895},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T37","span":{"begin":2887,"end":2895},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T38","span":{"begin":2887,"end":2895},"obj":"http://purl.obolibrary.org/obo/GO_0001906"},{"id":"T39","span":{"begin":2949,"end":2970},"obj":"http://purl.obolibrary.org/obo/GO_0031639"},{"id":"T40","span":{"begin":3054,"end":3062},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T41","span":{"begin":3054,"end":3062},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T42","span":{"begin":3054,"end":3062},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T43","span":{"begin":3054,"end":3062},"obj":"http://purl.obolibrary.org/obo/GO_0001906"},{"id":"T44","span":{"begin":6138,"end":6148},"obj":"http://purl.obolibrary.org/obo/GO_0046903"},{"id":"T45","span":{"begin":18364,"end":18376},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T46","span":{"begin":21556,"end":21572},"obj":"http://purl.obolibrary.org/obo/GO_0002524"},{"id":"T47","span":{"begin":23335,"end":23347},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T48","span":{"begin":25148,"end":25160},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-sentences","denotations":[{"id":"T601","span":{"begin":0,"end":51},"obj":"Sentence"},{"id":"T602","span":{"begin":52,"end":194},"obj":"Sentence"},{"id":"T603","span":{"begin":195,"end":273},"obj":"Sentence"},{"id":"T604","span":{"begin":274,"end":428},"obj":"Sentence"},{"id":"T605","span":{"begin":429,"end":515},"obj":"Sentence"},{"id":"T606","span":{"begin":516,"end":815},"obj":"Sentence"},{"id":"T607","span":{"begin":816,"end":1168},"obj":"Sentence"},{"id":"T608","span":{"begin":1169,"end":1309},"obj":"Sentence"},{"id":"T609","span":{"begin":1310,"end":1377},"obj":"Sentence"},{"id":"T610","span":{"begin":1378,"end":1490},"obj":"Sentence"},{"id":"T611","span":{"begin":1491,"end":1614},"obj":"Sentence"},{"id":"T612","span":{"begin":1615,"end":1760},"obj":"Sentence"},{"id":"T613","span":{"begin":1761,"end":1868},"obj":"Sentence"},{"id":"T614","span":{"begin":1869,"end":1991},"obj":"Sentence"},{"id":"T615","span":{"begin":1992,"end":2047},"obj":"Sentence"},{"id":"T616","span":{"begin":2048,"end":2169},"obj":"Sentence"},{"id":"T617","span":{"begin":2170,"end":3334},"obj":"Sentence"},{"id":"T618","span":{"begin":3335,"end":3626},"obj":"Sentence"},{"id":"T619","span":{"begin":3627,"end":3902},"obj":"Sentence"},{"id":"T620","span":{"begin":3903,"end":3949},"obj":"Sentence"},{"id":"T621","span":{"begin":3950,"end":4242},"obj":"Sentence"},{"id":"T622","span":{"begin":4243,"end":4589},"obj":"Sentence"},{"id":"T623","span":{"begin":4590,"end":4789},"obj":"Sentence"},{"id":"T624","span":{"begin":4790,"end":4972},"obj":"Sentence"},{"id":"T625","span":{"begin":4973,"end":4999},"obj":"Sentence"},{"id":"T626","span":{"begin":5000,"end":5016},"obj":"Sentence"},{"id":"T627","span":{"begin":5017,"end":5252},"obj":"Sentence"},{"id":"T628","span":{"begin":5253,"end":5698},"obj":"Sentence"},{"id":"T629","span":{"begin":5699,"end":5813},"obj":"Sentence"},{"id":"T630","span":{"begin":5814,"end":5852},"obj":"Sentence"},{"id":"T631","span":{"begin":5853,"end":6043},"obj":"Sentence"},{"id":"T632","span":{"begin":6044,"end":6452},"obj":"Sentence"},{"id":"T633","span":{"begin":6453,"end":6776},"obj":"Sentence"},{"id":"T634","span":{"begin":6777,"end":6867},"obj":"Sentence"},{"id":"T635","span":{"begin":6868,"end":6999},"obj":"Sentence"},{"id":"T636","span":{"begin":7000,"end":7655},"obj":"Sentence"},{"id":"T637","span":{"begin":7656,"end":8084},"obj":"Sentence"},{"id":"T638","span":{"begin":8085,"end":8382},"obj":"Sentence"},{"id":"T639","span":{"begin":8383,"end":8568},"obj":"Sentence"},{"id":"T640","span":{"begin":8569,"end":9025},"obj":"Sentence"},{"id":"T641","span":{"begin":9026,"end":9217},"obj":"Sentence"},{"id":"T642","span":{"begin":9218,"end":9519},"obj":"Sentence"},{"id":"T643","span":{"begin":9520,"end":9698},"obj":"Sentence"},{"id":"T644","span":{"begin":9699,"end":9754},"obj":"Sentence"},{"id":"T645","span":{"begin":9755,"end":9961},"obj":"Sentence"},{"id":"T646","span":{"begin":9962,"end":10238},"obj":"Sentence"},{"id":"T647","span":{"begin":10239,"end":10299},"obj":"Sentence"},{"id":"T648","span":{"begin":10300,"end":10421},"obj":"Sentence"},{"id":"T649","span":{"begin":10422,"end":10545},"obj":"Sentence"},{"id":"T650","span":{"begin":10546,"end":11184},"obj":"Sentence"},{"id":"T651","span":{"begin":11185,"end":11621},"obj":"Sentence"},{"id":"T652","span":{"begin":11622,"end":11655},"obj":"Sentence"},{"id":"T653","span":{"begin":11656,"end":11681},"obj":"Sentence"},{"id":"T654","span":{"begin":11682,"end":11918},"obj":"Sentence"},{"id":"T655","span":{"begin":11919,"end":11956},"obj":"Sentence"},{"id":"T656","span":{"begin":11957,"end":12039},"obj":"Sentence"},{"id":"T657","span":{"begin":12040,"end":12787},"obj":"Sentence"},{"id":"T658","span":{"begin":12788,"end":13069},"obj":"Sentence"},{"id":"T659","span":{"begin":13070,"end":13294},"obj":"Sentence"},{"id":"T660","span":{"begin":13295,"end":13553},"obj":"Sentence"},{"id":"T661","span":{"begin":13554,"end":13712},"obj":"Sentence"},{"id":"T662","span":{"begin":13713,"end":14039},"obj":"Sentence"},{"id":"T663","span":{"begin":14040,"end":14314},"obj":"Sentence"},{"id":"T664","span":{"begin":14315,"end":14794},"obj":"Sentence"},{"id":"T665","span":{"begin":14795,"end":15070},"obj":"Sentence"},{"id":"T666","span":{"begin":15071,"end":15137},"obj":"Sentence"},{"id":"T667","span":{"begin":15138,"end":15308},"obj":"Sentence"},{"id":"T668","span":{"begin":15309,"end":15377},"obj":"Sentence"},{"id":"T669","span":{"begin":15378,"end":15734},"obj":"Sentence"},{"id":"T670","span":{"begin":15735,"end":15903},"obj":"Sentence"},{"id":"T671","span":{"begin":15904,"end":15945},"obj":"Sentence"},{"id":"T672","span":{"begin":15946,"end":16023},"obj":"Sentence"},{"id":"T673","span":{"begin":16024,"end":16244},"obj":"Sentence"},{"id":"T674","span":{"begin":16245,"end":16433},"obj":"Sentence"},{"id":"T675","span":{"begin":16434,"end":16607},"obj":"Sentence"},{"id":"T676","span":{"begin":16608,"end":17039},"obj":"Sentence"},{"id":"T677","span":{"begin":17040,"end":17417},"obj":"Sentence"},{"id":"T678","span":{"begin":17418,"end":17870},"obj":"Sentence"},{"id":"T679","span":{"begin":17871,"end":18137},"obj":"Sentence"},{"id":"T680","span":{"begin":18138,"end":18550},"obj":"Sentence"},{"id":"T681","span":{"begin":18551,"end":18759},"obj":"Sentence"},{"id":"T682","span":{"begin":18760,"end":18868},"obj":"Sentence"},{"id":"T683","span":{"begin":18869,"end":19059},"obj":"Sentence"},{"id":"T684","span":{"begin":19060,"end":19338},"obj":"Sentence"},{"id":"T685","span":{"begin":19339,"end":19366},"obj":"Sentence"},{"id":"T686","span":{"begin":19367,"end":19455},"obj":"Sentence"},{"id":"T687","span":{"begin":19456,"end":19483},"obj":"Sentence"},{"id":"T688","span":{"begin":19484,"end":19780},"obj":"Sentence"},{"id":"T689","span":{"begin":19781,"end":21872},"obj":"Sentence"},{"id":"T690","span":{"begin":21873,"end":22305},"obj":"Sentence"},{"id":"T691","span":{"begin":22306,"end":22666},"obj":"Sentence"},{"id":"T692","span":{"begin":22667,"end":23109},"obj":"Sentence"},{"id":"T693","span":{"begin":23110,"end":23576},"obj":"Sentence"},{"id":"T694","span":{"begin":23577,"end":23909},"obj":"Sentence"},{"id":"T695","span":{"begin":23910,"end":24122},"obj":"Sentence"},{"id":"T696","span":{"begin":24123,"end":24133},"obj":"Sentence"},{"id":"T697","span":{"begin":24134,"end":24274},"obj":"Sentence"},{"id":"T698","span":{"begin":24275,"end":24659},"obj":"Sentence"},{"id":"T699","span":{"begin":24660,"end":24672},"obj":"Sentence"},{"id":"T700","span":{"begin":24673,"end":24811},"obj":"Sentence"},{"id":"T701","span":{"begin":24812,"end":24833},"obj":"Sentence"},{"id":"T702","span":{"begin":24834,"end":25325},"obj":"Sentence"},{"id":"T703","span":{"begin":25326,"end":25571},"obj":"Sentence"},{"id":"T704","span":{"begin":25572,"end":25603},"obj":"Sentence"},{"id":"T705","span":{"begin":25604,"end":25669},"obj":"Sentence"},{"id":"T706","span":{"begin":25670,"end":25699},"obj":"Sentence"},{"id":"T707","span":{"begin":25700,"end":25842},"obj":"Sentence"},{"id":"T708","span":{"begin":25843,"end":25894},"obj":"Sentence"},{"id":"T709","span":{"begin":25895,"end":26616},"obj":"Sentence"},{"id":"T710","span":{"begin":26617,"end":26661},"obj":"Sentence"},{"id":"T711","span":{"begin":26662,"end":27077},"obj":"Sentence"},{"id":"T712","span":{"begin":27078,"end":27390},"obj":"Sentence"},{"id":"T713","span":{"begin":27391,"end":27507},"obj":"Sentence"},{"id":"T714","span":{"begin":27508,"end":27678},"obj":"Sentence"},{"id":"T715","span":{"begin":27679,"end":27915},"obj":"Sentence"},{"id":"T716","span":{"begin":27916,"end":27972},"obj":"Sentence"},{"id":"T717","span":{"begin":27973,"end":28000},"obj":"Sentence"},{"id":"T718","span":{"begin":28001,"end":28085},"obj":"Sentence"},{"id":"T719","span":{"begin":28086,"end":28114},"obj":"Sentence"},{"id":"T720","span":{"begin":28115,"end":28141},"obj":"Sentence"},{"id":"T721","span":{"begin":28142,"end":28302},"obj":"Sentence"},{"id":"T722","span":{"begin":28303,"end":28489},"obj":"Sentence"},{"id":"T723","span":{"begin":28490,"end":28511},"obj":"Sentence"},{"id":"T724","span":{"begin":28512,"end":28625},"obj":"Sentence"},{"id":"T725","span":{"begin":28626,"end":28650},"obj":"Sentence"},{"id":"T726","span":{"begin":28651,"end":28677},"obj":"Sentence"},{"id":"T727","span":{"begin":28678,"end":29300},"obj":"Sentence"},{"id":"T728","span":{"begin":29301,"end":29434},"obj":"Sentence"},{"id":"T729","span":{"begin":29435,"end":29528},"obj":"Sentence"},{"id":"T730","span":{"begin":29529,"end":29612},"obj":"Sentence"},{"id":"T731","span":{"begin":29613,"end":29623},"obj":"Sentence"},{"id":"T732","span":{"begin":29624,"end":29778},"obj":"Sentence"},{"id":"T733","span":{"begin":29779,"end":29829},"obj":"Sentence"},{"id":"T734","span":{"begin":29830,"end":29840},"obj":"Sentence"},{"id":"T735","span":{"begin":29841,"end":30278},"obj":"Sentence"},{"id":"T736","span":{"begin":30279,"end":30497},"obj":"Sentence"},{"id":"T737","span":{"begin":30498,"end":30595},"obj":"Sentence"},{"id":"T738","span":{"begin":30596,"end":30623},"obj":"Sentence"},{"id":"T739","span":{"begin":30624,"end":30723},"obj":"Sentence"},{"id":"T740","span":{"begin":30724,"end":30783},"obj":"Sentence"},{"id":"T741","span":{"begin":30784,"end":31133},"obj":"Sentence"},{"id":"T742","span":{"begin":31134,"end":31314},"obj":"Sentence"},{"id":"T743","span":{"begin":31315,"end":31357},"obj":"Sentence"},{"id":"T744","span":{"begin":31358,"end":31381},"obj":"Sentence"},{"id":"T745","span":{"begin":31382,"end":31430},"obj":"Sentence"},{"id":"T746","span":{"begin":31431,"end":31499},"obj":"Sentence"},{"id":"T747","span":{"begin":31500,"end":31527},"obj":"Sentence"},{"id":"T748","span":{"begin":31528,"end":31595},"obj":"Sentence"},{"id":"T749","span":{"begin":31596,"end":31776},"obj":"Sentence"},{"id":"T750","span":{"begin":31777,"end":31805},"obj":"Sentence"},{"id":"T751","span":{"begin":31806,"end":31871},"obj":"Sentence"},{"id":"T752","span":{"begin":31872,"end":31903},"obj":"Sentence"},{"id":"T753","span":{"begin":31904,"end":31969},"obj":"Sentence"},{"id":"T754","span":{"begin":31970,"end":32106},"obj":"Sentence"},{"id":"T755","span":{"begin":32107,"end":32142},"obj":"Sentence"},{"id":"T756","span":{"begin":32143,"end":32214},"obj":"Sentence"},{"id":"T757","span":{"begin":32215,"end":33105},"obj":"Sentence"},{"id":"T758","span":{"begin":33106,"end":33149},"obj":"Sentence"},{"id":"T759","span":{"begin":33150,"end":33805},"obj":"Sentence"},{"id":"T760","span":{"begin":33806,"end":34076},"obj":"Sentence"},{"id":"T761","span":{"begin":34077,"end":34089},"obj":"Sentence"},{"id":"T762","span":{"begin":34090,"end":34198},"obj":"Sentence"},{"id":"T763","span":{"begin":34199,"end":34277},"obj":"Sentence"},{"id":"T764","span":{"begin":34278,"end":34354},"obj":"Sentence"},{"id":"T765","span":{"begin":34355,"end":34542},"obj":"Sentence"},{"id":"T766","span":{"begin":34543,"end":34564},"obj":"Sentence"},{"id":"T767","span":{"begin":34565,"end":34656},"obj":"Sentence"},{"id":"T768","span":{"begin":34657,"end":34693},"obj":"Sentence"},{"id":"T769","span":{"begin":34694,"end":34802},"obj":"Sentence"},{"id":"T770","span":{"begin":34803,"end":34880},"obj":"Sentence"},{"id":"T771","span":{"begin":34881,"end":34917},"obj":"Sentence"},{"id":"T772","span":{"begin":34918,"end":34981},"obj":"Sentence"},{"id":"T773","span":{"begin":34982,"end":35169},"obj":"Sentence"},{"id":"T774","span":{"begin":35170,"end":35320},"obj":"Sentence"},{"id":"T775","span":{"begin":35321,"end":35339},"obj":"Sentence"},{"id":"T776","span":{"begin":35340,"end":35382},"obj":"Sentence"},{"id":"T777","span":{"begin":35383,"end":35752},"obj":"Sentence"},{"id":"T778","span":{"begin":35753,"end":35973},"obj":"Sentence"},{"id":"T779","span":{"begin":35974,"end":36070},"obj":"Sentence"},{"id":"T780","span":{"begin":36071,"end":36120},"obj":"Sentence"},{"id":"T781","span":{"begin":36121,"end":36131},"obj":"Sentence"},{"id":"T782","span":{"begin":36132,"end":36310},"obj":"Sentence"},{"id":"T783","span":{"begin":36311,"end":36663},"obj":"Sentence"},{"id":"T784","span":{"begin":36664,"end":36840},"obj":"Sentence"},{"id":"T785","span":{"begin":36841,"end":36895},"obj":"Sentence"},{"id":"T786","span":{"begin":36896,"end":36994},"obj":"Sentence"},{"id":"T787","span":{"begin":36995,"end":37047},"obj":"Sentence"},{"id":"T788","span":{"begin":37048,"end":37249},"obj":"Sentence"},{"id":"T789","span":{"begin":37250,"end":37342},"obj":"Sentence"},{"id":"T790","span":{"begin":37343,"end":37514},"obj":"Sentence"},{"id":"T791","span":{"begin":37515,"end":37534},"obj":"Sentence"},{"id":"T792","span":{"begin":37535,"end":37555},"obj":"Sentence"},{"id":"T793","span":{"begin":37556,"end":37576},"obj":"Sentence"},{"id":"T794","span":{"begin":37577,"end":37628},"obj":"Sentence"},{"id":"T795","span":{"begin":37629,"end":37867},"obj":"Sentence"},{"id":"T796","span":{"begin":37868,"end":37987},"obj":"Sentence"},{"id":"T797","span":{"begin":37988,"end":38066},"obj":"Sentence"},{"id":"T798","span":{"begin":38067,"end":38108},"obj":"Sentence"},{"id":"T799","span":{"begin":38109,"end":38144},"obj":"Sentence"},{"id":"T800","span":{"begin":38145,"end":38413},"obj":"Sentence"},{"id":"T801","span":{"begin":38414,"end":38445},"obj":"Sentence"},{"id":"T802","span":{"begin":38446,"end":38534},"obj":"Sentence"},{"id":"T803","span":{"begin":38535,"end":38607},"obj":"Sentence"},{"id":"T804","span":{"begin":38608,"end":38638},"obj":"Sentence"},{"id":"T805","span":{"begin":38639,"end":38680},"obj":"Sentence"},{"id":"T806","span":{"begin":38681,"end":38840},"obj":"Sentence"},{"id":"T807","span":{"begin":38841,"end":38872},"obj":"Sentence"},{"id":"T808","span":{"begin":38873,"end":38996},"obj":"Sentence"},{"id":"T809","span":{"begin":38997,"end":39002},"obj":"Sentence"},{"id":"T810","span":{"begin":39003,"end":39184},"obj":"Sentence"},{"id":"T811","span":{"begin":39185,"end":39293},"obj":"Sentence"},{"id":"T812","span":{"begin":39294,"end":39360},"obj":"Sentence"},{"id":"T813","span":{"begin":39361,"end":39547},"obj":"Sentence"},{"id":"T814","span":{"begin":39548,"end":39567},"obj":"Sentence"},{"id":"T815","span":{"begin":39568,"end":39606},"obj":"Sentence"},{"id":"T816","span":{"begin":39607,"end":39741},"obj":"Sentence"},{"id":"T817","span":{"begin":39742,"end":39747},"obj":"Sentence"},{"id":"T818","span":{"begin":39748,"end":39859},"obj":"Sentence"},{"id":"T819","span":{"begin":39860,"end":39958},"obj":"Sentence"},{"id":"T820","span":{"begin":39959,"end":40025},"obj":"Sentence"},{"id":"T821","span":{"begin":40026,"end":40238},"obj":"Sentence"},{"id":"T822","span":{"begin":40239,"end":40303},"obj":"Sentence"},{"id":"T823","span":{"begin":40304,"end":40443},"obj":"Sentence"},{"id":"T824","span":{"begin":40444,"end":40588},"obj":"Sentence"},{"id":"T825","span":{"begin":40589,"end":40680},"obj":"Sentence"},{"id":"T826","span":{"begin":40681,"end":40687},"obj":"Sentence"},{"id":"T827","span":{"begin":40688,"end":40714},"obj":"Sentence"},{"id":"T828","span":{"begin":40715,"end":40852},"obj":"Sentence"},{"id":"T829","span":{"begin":40853,"end":40895},"obj":"Sentence"},{"id":"T830","span":{"begin":40896,"end":41069},"obj":"Sentence"},{"id":"T831","span":{"begin":41070,"end":41099},"obj":"Sentence"},{"id":"T832","span":{"begin":41100,"end":41127},"obj":"Sentence"},{"id":"T833","span":{"begin":41128,"end":41154},"obj":"Sentence"},{"id":"T834","span":{"begin":41155,"end":41662},"obj":"Sentence"},{"id":"T835","span":{"begin":41663,"end":41962},"obj":"Sentence"},{"id":"T836","span":{"begin":41963,"end":42096},"obj":"Sentence"},{"id":"T837","span":{"begin":42097,"end":42194},"obj":"Sentence"},{"id":"T838","span":{"begin":42195,"end":42202},"obj":"Sentence"},{"id":"T839","span":{"begin":42203,"end":42332},"obj":"Sentence"},{"id":"T840","span":{"begin":42333,"end":42405},"obj":"Sentence"},{"id":"T841","span":{"begin":42406,"end":42432},"obj":"Sentence"},{"id":"T842","span":{"begin":42433,"end":42584},"obj":"Sentence"},{"id":"T843","span":{"begin":42585,"end":43046},"obj":"Sentence"},{"id":"T844","span":{"begin":43047,"end":43112},"obj":"Sentence"},{"id":"T845","span":{"begin":43113,"end":43237},"obj":"Sentence"},{"id":"T846","span":{"begin":43238,"end":43307},"obj":"Sentence"},{"id":"T847","span":{"begin":43308,"end":43347},"obj":"Sentence"},{"id":"T848","span":{"begin":43348,"end":43471},"obj":"Sentence"},{"id":"T849","span":{"begin":43472,"end":43491},"obj":"Sentence"},{"id":"T850","span":{"begin":43492,"end":43533},"obj":"Sentence"},{"id":"T851","span":{"begin":43534,"end":43570},"obj":"Sentence"},{"id":"T852","span":{"begin":43571,"end":43765},"obj":"Sentence"},{"id":"T853","span":{"begin":43766,"end":43810},"obj":"Sentence"},{"id":"T854","span":{"begin":43811,"end":44006},"obj":"Sentence"},{"id":"T855","span":{"begin":44007,"end":44048},"obj":"Sentence"},{"id":"T856","span":{"begin":44049,"end":44105},"obj":"Sentence"},{"id":"T857","span":{"begin":44106,"end":44655},"obj":"Sentence"},{"id":"T858","span":{"begin":44656,"end":44934},"obj":"Sentence"},{"id":"T859","span":{"begin":44935,"end":45010},"obj":"Sentence"},{"id":"T860","span":{"begin":45011,"end":45065},"obj":"Sentence"},{"id":"T861","span":{"begin":45066,"end":45242},"obj":"Sentence"},{"id":"T862","span":{"begin":45243,"end":45313},"obj":"Sentence"},{"id":"T863","span":{"begin":45314,"end":45401},"obj":"Sentence"},{"id":"T864","span":{"begin":45402,"end":45478},"obj":"Sentence"},{"id":"T865","span":{"begin":45479,"end":45588},"obj":"Sentence"},{"id":"T866","span":{"begin":45589,"end":45643},"obj":"Sentence"},{"id":"T867","span":{"begin":45644,"end":45653},"obj":"Sentence"},{"id":"T868","span":{"begin":45654,"end":45854},"obj":"Sentence"},{"id":"T869","span":{"begin":45855,"end":45923},"obj":"Sentence"},{"id":"T870","span":{"begin":45924,"end":46093},"obj":"Sentence"},{"id":"T871","span":{"begin":46094,"end":46162},"obj":"Sentence"},{"id":"T872","span":{"begin":46163,"end":46408},"obj":"Sentence"},{"id":"T873","span":{"begin":46409,"end":46448},"obj":"Sentence"},{"id":"T874","span":{"begin":46449,"end":46557},"obj":"Sentence"},{"id":"T875","span":{"begin":46558,"end":46585},"obj":"Sentence"},{"id":"T876","span":{"begin":46586,"end":46613},"obj":"Sentence"},{"id":"T877","span":{"begin":46614,"end":46878},"obj":"Sentence"},{"id":"T878","span":{"begin":46879,"end":46902},"obj":"Sentence"},{"id":"T879","span":{"begin":46903,"end":47020},"obj":"Sentence"},{"id":"T880","span":{"begin":47021,"end":47086},"obj":"Sentence"},{"id":"T881","span":{"begin":47087,"end":47115},"obj":"Sentence"},{"id":"T882","span":{"begin":47116,"end":47292},"obj":"Sentence"},{"id":"T883","span":{"begin":47293,"end":47321},"obj":"Sentence"},{"id":"T884","span":{"begin":47322,"end":47327},"obj":"Sentence"},{"id":"T885","span":{"begin":47328,"end":47349},"obj":"Sentence"},{"id":"T886","span":{"begin":47350,"end":47557},"obj":"Sentence"},{"id":"T887","span":{"begin":47558,"end":47656},"obj":"Sentence"},{"id":"T888","span":{"begin":47657,"end":47724},"obj":"Sentence"},{"id":"T889","span":{"begin":47725,"end":47929},"obj":"Sentence"},{"id":"T890","span":{"begin":47930,"end":47949},"obj":"Sentence"},{"id":"T891","span":{"begin":47950,"end":47987},"obj":"Sentence"},{"id":"T892","span":{"begin":47988,"end":47993},"obj":"Sentence"},{"id":"T893","span":{"begin":47994,"end":48029},"obj":"Sentence"},{"id":"T894","span":{"begin":48030,"end":48192},"obj":"Sentence"},{"id":"T895","span":{"begin":48193,"end":48397},"obj":"Sentence"},{"id":"T896","span":{"begin":48399,"end":48420},"obj":"Sentence"},{"id":"T897","span":{"begin":48421,"end":48471},"obj":"Sentence"},{"id":"T898","span":{"begin":48472,"end":48498},"obj":"Sentence"},{"id":"T899","span":{"begin":48499,"end":49275},"obj":"Sentence"},{"id":"T900","span":{"begin":49276,"end":49444},"obj":"Sentence"},{"id":"T901","span":{"begin":49445,"end":49594},"obj":"Sentence"},{"id":"T902","span":{"begin":49595,"end":49816},"obj":"Sentence"},{"id":"T903","span":{"begin":49817,"end":49923},"obj":"Sentence"},{"id":"T904","span":{"begin":49924,"end":49944},"obj":"Sentence"},{"id":"T905","span":{"begin":49945,"end":50404},"obj":"Sentence"},{"id":"T906","span":{"begin":50405,"end":50609},"obj":"Sentence"},{"id":"T907","span":{"begin":50610,"end":50989},"obj":"Sentence"},{"id":"T908","span":{"begin":50990,"end":51030},"obj":"Sentence"},{"id":"T909","span":{"begin":51031,"end":51225},"obj":"Sentence"},{"id":"T910","span":{"begin":51227,"end":51401},"obj":"Sentence"},{"id":"T911","span":{"begin":51402,"end":51427},"obj":"Sentence"},{"id":"T912","span":{"begin":51428,"end":52612},"obj":"Sentence"},{"id":"T913","span":{"begin":52613,"end":52709},"obj":"Sentence"},{"id":"T914","span":{"begin":52710,"end":52851},"obj":"Sentence"},{"id":"T915","span":{"begin":52852,"end":52892},"obj":"Sentence"},{"id":"T916","span":{"begin":52893,"end":52921},"obj":"Sentence"},{"id":"T917","span":{"begin":52922,"end":52961},"obj":"Sentence"},{"id":"T918","span":{"begin":52962,"end":53034},"obj":"Sentence"},{"id":"T919","span":{"begin":53035,"end":53052},"obj":"Sentence"},{"id":"T920","span":{"begin":53053,"end":53063},"obj":"Sentence"},{"id":"T921","span":{"begin":53064,"end":53334},"obj":"Sentence"},{"id":"T922","span":{"begin":53335,"end":53604},"obj":"Sentence"},{"id":"T923","span":{"begin":53605,"end":53742},"obj":"Sentence"},{"id":"T924","span":{"begin":53743,"end":53818},"obj":"Sentence"},{"id":"T925","span":{"begin":53819,"end":53966},"obj":"Sentence"},{"id":"T926","span":{"begin":53967,"end":53980},"obj":"Sentence"},{"id":"T927","span":{"begin":53981,"end":54075},"obj":"Sentence"},{"id":"T928","span":{"begin":54076,"end":54152},"obj":"Sentence"},{"id":"T929","span":{"begin":54153,"end":54163},"obj":"Sentence"},{"id":"T930","span":{"begin":54164,"end":54743},"obj":"Sentence"},{"id":"T931","span":{"begin":54744,"end":55007},"obj":"Sentence"},{"id":"T932","span":{"begin":55008,"end":55081},"obj":"Sentence"},{"id":"T933","span":{"begin":55082,"end":55155},"obj":"Sentence"},{"id":"T934","span":{"begin":55156,"end":55263},"obj":"Sentence"},{"id":"T935","span":{"begin":55264,"end":55285},"obj":"Sentence"},{"id":"T936","span":{"begin":55286,"end":55579},"obj":"Sentence"},{"id":"T937","span":{"begin":55580,"end":55603},"obj":"Sentence"},{"id":"T938","span":{"begin":55604,"end":55728},"obj":"Sentence"},{"id":"T939","span":{"begin":55729,"end":55911},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T216","span":{"begin":2450,"end":2459},"obj":"Phenotype"},{"id":"T217","span":{"begin":2881,"end":2886},"obj":"Phenotype"},{"id":"T218","span":{"begin":3048,"end":3053},"obj":"Phenotype"},{"id":"T219","span":{"begin":4275,"end":4280},"obj":"Phenotype"},{"id":"T220","span":{"begin":4845,"end":4864},"obj":"Phenotype"},{"id":"T221","span":{"begin":8340,"end":8345},"obj":"Phenotype"},{"id":"T222","span":{"begin":9577,"end":9586},"obj":"Phenotype"},{"id":"T223","span":{"begin":9626,"end":9635},"obj":"Phenotype"},{"id":"T224","span":{"begin":10066,"end":10075},"obj":"Phenotype"},{"id":"T225","span":{"begin":10577,"end":10582},"obj":"Phenotype"},{"id":"T226","span":{"begin":13637,"end":13646},"obj":"Phenotype"},{"id":"T227","span":{"begin":13725,"end":13734},"obj":"Phenotype"},{"id":"T228","span":{"begin":16075,"end":16098},"obj":"Phenotype"},{"id":"T229","span":{"begin":18326,"end":18331},"obj":"Phenotype"},{"id":"T230","span":{"begin":19619,"end":19624},"obj":"Phenotype"},{"id":"T231","span":{"begin":20059,"end":20064},"obj":"Phenotype"},{"id":"T232","span":{"begin":20149,"end":20154},"obj":"Phenotype"},{"id":"T233","span":{"begin":20397,"end":20402},"obj":"Phenotype"},{"id":"T234","span":{"begin":20650,"end":20655},"obj":"Phenotype"},{"id":"T235","span":{"begin":20774,"end":20783},"obj":"Phenotype"},{"id":"T236","span":{"begin":21385,"end":21408},"obj":"Phenotype"},{"id":"T237","span":{"begin":21481,"end":21504},"obj":"Phenotype"},{"id":"T238","span":{"begin":21530,"end":21541},"obj":"Phenotype"},{"id":"T239","span":{"begin":21556,"end":21572},"obj":"Phenotype"},{"id":"T240","span":{"begin":23660,"end":23669},"obj":"Phenotype"},{"id":"T241","span":{"begin":23687,"end":23696},"obj":"Phenotype"},{"id":"T242","span":{"begin":23817,"end":23826},"obj":"Phenotype"},{"id":"T243","span":{"begin":23852,"end":23861},"obj":"Phenotype"},{"id":"T244","span":{"begin":27728,"end":27747},"obj":"Phenotype"},{"id":"T245","span":{"begin":28327,"end":28336},"obj":"Phenotype"},{"id":"T246","span":{"begin":28395,"end":28404},"obj":"Phenotype"},{"id":"T247","span":{"begin":29506,"end":29515},"obj":"Phenotype"},{"id":"T248","span":{"begin":29549,"end":29558},"obj":"Phenotype"},{"id":"T249","span":{"begin":29930,"end":29935},"obj":"Phenotype"},{"id":"T250","span":{"begin":31134,"end":31153},"obj":"Phenotype"},{"id":"T251","span":{"begin":31212,"end":31231},"obj":"Phenotype"},{"id":"T252","span":{"begin":31294,"end":31313},"obj":"Phenotype"},{"id":"T253","span":{"begin":31338,"end":31357},"obj":"Phenotype"},{"id":"T254","span":{"begin":31408,"end":31427},"obj":"Phenotype"},{"id":"T255","span":{"begin":31508,"end":31527},"obj":"Phenotype"},{"id":"T256","span":{"begin":34359,"end":34364},"obj":"Phenotype"},{"id":"T257","span":{"begin":34454,"end":34459},"obj":"Phenotype"},{"id":"T258","span":{"begin":34986,"end":34991},"obj":"Phenotype"},{"id":"T259","span":{"begin":35081,"end":35086},"obj":"Phenotype"},{"id":"T260","span":{"begin":35480,"end":35485},"obj":"Phenotype"},{"id":"T261","span":{"begin":35642,"end":35661},"obj":"Phenotype"},{"id":"T262","span":{"begin":35786,"end":35795},"obj":"Phenotype"},{"id":"T263","span":{"begin":36434,"end":36443},"obj":"Phenotype"},{"id":"T264","span":{"begin":37773,"end":37794},"obj":"Phenotype"},{"id":"T265","span":{"begin":38268,"end":38289},"obj":"Phenotype"},{"id":"T266","span":{"begin":41384,"end":41389},"obj":"Phenotype"},{"id":"T267","span":{"begin":41414,"end":41419},"obj":"Phenotype"},{"id":"T268","span":{"begin":41462,"end":41467},"obj":"Phenotype"},{"id":"T269","span":{"begin":41517,"end":41524},"obj":"Phenotype"},{"id":"T270","span":{"begin":41612,"end":41619},"obj":"Phenotype"},{"id":"T271","span":{"begin":42020,"end":42032},"obj":"Phenotype"},{"id":"T272","span":{"begin":42097,"end":42109},"obj":"Phenotype"},{"id":"T273","span":{"begin":42203,"end":42215},"obj":"Phenotype"},{"id":"T274","span":{"begin":42762,"end":42771},"obj":"Phenotype"},{"id":"T275","span":{"begin":42960,"end":42969},"obj":"Phenotype"},{"id":"T276","span":{"begin":43164,"end":43173},"obj":"Phenotype"},{"id":"T277","span":{"begin":43399,"end":43408},"obj":"Phenotype"},{"id":"T278","span":{"begin":43622,"end":43631},"obj":"Phenotype"},{"id":"T279","span":{"begin":43862,"end":43871},"obj":"Phenotype"},{"id":"T280","span":{"begin":44249,"end":44254},"obj":"Phenotype"},{"id":"T281","span":{"begin":46833,"end":46853},"obj":"Phenotype"},{"id":"T282","span":{"begin":46932,"end":46952},"obj":"Phenotype"},{"id":"T283","span":{"begin":47210,"end":47219},"obj":"Phenotype"},{"id":"T284","span":{"begin":49537,"end":49546},"obj":"Phenotype"},{"id":"T285","span":{"begin":49636,"end":49645},"obj":"Phenotype"},{"id":"T286","span":{"begin":49679,"end":49688},"obj":"Phenotype"},{"id":"T287","span":{"begin":49957,"end":49962},"obj":"Phenotype"},{"id":"T288","span":{"begin":50109,"end":50129},"obj":"Phenotype"},{"id":"T289","span":{"begin":50211,"end":50216},"obj":"Phenotype"},{"id":"T290","span":{"begin":50218,"end":50231},"obj":"Phenotype"},{"id":"T291","span":{"begin":50257,"end":50273},"obj":"Phenotype"},{"id":"T292","span":{"begin":50557,"end":50566},"obj":"Phenotype"},{"id":"T293","span":{"begin":51488,"end":51495},"obj":"Phenotype"},{"id":"T294","span":{"begin":51497,"end":51513},"obj":"Phenotype"},{"id":"T295","span":{"begin":51515,"end":51530},"obj":"Phenotype"},{"id":"T296","span":{"begin":51532,"end":51551},"obj":"Phenotype"},{"id":"T297","span":{"begin":52366,"end":52374},"obj":"Phenotype"},{"id":"T298","span":{"begin":53372,"end":53397},"obj":"Phenotype"},{"id":"T299","span":{"begin":53531,"end":53545},"obj":"Phenotype"},{"id":"T300","span":{"begin":54125,"end":54130},"obj":"Phenotype"},{"id":"T301","span":{"begin":54258,"end":54263},"obj":"Phenotype"}],"attributes":[{"id":"A216","pred":"hp_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A217","pred":"hp_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A218","pred":"hp_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A219","pred":"hp_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A220","pred":"hp_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A221","pred":"hp_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A222","pred":"hp_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A223","pred":"hp_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A224","pred":"hp_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A225","pred":"hp_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A226","pred":"hp_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A227","pred":"hp_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A228","pred":"hp_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A229","pred":"hp_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A230","pred":"hp_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A231","pred":"hp_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A232","pred":"hp_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A233","pred":"hp_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A234","pred":"hp_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A235","pred":"hp_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/HP_0012418"},{"id":"A236","pred":"hp_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/HP_0031690"},{"id":"A237","pred":"hp_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/HP_0031690"},{"id":"A238","pred":"hp_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A239","pred":"hp_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/HP_0041092"},{"id":"A240","pred":"hp_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A241","pred":"hp_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A242","pred":"hp_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A243","pred":"hp_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A244","pred":"hp_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/HP_0006532"},{"id":"A245","pred":"hp_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A246","pred":"hp_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A247","pred":"hp_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A248","pred":"hp_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A249","pred":"hp_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A250","pred":"hp_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A251","pred":"hp_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A252","pred":"hp_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A253","pred":"hp_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A254","pred":"hp_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A255","pred":"hp_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/HP_0001919"},{"id":"A256","pred":"hp_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A257","pred":"hp_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A258","pred":"hp_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A259","pred":"hp_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A260","pred":"hp_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A261","pred":"hp_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A262","pred":"hp_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A263","pred":"hp_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A264","pred":"hp_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A265","pred":"hp_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A266","pred":"hp_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A267","pred":"hp_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A268","pred":"hp_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A269","pred":"hp_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A270","pred":"hp_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A271","pred":"hp_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A272","pred":"hp_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A273","pred":"hp_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A274","pred":"hp_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A275","pred":"hp_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A276","pred":"hp_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A277","pred":"hp_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A278","pred":"hp_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A279","pred":"hp_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A280","pred":"hp_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A281","pred":"hp_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A282","pred":"hp_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A283","pred":"hp_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A284","pred":"hp_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A285","pred":"hp_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A286","pred":"hp_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A287","pred":"hp_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A288","pred":"hp_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A289","pred":"hp_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/HP_0031273"},{"id":"A290","pred":"hp_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/HP_0000083"},{"id":"A291","pred":"hp_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/HP_0012156"},{"id":"A292","pred":"hp_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A293","pred":"hp_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A294","pred":"hp_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A295","pred":"hp_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/HP_0031352"},{"id":"A296","pred":"hp_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A297","pred":"hp_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/HP_0001941"},{"id":"A298","pred":"hp_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A299","pred":"hp_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A300","pred":"hp_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A301","pred":"hp_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1806","span":{"begin":806,"end":810},"obj":"Gene"},{"id":"1807","span":{"begin":1779,"end":1810},"obj":"Gene"},{"id":"1808","span":{"begin":1887,"end":1918},"obj":"Gene"},{"id":"1809","span":{"begin":2492,"end":2510},"obj":"Gene"},{"id":"1810","span":{"begin":2529,"end":2543},"obj":"Gene"},{"id":"1811","span":{"begin":2545,"end":2551},"obj":"Gene"},{"id":"1812","span":{"begin":2589,"end":2596},"obj":"Gene"},{"id":"1813","span":{"begin":2634,"end":2641},"obj":"Gene"},{"id":"1814","span":{"begin":2718,"end":2747},"obj":"Gene"},{"id":"1815","span":{"begin":2767,"end":2798},"obj":"Gene"},{"id":"1816","span":{"begin":2800,"end":2804},"obj":"Gene"},{"id":"1817","span":{"begin":2825,"end":2829},"obj":"Gene"},{"id":"1818","span":{"begin":2849,"end":2853},"obj":"Gene"},{"id":"1819","span":{"begin":2881,"end":2919},"obj":"Gene"},{"id":"1820","span":{"begin":3048,"end":3071},"obj":"Gene"},{"id":"1821","span":{"begin":3211,"end":3225},"obj":"Gene"},{"id":"1822","span":{"begin":4360,"end":4378},"obj":"Gene"},{"id":"1823","span":{"begin":4380,"end":4383},"obj":"Gene"},{"id":"1824","span":{"begin":11008,"end":11013},"obj":"Gene"},{"id":"1825","span":{"begin":11015,"end":11020},"obj":"Gene"},{"id":"1826","span":{"begin":11022,"end":11026},"obj":"Gene"},{"id":"1827","span":{"begin":11028,"end":11032},"obj":"Gene"},{"id":"1828","span":{"begin":11034,"end":11038},"obj":"Gene"},{"id":"1829","span":{"begin":11040,"end":11045},"obj":"Gene"},{"id":"1830","span":{"begin":11053,"end":11057},"obj":"Gene"},{"id":"1831","span":{"begin":11059,"end":11063},"obj":"Gene"},{"id":"1832","span":{"begin":11065,"end":11070},"obj":"Gene"},{"id":"1833","span":{"begin":12611,"end":12616},"obj":"Gene"},{"id":"1834","span":{"begin":12618,"end":12623},"obj":"Gene"},{"id":"1835","span":{"begin":12625,"end":12629},"obj":"Gene"},{"id":"1836","span":{"begin":12631,"end":12635},"obj":"Gene"},{"id":"1837","span":{"begin":12637,"end":12641},"obj":"Gene"},{"id":"1838","span":{"begin":12643,"end":12648},"obj":"Gene"},{"id":"1839","span":{"begin":12656,"end":12660},"obj":"Gene"},{"id":"1840","span":{"begin":12661,"end":12665},"obj":"Gene"},{"id":"1841","span":{"begin":12667,"end":12672},"obj":"Gene"},{"id":"1842","span":{"begin":14609,"end":14612},"obj":"Gene"},{"id":"1843","span":{"begin":14619,"end":14622},"obj":"Gene"},{"id":"1844","span":{"begin":14677,"end":14682},"obj":"Gene"},{"id":"1845","span":{"begin":14684,"end":14688},"obj":"Gene"},{"id":"1846","span":{"begin":14690,"end":14694},"obj":"Gene"},{"id":"1847","span":{"begin":14695,"end":14700},"obj":"Gene"},{"id":"1848","span":{"begin":14701,"end":14706},"obj":"Gene"},{"id":"1849","span":{"begin":15365,"end":15368},"obj":"Gene"},{"id":"1850","span":{"begin":15823,"end":15836},"obj":"Gene"},{"id":"1851","span":{"begin":16752,"end":16765},"obj":"Gene"},{"id":"1852","span":{"begin":17205,"end":17218},"obj":"Gene"},{"id":"1853","span":{"begin":17737,"end":17740},"obj":"Gene"},{"id":"1854","span":{"begin":20207,"end":20211},"obj":"Gene"},{"id":"1855","span":{"begin":20362,"end":20366},"obj":"Gene"},{"id":"1856","span":{"begin":21761,"end":21785},"obj":"Gene"},{"id":"1857","span":{"begin":28678,"end":28691},"obj":"Gene"},{"id":"1858","span":{"begin":28717,"end":28735},"obj":"Gene"},{"id":"1859","span":{"begin":30042,"end":30045},"obj":"Gene"},{"id":"1860","span":{"begin":30051,"end":30054},"obj":"Gene"},{"id":"1861","span":{"begin":30266,"end":30269},"obj":"Gene"},{"id":"1862","span":{"begin":33340,"end":33349},"obj":"Gene"},{"id":"1863","span":{"begin":36795,"end":36834},"obj":"Gene"},{"id":"1864","span":{"begin":37179,"end":37218},"obj":"Gene"},{"id":"1865","span":{"begin":42886,"end":42900},"obj":"Gene"},{"id":"1866","span":{"begin":43326,"end":43340},"obj":"Gene"},{"id":"1867","span":{"begin":43790,"end":43804},"obj":"Gene"},{"id":"1868","span":{"begin":52602,"end":52607},"obj":"Gene"},{"id":"1869","span":{"begin":52659,"end":52663},"obj":"Gene"},{"id":"1870","span":{"begin":53127,"end":53130},"obj":"Gene"},{"id":"1871","span":{"begin":53140,"end":53144},"obj":"Gene"},{"id":"1872","span":{"begin":54560,"end":54565},"obj":"Gene"},{"id":"1873","span":{"begin":54567,"end":54572},"obj":"Gene"},{"id":"1874","span":{"begin":54582,"end":54586},"obj":"Gene"},{"id":"1875","span":{"begin":54588,"end":54592},"obj":"Gene"},{"id":"1876","span":{"begin":54597,"end":54602},"obj":"Gene"},{"id":"1877","span":{"begin":54658,"end":54661},"obj":"Gene"},{"id":"1878","span":{"begin":54668,"end":54671},"obj":"Gene"},{"id":"1879","span":{"begin":1648,"end":1651},"obj":"Gene"},{"id":"1880","span":{"begin":1773,"end":1778},"obj":"Species"},{"id":"1881","span":{"begin":1839,"end":1847},"obj":"Species"},{"id":"1882","span":{"begin":1881,"end":1886},"obj":"Species"},{"id":"1883","span":{"begin":4605,"end":4613},"obj":"Species"},{"id":"1884","span":{"begin":4756,"end":4764},"obj":"Species"},{"id":"1885","span":{"begin":6217,"end":6229},"obj":"Species"},{"id":"1886","span":{"begin":6309,"end":6321},"obj":"Species"},{"id":"1887","span":{"begin":6512,"end":6520},"obj":"Species"},{"id":"1888","span":{"begin":7736,"end":7748},"obj":"Species"},{"id":"1889","span":{"begin":7944,"end":7956},"obj":"Species"},{"id":"1890","span":{"begin":8119,"end":8131},"obj":"Species"},{"id":"1891","span":{"begin":8305,"end":8317},"obj":"Species"},{"id":"1892","span":{"begin":8408,"end":8420},"obj":"Species"},{"id":"1893","span":{"begin":8649,"end":8661},"obj":"Species"},{"id":"1894","span":{"begin":8884,"end":8896},"obj":"Species"},{"id":"1895","span":{"begin":9060,"end":9072},"obj":"Species"},{"id":"1896","span":{"begin":9317,"end":9329},"obj":"Species"},{"id":"1897","span":{"begin":9392,"end":9404},"obj":"Species"},{"id":"1898","span":{"begin":9554,"end":9562},"obj":"Species"},{"id":"1899","span":{"begin":9826,"end":9834},"obj":"Species"},{"id":"1900","span":{"begin":10039,"end":10054},"obj":"Species"},{"id":"1901","span":{"begin":10726,"end":10735},"obj":"Species"},{"id":"1902","span":{"begin":10811,"end":10820},"obj":"Species"},{"id":"1903","span":{"begin":12411,"end":12420},"obj":"Species"},{"id":"1904","span":{"begin":12451,"end":12460},"obj":"Species"},{"id":"1905","span":{"begin":13435,"end":13442},"obj":"Species"},{"id":"1906","span":{"begin":13735,"end":13743},"obj":"Species"},{"id":"1907","span":{"begin":13756,"end":13778},"obj":"Species"},{"id":"1908","span":{"begin":13899,"end":13911},"obj":"Species"},{"id":"1909","span":{"begin":14075,"end":14087},"obj":"Species"},{"id":"1910","span":{"begin":14872,"end":14882},"obj":"Species"},{"id":"1911","span":{"begin":15400,"end":15408},"obj":"Species"},{"id":"1912","span":{"begin":15667,"end":15671},"obj":"Species"},{"id":"1913","span":{"begin":15859,"end":15866},"obj":"Species"},{"id":"1914","span":{"begin":16212,"end":16219},"obj":"Species"},{"id":"1915","span":{"begin":16309,"end":16316},"obj":"Species"},{"id":"1916","span":{"begin":16657,"end":16669},"obj":"Species"},{"id":"1917","span":{"begin":16905,"end":16917},"obj":"Species"},{"id":"1918","span":{"begin":17104,"end":17116},"obj":"Species"},{"id":"1919","span":{"begin":17443,"end":17451},"obj":"Species"},{"id":"1920","span":{"begin":17917,"end":17925},"obj":"Species"},{"id":"1921","span":{"begin":19127,"end":19135},"obj":"Species"},{"id":"1922","span":{"begin":19705,"end":19713},"obj":"Species"},{"id":"1923","span":{"begin":20667,"end":20675},"obj":"Species"},{"id":"1924","span":{"begin":20928,"end":20936},"obj":"Species"},{"id":"1925","span":{"begin":20995,"end":21003},"obj":"Species"},{"id":"1926","span":{"begin":21049,"end":21057},"obj":"Species"},{"id":"1927","span":{"begin":21114,"end":21122},"obj":"Species"},{"id":"1928","span":{"begin":21508,"end":21516},"obj":"Species"},{"id":"1929","span":{"begin":21911,"end":21919},"obj":"Species"},{"id":"1930","span":{"begin":21925,"end":21934},"obj":"Species"},{"id":"1931","span":{"begin":22565,"end":22577},"obj":"Species"},{"id":"1932","span":{"begin":23207,"end":23215},"obj":"Species"},{"id":"1933","span":{"begin":23310,"end":23318},"obj":"Species"},{"id":"1934","span":{"begin":23630,"end":23638},"obj":"Species"},{"id":"1935","span":{"begin":24523,"end":24531},"obj":"Species"},{"id":"1936","span":{"begin":24931,"end":24939},"obj":"Species"},{"id":"1937","span":{"begin":25020,"end":25028},"obj":"Species"},{"id":"1938","span":{"begin":25123,"end":25131},"obj":"Species"},{"id":"1939","span":{"begin":25391,"end":25408},"obj":"Species"},{"id":"1940","span":{"begin":25418,"end":25435},"obj":"Species"},{"id":"1941","span":{"begin":25548,"end":25552},"obj":"Species"},{"id":"1942","span":{"begin":25646,"end":25650},"obj":"Species"},{"id":"1943","span":{"begin":25743,"end":25747},"obj":"Species"},{"id":"1944","span":{"begin":27112,"end":27127},"obj":"Species"},{"id":"1945","span":{"begin":27486,"end":27494},"obj":"Species"},{"id":"1946","span":{"begin":28411,"end":28416},"obj":"Species"},{"id":"1947","span":{"begin":28438,"end":28443},"obj":"Species"},{"id":"1948","span":{"begin":29048,"end":29060},"obj":"Species"},{"id":"1949","span":{"begin":29333,"end":29340},"obj":"Species"},{"id":"1950","span":{"begin":29476,"end":29484},"obj":"Species"},{"id":"1951","span":{"begin":29628,"end":29636},"obj":"Species"},{"id":"1952","span":{"begin":30394,"end":30405},"obj":"Species"},{"id":"1953","span":{"begin":31157,"end":31165},"obj":"Species"},{"id":"1954","span":{"begin":31324,"end":31332},"obj":"Species"},{"id":"1955","span":{"begin":31391,"end":31399},"obj":"Species"},{"id":"1956","span":{"begin":31658,"end":31675},"obj":"Species"},{"id":"1957","span":{"begin":31685,"end":31702},"obj":"Species"},{"id":"1958","span":{"begin":31751,"end":31768},"obj":"Species"},{"id":"1959","span":{"begin":31848,"end":31852},"obj":"Species"},{"id":"1960","span":{"begin":31946,"end":31950},"obj":"Species"},{"id":"1961","span":{"begin":32043,"end":32047},"obj":"Species"},{"id":"1962","span":{"begin":33864,"end":33876},"obj":"Species"},{"id":"1963","span":{"begin":34365,"end":34373},"obj":"Species"},{"id":"1964","span":{"begin":34992,"end":35000},"obj":"Species"},{"id":"1965","span":{"begin":35544,"end":35556},"obj":"Species"},{"id":"1966","span":{"begin":35753,"end":35770},"obj":"Species"},{"id":"1967","span":{"begin":36408,"end":36423},"obj":"Species"},{"id":"1968","span":{"begin":37365,"end":37373},"obj":"Species"},{"id":"1969","span":{"begin":37398,"end":37408},"obj":"Species"},{"id":"1970","span":{"begin":37467,"end":37477},"obj":"Species"},{"id":"1971","span":{"begin":37655,"end":37666},"obj":"Species"},{"id":"1972","span":{"begin":37747,"end":37766},"obj":"Species"},{"id":"1973","span":{"begin":38927,"end":38935},"obj":"Species"},{"id":"1974","span":{"begin":39083,"end":39098},"obj":"Species"},{"id":"1975","span":{"begin":39115,"end":39135},"obj":"Species"},{"id":"1976","span":{"begin":39661,"end":39669},"obj":"Species"},{"id":"1977","span":{"begin":40358,"end":40366},"obj":"Species"},{"id":"1978","span":{"begin":40832,"end":40840},"obj":"Species"},{"id":"1979","span":{"begin":41994,"end":42002},"obj":"Species"},{"id":"1980","span":{"begin":42110,"end":42118},"obj":"Species"},{"id":"1981","span":{"begin":42158,"end":42175},"obj":"Species"},{"id":"1982","span":{"begin":42216,"end":42224},"obj":"Species"},{"id":"1983","span":{"begin":42267,"end":42284},"obj":"Species"},{"id":"1984","span":{"begin":42711,"end":42719},"obj":"Species"},{"id":"1985","span":{"begin":42744,"end":42761},"obj":"Species"},{"id":"1986","span":{"begin":42880,"end":42885},"obj":"Species"},{"id":"1987","span":{"begin":42942,"end":42959},"obj":"Species"},{"id":"1988","span":{"begin":42970,"end":42979},"obj":"Species"},{"id":"1989","span":{"begin":43209,"end":43226},"obj":"Species"},{"id":"1990","span":{"begin":43320,"end":43325},"obj":"Species"},{"id":"1991","span":{"begin":43444,"end":43461},"obj":"Species"},{"id":"1992","span":{"begin":43667,"end":43684},"obj":"Species"},{"id":"1993","span":{"begin":43784,"end":43789},"obj":"Species"},{"id":"1994","span":{"begin":43907,"end":43924},"obj":"Species"},{"id":"1995","span":{"begin":44307,"end":44315},"obj":"Species"},{"id":"1996","span":{"begin":44359,"end":44367},"obj":"Species"},{"id":"1997","span":{"begin":44817,"end":44828},"obj":"Species"},{"id":"1998","span":{"begin":46558,"end":46568},"obj":"Species"},{"id":"1999","span":{"begin":46624,"end":46631},"obj":"Species"},{"id":"2000","span":{"begin":46654,"end":46661},"obj":"Species"},{"id":"2001","span":{"begin":46809,"end":46816},"obj":"Species"},{"id":"2002","span":{"begin":46913,"end":46920},"obj":"Species"},{"id":"2003","span":{"begin":47465,"end":47480},"obj":"Species"},{"id":"2004","span":{"begin":47497,"end":47517},"obj":"Species"},{"id":"2005","span":{"begin":48904,"end":48912},"obj":"Species"},{"id":"2006","span":{"begin":48923,"end":48932},"obj":"Species"},{"id":"2007","span":{"begin":49328,"end":49337},"obj":"Species"},{"id":"2008","span":{"begin":49351,"end":49359},"obj":"Species"},{"id":"2009","span":{"begin":49371,"end":49380},"obj":"Species"},{"id":"2010","span":{"begin":49419,"end":49428},"obj":"Species"},{"id":"2011","span":{"begin":49503,"end":49520},"obj":"Species"},{"id":"2012","span":{"begin":49569,"end":49578},"obj":"Species"},{"id":"2013","span":{"begin":49609,"end":49617},"obj":"Species"},{"id":"2014","span":{"begin":49661,"end":49678},"obj":"Species"},{"id":"2015","span":{"begin":49731,"end":49740},"obj":"Species"},{"id":"2016","span":{"begin":49834,"end":49843},"obj":"Species"},{"id":"2017","span":{"begin":49869,"end":49878},"obj":"Species"},{"id":"2018","span":{"begin":50037,"end":50048},"obj":"Species"},{"id":"2019","span":{"begin":50083,"end":50094},"obj":"Species"},{"id":"2020","span":{"begin":50150,"end":50161},"obj":"Species"},{"id":"2021","span":{"begin":50302,"end":50313},"obj":"Species"},{"id":"2022","span":{"begin":50479,"end":50487},"obj":"Species"},{"id":"2023","span":{"begin":50514,"end":50525},"obj":"Species"},{"id":"2024","span":{"begin":50534,"end":50556},"obj":"Species"},{"id":"2025","span":{"begin":51348,"end":51356},"obj":"Species"},{"id":"2026","span":{"begin":51467,"end":51475},"obj":"Species"},{"id":"2027","span":{"begin":51668,"end":51676},"obj":"Species"},{"id":"2028","span":{"begin":51831,"end":51839},"obj":"Species"},{"id":"2029","span":{"begin":51974,"end":51982},"obj":"Species"},{"id":"2030","span":{"begin":52117,"end":52125},"obj":"Species"},{"id":"2031","span":{"begin":52203,"end":52211},"obj":"Species"},{"id":"2032","span":{"begin":52352,"end":52360},"obj":"Species"},{"id":"2033","span":{"begin":52402,"end":52410},"obj":"Species"},{"id":"2034","span":{"begin":52642,"end":52651},"obj":"Species"},{"id":"2035","span":{"begin":52769,"end":52778},"obj":"Species"},{"id":"2036","span":{"begin":54090,"end":54102},"obj":"Species"},{"id":"2037","span":{"begin":54223,"end":54235},"obj":"Species"},{"id":"2038","span":{"begin":54388,"end":54411},"obj":"Species"},{"id":"2039","span":{"begin":54744,"end":54753},"obj":"Species"},{"id":"2040","span":{"begin":54941,"end":54950},"obj":"Species"},{"id":"2041","span":{"begin":54964,"end":54969},"obj":"Species"},{"id":"2042","span":{"begin":55183,"end":55191},"obj":"Species"},{"id":"2043","span":{"begin":55208,"end":55217},"obj":"Species"},{"id":"2044","span":{"begin":54855,"end":54865},"obj":"Species"},{"id":"2045","span":{"begin":55053,"end":55063},"obj":"Species"},{"id":"2046","span":{"begin":15817,"end":15822},"obj":"Species"},{"id":"2047","span":{"begin":16746,"end":16751},"obj":"Species"},{"id":"2048","span":{"begin":17199,"end":17204},"obj":"Species"},{"id":"2049","span":{"begin":3326,"end":3329},"obj":"Gene"},{"id":"2050","span":{"begin":52857,"end":52861},"obj":"Gene"},{"id":"2051","span":{"begin":52841,"end":52845},"obj":"Gene"},{"id":"2052","span":{"begin":52780,"end":52784},"obj":"Gene"},{"id":"2053","span":{"begin":26810,"end":26819},"obj":"Gene"},{"id":"2054","span":{"begin":5735,"end":5753},"obj":"Chemical"},{"id":"2055","span":{"begin":6467,"end":6486},"obj":"Chemical"},{"id":"2056","span":{"begin":6569,"end":6588},"obj":"Chemical"},{"id":"2057","span":{"begin":6697,"end":6716},"obj":"Chemical"},{"id":"2058","span":{"begin":6897,"end":6916},"obj":"Chemical"},{"id":"2059","span":{"begin":7416,"end":7435},"obj":"Chemical"},{"id":"2060","span":{"begin":7518,"end":7537},"obj":"Chemical"},{"id":"2061","span":{"begin":7711,"end":7721},"obj":"Chemical"},{"id":"2062","span":{"begin":7799,"end":7809},"obj":"Chemical"},{"id":"2063","span":{"begin":8099,"end":8109},"obj":"Chemical"},{"id":"2064","span":{"begin":8624,"end":8634},"obj":"Chemical"},{"id":"2065","span":{"begin":8753,"end":8763},"obj":"Chemical"},{"id":"2066","span":{"begin":8865,"end":8875},"obj":"Chemical"},{"id":"2067","span":{"begin":9040,"end":9050},"obj":"Chemical"},{"id":"2068","span":{"begin":11506,"end":11511},"obj":"Chemical"},{"id":"2069","span":{"begin":11696,"end":11707},"obj":"Chemical"},{"id":"2070","span":{"begin":11803,"end":11808},"obj":"Chemical"},{"id":"2071","span":{"begin":11851,"end":11857},"obj":"Chemical"},{"id":"2072","span":{"begin":11899,"end":11917},"obj":"Chemical"},{"id":"2073","span":{"begin":17965,"end":17984},"obj":"Chemical"},{"id":"2074","span":{"begin":18157,"end":18176},"obj":"Chemical"},{"id":"2075","span":{"begin":18238,"end":18257},"obj":"Chemical"},{"id":"2076","span":{"begin":21719,"end":21729},"obj":"Chemical"},{"id":"2077","span":{"begin":34278,"end":34289},"obj":"Chemical"},{"id":"2078","span":{"begin":34676,"end":34687},"obj":"Chemical"},{"id":"2079","span":{"begin":34900,"end":34911},"obj":"Chemical"},{"id":"2080","span":{"begin":36472,"end":36491},"obj":"Chemical"},{"id":"2081","span":{"begin":36540,"end":36559},"obj":"Chemical"},{"id":"2082","span":{"begin":36756,"end":36765},"obj":"Chemical"},{"id":"2083","span":{"begin":36896,"end":36915},"obj":"Chemical"},{"id":"2084","span":{"begin":37140,"end":37149},"obj":"Chemical"},{"id":"2085","span":{"begin":43238,"end":43259},"obj":"Chemical"},{"id":"2086","span":{"begin":43540,"end":43561},"obj":"Chemical"},{"id":"2087","span":{"begin":45025,"end":45034},"obj":"Chemical"},{"id":"2088","span":{"begin":45257,"end":45266},"obj":"Chemical"},{"id":"2089","span":{"begin":45416,"end":45425},"obj":"Chemical"},{"id":"2090","span":{"begin":45615,"end":45634},"obj":"Chemical"},{"id":"2091","span":{"begin":52244,"end":52251},"obj":"Chemical"},{"id":"2092","span":{"begin":53743,"end":53754},"obj":"Chemical"},{"id":"2093","span":{"begin":258,"end":266},"obj":"Disease"},{"id":"2094","span":{"begin":290,"end":298},"obj":"Disease"},{"id":"2095","span":{"begin":894,"end":902},"obj":"Disease"},{"id":"2096","span":{"begin":935,"end":943},"obj":"Disease"},{"id":"2097","span":{"begin":1853,"end":1861},"obj":"Disease"},{"id":"2098","span":{"begin":1935,"end":1943},"obj":"Disease"},{"id":"2099","span":{"begin":2223,"end":2236},"obj":"Disease"},{"id":"2100","span":{"begin":2370,"end":2386},"obj":"Disease"},{"id":"2101","span":{"begin":2390,"end":2395},"obj":"Disease"},{"id":"2102","span":{"begin":2450,"end":2459},"obj":"Disease"},{"id":"2103","span":{"begin":3007,"end":3021},"obj":"Disease"},{"id":"2104","span":{"begin":3339,"end":3347},"obj":"Disease"},{"id":"2105","span":{"begin":3430,"end":3438},"obj":"Disease"},{"id":"2106","span":{"begin":3618,"end":3623},"obj":"Disease"},{"id":"2107","span":{"begin":3780,"end":3788},"obj":"Disease"},{"id":"2108","span":{"begin":3828,"end":3836},"obj":"Disease"},{"id":"2109","span":{"begin":3934,"end":3942},"obj":"Disease"},{"id":"2110","span":{"begin":3989,"end":3997},"obj":"Disease"},{"id":"2111","span":{"begin":4275,"end":4280},"obj":"Disease"},{"id":"2112","span":{"begin":4590,"end":4604},"obj":"Disease"},{"id":"2113","span":{"begin":4619,"end":4627},"obj":"Disease"},{"id":"2114","span":{"begin":4697,"end":4705},"obj":"Disease"},{"id":"2115","span":{"begin":4845,"end":4864},"obj":"Disease"},{"id":"2116","span":{"begin":4957,"end":4966},"obj":"Disease"},{"id":"2117","span":{"begin":5331,"end":5339},"obj":"Disease"},{"id":"2118","span":{"begin":5426,"end":5434},"obj":"Disease"},{"id":"2119","span":{"begin":6029,"end":6037},"obj":"Disease"},{"id":"2120","span":{"begin":6164,"end":6173},"obj":"Disease"},{"id":"2121","span":{"begin":6531,"end":6550},"obj":"Disease"},{"id":"2122","span":{"begin":6552,"end":6560},"obj":"Disease"},{"id":"2123","span":{"begin":6630,"end":6638},"obj":"Disease"},{"id":"2124","span":{"begin":7333,"end":7338},"obj":"Disease"},{"id":"2125","span":{"begin":7761,"end":7780},"obj":"Disease"},{"id":"2126","span":{"begin":7782,"end":7790},"obj":"Disease"},{"id":"2127","span":{"begin":7854,"end":7862},"obj":"Disease"},{"id":"2128","span":{"begin":8340,"end":8345},"obj":"Disease"},{"id":"2129","span":{"begin":8676,"end":8695},"obj":"Disease"},{"id":"2130","span":{"begin":8697,"end":8705},"obj":"Disease"},{"id":"2131","span":{"begin":9568,"end":9586},"obj":"Disease"},{"id":"2132","span":{"begin":9617,"end":9635},"obj":"Disease"},{"id":"2133","span":{"begin":10056,"end":10064},"obj":"Disease"},{"id":"2134","span":{"begin":10066,"end":10075},"obj":"Disease"},{"id":"2135","span":{"begin":10105,"end":10113},"obj":"Disease"},{"id":"2138","span":{"begin":46,"end":50},"obj":"Species"},{"id":"2139","span":{"begin":29,"end":37},"obj":"Disease"},{"id":"2141","span":{"begin":55686,"end":55694},"obj":"Disease"}],"attributes":[{"id":"A1806","pred":"tao:has_database_id","subj":"1806","obj":"Gene:1731"},{"id":"A1807","pred":"tao:has_database_id","subj":"1807","obj":"Gene:59272"},{"id":"A1808","pred":"tao:has_database_id","subj":"1808","obj":"Gene:59272"},{"id":"A1809","pred":"tao:has_database_id","subj":"1809","obj":"Gene:1401"},{"id":"A1810","pred":"tao:has_database_id","subj":"1810","obj":"Gene:183"},{"id":"A1811","pred":"tao:has_database_id","subj":"1811","obj":"Gene:183"},{"id":"A1812","pred":"tao:has_database_id","subj":"1812","obj":"Gene:284"},{"id":"A1813","pred":"tao:has_database_id","subj":"1813","obj":"Gene:284"},{"id":"A1814","pred":"tao:has_database_id","subj":"1814","obj":"Gene:1636"},{"id":"A1815","pred":"tao:has_database_id","subj":"1815","obj":"Gene:59272"},{"id":"A1816","pred":"tao:has_database_id","subj":"1816","obj":"Gene:59272"},{"id":"A1817","pred":"tao:has_database_id","subj":"1817","obj":"Gene:3569"},{"id":"A1818","pred":"tao:has_database_id","subj":"1818","obj":"Gene:3576"},{"id":"A1819","pred":"tao:has_database_id","subj":"1819","obj":"Gene:7133"},{"id":"A1820","pred":"tao:has_database_id","subj":"1820","obj":"Gene:7124"},{"id":"A1821","pred":"tao:has_database_id","subj":"1821","obj":"Gene:285"},{"id":"A1822","pred":"tao:has_database_id","subj":"1822","obj":"Gene:1401"},{"id":"A1823","pred":"tao:has_database_id","subj":"1823","obj":"Gene:1401"},{"id":"A1824","pred":"tao:has_database_id","subj":"1824","obj":"Gene:7124"},{"id":"A1825","pred":"tao:has_database_id","subj":"1825","obj":"Gene:3552"},{"id":"A1826","pred":"tao:has_database_id","subj":"1826","obj":"Gene:3558"},{"id":"A1827","pred":"tao:has_database_id","subj":"1827","obj":"Gene:3569"},{"id":"A1828","pred":"tao:has_database_id","subj":"1828","obj":"Gene:3574"},{"id":"A1829","pred":"tao:has_database_id","subj":"1829","obj":"Gene:3586"},{"id":"A1830","pred":"tao:has_database_id","subj":"1830","obj":"Gene:3627"},{"id":"A1831","pred":"tao:has_database_id","subj":"1831","obj":"Gene:6347"},{"id":"A1832","pred":"tao:has_database_id","subj":"1832","obj":"Gene:6348"},{"id":"A1833","pred":"tao:has_database_id","subj":"1833","obj":"Gene:7124"},{"id":"A1834","pred":"tao:has_database_id","subj":"1834","obj":"Gene:3552"},{"id":"A1835","pred":"tao:has_database_id","subj":"1835","obj":"Gene:3558"},{"id":"A1836","pred":"tao:has_database_id","subj":"1836","obj":"Gene:3569"},{"id":"A1837","pred":"tao:has_database_id","subj":"1837","obj":"Gene:3574"},{"id":"A1838","pred":"tao:has_database_id","subj":"1838","obj":"Gene:3586"},{"id":"A1839","pred":"tao:has_database_id","subj":"1839","obj":"Gene:3627"},{"id":"A1840","pred":"tao:has_database_id","subj":"1840","obj":"Gene:6347"},{"id":"A1841","pred":"tao:has_database_id","subj":"1841","obj":"Gene:6348"},{"id":"A1842","pred":"tao:has_database_id","subj":"1842","obj":"Gene:920"},{"id":"A1843","pred":"tao:has_database_id","subj":"1843","obj":"Gene:925"},{"id":"A1844","pred":"tao:has_database_id","subj":"1844","obj":"Gene:3552"},{"id":"A1845","pred":"tao:has_database_id","subj":"1845","obj":"Gene:3569"},{"id":"A1846","pred":"tao:has_database_id","subj":"1846","obj":"Gene:3576"},{"id":"A1847","pred":"tao:has_database_id","subj":"1847","obj":"Gene:3586"},{"id":"A1848","pred":"tao:has_database_id","subj":"1848","obj":"Gene:7124"},{"id":"A1849","pred":"tao:has_database_id","subj":"1849","obj":"Gene:5366"},{"id":"A1850","pred":"tao:has_database_id","subj":"1850","obj":"Gene:213"},{"id":"A1851","pred":"tao:has_database_id","subj":"1851","obj":"Gene:213"},{"id":"A1852","pred":"tao:has_database_id","subj":"1852","obj":"Gene:213"},{"id":"A1853","pred":"tao:has_database_id","subj":"1853","obj":"Gene:920"},{"id":"A1854","pred":"tao:has_database_id","subj":"1854","obj":"Gene:3569"},{"id":"A1855","pred":"tao:has_database_id","subj":"1855","obj":"Gene:3569"},{"id":"A1856","pred":"tao:has_database_id","subj":"1856","obj":"Gene:2875"},{"id":"A1857","pred":"tao:has_database_id","subj":"1857","obj":"Gene:3569"},{"id":"A1858","pred":"tao:has_database_id","subj":"1858","obj":"Gene:1401"},{"id":"A1859","pred":"tao:has_database_id","subj":"1859","obj":"Gene:920"},{"id":"A1860","pred":"tao:has_database_id","subj":"1860","obj":"Gene:925"},{"id":"A1861","pred":"tao:has_database_id","subj":"1861","obj":"Gene:5366"},{"id":"A1862","pred":"tao:has_database_id","subj":"1862","obj":"Gene:43740568"},{"id":"A1865","pred":"tao:has_database_id","subj":"1865","obj":"Gene:3440"},{"id":"A1866","pred":"tao:has_database_id","subj":"1866","obj":"Gene:3440"},{"id":"A1867","pred":"tao:has_database_id","subj":"1867","obj":"Gene:3440"},{"id":"A1868","pred":"tao:has_database_id","subj":"1868","obj":"Gene:9403"},{"id":"A1869","pred":"tao:has_database_id","subj":"1869","obj":"Gene:6622"},{"id":"A1870","pred":"tao:has_database_id","subj":"1870","obj":"Gene:1401"},{"id":"A1871","pred":"tao:has_database_id","subj":"1871","obj":"Gene:3569"},{"id":"A1872","pred":"tao:has_database_id","subj":"1872","obj":"Gene:3552"},{"id":"A1873","pred":"tao:has_database_id","subj":"1873","obj":"Gene:3586"},{"id":"A1874","pred":"tao:has_database_id","subj":"1874","obj":"Gene:3569"},{"id":"A1875","pred":"tao:has_database_id","subj":"1875","obj":"Gene:3576"},{"id":"A1876","pred":"tao:has_database_id","subj":"1876","obj":"Gene:7124"},{"id":"A1877","pred":"tao:has_database_id","subj":"1877","obj":"Gene:920"},{"id":"A1878","pred":"tao:has_database_id","subj":"1878","obj":"Gene:925"},{"id":"A1879","pred":"tao:has_database_id","subj":"1879","obj":"Gene:1401"},{"id":"A1880","pred":"tao:has_database_id","subj":"1880","obj":"Tax:9606"},{"id":"A1881","pred":"tao:has_database_id","subj":"1881","obj":"Tax:9606"},{"id":"A1882","pred":"tao:has_database_id","subj":"1882","obj":"Tax:9606"},{"id":"A1883","pred":"tao:has_database_id","subj":"1883","obj":"Tax:9606"},{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"Tax:9606"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"Tax:9606"},{"id":"A1886","pred":"tao:has_database_id","subj":"1886","obj":"Tax:9606"},{"id":"A1887","pred":"tao:has_database_id","subj":"1887","obj":"Tax:9606"},{"id":"A1888","pred":"tao:has_database_id","subj":"1888","obj":"Tax:9606"},{"id":"A1889","pred":"tao:has_database_id","subj":"1889","obj":"Tax:9606"},{"id":"A1890","pred":"tao:has_database_id","subj":"1890","obj":"Tax:9606"},{"id":"A1891","pred":"tao:has_database_id","subj":"1891","obj":"Tax:9606"},{"id":"A1892","pred":"tao:has_database_id","subj":"1892","obj":"Tax:9606"},{"id":"A1893","pred":"tao:has_database_id","subj":"1893","obj":"Tax:9606"},{"id":"A1894","pred":"tao:has_database_id","subj":"1894","obj":"Tax:9606"},{"id":"A1895","pred":"tao:has_database_id","subj":"1895","obj":"Tax:9606"},{"id":"A1896","pred":"tao:has_database_id","subj":"1896","obj":"Tax:9606"},{"id":"A1897","pred":"tao:has_database_id","subj":"1897","obj":"Tax:9606"},{"id":"A1898","pred":"tao:has_database_id","subj":"1898","obj":"Tax:9606"},{"id":"A1899","pred":"tao:has_database_id","subj":"1899","obj":"Tax:9606"},{"id":"A1900","pred":"tao:has_database_id","subj":"1900","obj":"Tax:2697049"},{"id":"A1901","pred":"tao:has_database_id","subj":"1901","obj":"Tax:2697049"},{"id":"A1902","pred":"tao:has_database_id","subj":"1902","obj":"Tax:2697049"},{"id":"A1903","pred":"tao:has_database_id","subj":"1903","obj":"Tax:2697049"},{"id":"A1904","pred":"tao:has_database_id","subj":"1904","obj":"Tax:2697049"},{"id":"A1905","pred":"tao:has_database_id","subj":"1905","obj":"Tax:9606"},{"id":"A1906","pred":"tao:has_database_id","subj":"1906","obj":"Tax:9606"},{"id":"A1907","pred":"tao:has_database_id","subj":"1907","obj":"Tax:2697049"},{"id":"A1908","pred":"tao:has_database_id","subj":"1908","obj":"Tax:9606"},{"id":"A1909","pred":"tao:has_database_id","subj":"1909","obj":"Tax:9606"},{"id":"A1910","pred":"tao:has_database_id","subj":"1910","obj":"Tax:2697049"},{"id":"A1911","pred":"tao:has_database_id","subj":"1911","obj":"Tax:9606"},{"id":"A1912","pred":"tao:has_database_id","subj":"1912","obj":"Tax:11676"},{"id":"A1913","pred":"tao:has_database_id","subj":"1913","obj":"Tax:9606"},{"id":"A1914","pred":"tao:has_database_id","subj":"1914","obj":"Tax:9606"},{"id":"A1915","pred":"tao:has_database_id","subj":"1915","obj":"Tax:9606"},{"id":"A1916","pred":"tao:has_database_id","subj":"1916","obj":"Tax:11118"},{"id":"A1917","pred":"tao:has_database_id","subj":"1917","obj":"Tax:9606"},{"id":"A1918","pred":"tao:has_database_id","subj":"1918","obj":"Tax:9606"},{"id":"A1919","pred":"tao:has_database_id","subj":"1919","obj":"Tax:9606"},{"id":"A1920","pred":"tao:has_database_id","subj":"1920","obj":"Tax:9606"},{"id":"A1921","pred":"tao:has_database_id","subj":"1921","obj":"Tax:9606"},{"id":"A1922","pred":"tao:has_database_id","subj":"1922","obj":"Tax:9606"},{"id":"A1923","pred":"tao:has_database_id","subj":"1923","obj":"Tax:9606"},{"id":"A1924","pred":"tao:has_database_id","subj":"1924","obj":"Tax:9606"},{"id":"A1925","pred":"tao:has_database_id","subj":"1925","obj":"Tax:9606"},{"id":"A1926","pred":"tao:has_database_id","subj":"1926","obj":"Tax:9606"},{"id":"A1927","pred":"tao:has_database_id","subj":"1927","obj":"Tax:9606"},{"id":"A1928","pred":"tao:has_database_id","subj":"1928","obj":"Tax:9606"},{"id":"A1929","pred":"tao:has_database_id","subj":"1929","obj":"Tax:9606"},{"id":"A1930","pred":"tao:has_database_id","subj":"1930","obj":"Tax:2697049"},{"id":"A1931","pred":"tao:has_database_id","subj":"1931","obj":"Tax:9606"},{"id":"A1932","pred":"tao:has_database_id","subj":"1932","obj":"Tax:9606"},{"id":"A1933","pred":"tao:has_database_id","subj":"1933","obj":"Tax:9606"},{"id":"A1934","pred":"tao:has_database_id","subj":"1934","obj":"Tax:9606"},{"id":"A1935","pred":"tao:has_database_id","subj":"1935","obj":"Tax:9606"},{"id":"A1936","pred":"tao:has_database_id","subj":"1936","obj":"Tax:9606"},{"id":"A1937","pred":"tao:has_database_id","subj":"1937","obj":"Tax:9606"},{"id":"A1938","pred":"tao:has_database_id","subj":"1938","obj":"Tax:9606"},{"id":"A1939","pred":"tao:has_database_id","subj":"1939","obj":"Tax:2697049"},{"id":"A1940","pred":"tao:has_database_id","subj":"1940","obj":"Tax:28285"},{"id":"A1941","pred":"tao:has_database_id","subj":"1941","obj":"Tax:2697049"},{"id":"A1942","pred":"tao:has_database_id","subj":"1942","obj":"Tax:2697049"},{"id":"A1943","pred":"tao:has_database_id","subj":"1943","obj":"Tax:2697049"},{"id":"A1944","pred":"tao:has_database_id","subj":"1944","obj":"Tax:2697049"},{"id":"A1945","pred":"tao:has_database_id","subj":"1945","obj":"Tax:9606"},{"id":"A1946","pred":"tao:has_database_id","subj":"1946","obj":"Tax:9606"},{"id":"A1947","pred":"tao:has_database_id","subj":"1947","obj":"Tax:9606"},{"id":"A1948","pred":"tao:has_database_id","subj":"1948","obj":"Tax:9606"},{"id":"A1949","pred":"tao:has_database_id","subj":"1949","obj":"Tax:9606"},{"id":"A1950","pred":"tao:has_database_id","subj":"1950","obj":"Tax:9606"},{"id":"A1951","pred":"tao:has_database_id","subj":"1951","obj":"Tax:9606"},{"id":"A1952","pred":"tao:has_database_id","subj":"1952","obj":"Tax:11118"},{"id":"A1953","pred":"tao:has_database_id","subj":"1953","obj":"Tax:9606"},{"id":"A1954","pred":"tao:has_database_id","subj":"1954","obj":"Tax:9606"},{"id":"A1955","pred":"tao:has_database_id","subj":"1955","obj":"Tax:9606"},{"id":"A1956","pred":"tao:has_database_id","subj":"1956","obj":"Tax:2697049"},{"id":"A1957","pred":"tao:has_database_id","subj":"1957","obj":"Tax:28285"},{"id":"A1958","pred":"tao:has_database_id","subj":"1958","obj":"Tax:28285"},{"id":"A1959","pred":"tao:has_database_id","subj":"1959","obj":"Tax:2697049"},{"id":"A1960","pred":"tao:has_database_id","subj":"1960","obj":"Tax:2697049"},{"id":"A1961","pred":"tao:has_database_id","subj":"1961","obj":"Tax:2697049"},{"id":"A1962","pred":"tao:has_database_id","subj":"1962","obj":"Tax:11118"},{"id":"A1963","pred":"tao:has_database_id","subj":"1963","obj":"Tax:9606"},{"id":"A1964","pred":"tao:has_database_id","subj":"1964","obj":"Tax:9606"},{"id":"A1965","pred":"tao:has_database_id","subj":"1965","obj":"Tax:11118"},{"id":"A1966","pred":"tao:has_database_id","subj":"1966","obj":"Tax:2697049"},{"id":"A1967","pred":"tao:has_database_id","subj":"1967","obj":"Tax:2697049"},{"id":"A1968","pred":"tao:has_database_id","subj":"1968","obj":"Tax:9606"},{"id":"A1969","pred":"tao:has_database_id","subj":"1969","obj":"Tax:2697049"},{"id":"A1970","pred":"tao:has_database_id","subj":"1970","obj":"Tax:2697049"},{"id":"A1971","pred":"tao:has_database_id","subj":"1971","obj":"Tax:11118"},{"id":"A1972","pred":"tao:has_database_id","subj":"1972","obj":"Tax:2697049"},{"id":"A1973","pred":"tao:has_database_id","subj":"1973","obj":"Tax:9606"},{"id":"A1974","pred":"tao:has_database_id","subj":"1974","obj":"Tax:1407750"},{"id":"A1975","pred":"tao:has_database_id","subj":"1975","obj":"Tax:83819"},{"id":"A1976","pred":"tao:has_database_id","subj":"1976","obj":"Tax:9606"},{"id":"A1977","pred":"tao:has_database_id","subj":"1977","obj":"Tax:9606"},{"id":"A1978","pred":"tao:has_database_id","subj":"1978","obj":"Tax:9606"},{"id":"A1979","pred":"tao:has_database_id","subj":"1979","obj":"Tax:9606"},{"id":"A1980","pred":"tao:has_database_id","subj":"1980","obj":"Tax:9606"},{"id":"A1981","pred":"tao:has_database_id","subj":"1981","obj":"Tax:2697049"},{"id":"A1982","pred":"tao:has_database_id","subj":"1982","obj":"Tax:9606"},{"id":"A1983","pred":"tao:has_database_id","subj":"1983","obj":"Tax:2697049"},{"id":"A1984","pred":"tao:has_database_id","subj":"1984","obj":"Tax:9606"},{"id":"A1985","pred":"tao:has_database_id","subj":"1985","obj":"Tax:2697049"},{"id":"A1986","pred":"tao:has_database_id","subj":"1986","obj":"Tax:9606"},{"id":"A1987","pred":"tao:has_database_id","subj":"1987","obj":"Tax:2697049"},{"id":"A1988","pred":"tao:has_database_id","subj":"1988","obj":"Tax:2697049"},{"id":"A1989","pred":"tao:has_database_id","subj":"1989","obj":"Tax:2697049"},{"id":"A1990","pred":"tao:has_database_id","subj":"1990","obj":"Tax:9606"},{"id":"A1991","pred":"tao:has_database_id","subj":"1991","obj":"Tax:2697049"},{"id":"A1992","pred":"tao:has_database_id","subj":"1992","obj":"Tax:2697049"},{"id":"A1993","pred":"tao:has_database_id","subj":"1993","obj":"Tax:9606"},{"id":"A1994","pred":"tao:has_database_id","subj":"1994","obj":"Tax:2697049"},{"id":"A1995","pred":"tao:has_database_id","subj":"1995","obj":"Tax:9606"},{"id":"A1996","pred":"tao:has_database_id","subj":"1996","obj":"Tax:9606"},{"id":"A1997","pred":"tao:has_database_id","subj":"1997","obj":"Tax:11118"},{"id":"A1998","pred":"tao:has_database_id","subj":"1998","obj":"Tax:2697049"},{"id":"A1999","pred":"tao:has_database_id","subj":"1999","obj":"Tax:9606"},{"id":"A2000","pred":"tao:has_database_id","subj":"2000","obj":"Tax:9606"},{"id":"A2001","pred":"tao:has_database_id","subj":"2001","obj":"Tax:9606"},{"id":"A2002","pred":"tao:has_database_id","subj":"2002","obj":"Tax:9606"},{"id":"A2003","pred":"tao:has_database_id","subj":"2003","obj":"Tax:1407750"},{"id":"A2004","pred":"tao:has_database_id","subj":"2004","obj":"Tax:83819"},{"id":"A2005","pred":"tao:has_database_id","subj":"2005","obj":"Tax:9606"},{"id":"A2006","pred":"tao:has_database_id","subj":"2006","obj":"Tax:2697049"},{"id":"A2007","pred":"tao:has_database_id","subj":"2007","obj":"Tax:2697049"},{"id":"A2008","pred":"tao:has_database_id","subj":"2008","obj":"Tax:9606"},{"id":"A2009","pred":"tao:has_database_id","subj":"2009","obj":"Tax:2697049"},{"id":"A2010","pred":"tao:has_database_id","subj":"2010","obj":"Tax:2697049"},{"id":"A2011","pred":"tao:has_database_id","subj":"2011","obj":"Tax:2697049"},{"id":"A2012","pred":"tao:has_database_id","subj":"2012","obj":"Tax:2697049"},{"id":"A2013","pred":"tao:has_database_id","subj":"2013","obj":"Tax:9606"},{"id":"A2014","pred":"tao:has_database_id","subj":"2014","obj":"Tax:2697049"},{"id":"A2015","pred":"tao:has_database_id","subj":"2015","obj":"Tax:2697049"},{"id":"A2016","pred":"tao:has_database_id","subj":"2016","obj":"Tax:2697049"},{"id":"A2017","pred":"tao:has_database_id","subj":"2017","obj":"Tax:2697049"},{"id":"A2018","pred":"tao:has_database_id","subj":"2018","obj":"Tax:9606"},{"id":"A2019","pred":"tao:has_database_id","subj":"2019","obj":"Tax:9606"},{"id":"A2020","pred":"tao:has_database_id","subj":"2020","obj":"Tax:9606"},{"id":"A2021","pred":"tao:has_database_id","subj":"2021","obj":"Tax:9606"},{"id":"A2022","pred":"tao:has_database_id","subj":"2022","obj":"Tax:9606"},{"id":"A2023","pred":"tao:has_database_id","subj":"2023","obj":"Tax:11118"},{"id":"A2024","pred":"tao:has_database_id","subj":"2024","obj":"Tax:2697049"},{"id":"A2025","pred":"tao:has_database_id","subj":"2025","obj":"Tax:9606"},{"id":"A2026","pred":"tao:has_database_id","subj":"2026","obj":"Tax:9606"},{"id":"A2027","pred":"tao:has_database_id","subj":"2027","obj":"Tax:9606"},{"id":"A2028","pred":"tao:has_database_id","subj":"2028","obj":"Tax:9606"},{"id":"A2029","pred":"tao:has_database_id","subj":"2029","obj":"Tax:9606"},{"id":"A2030","pred":"tao:has_database_id","subj":"2030","obj":"Tax:9606"},{"id":"A2031","pred":"tao:has_database_id","subj":"2031","obj":"Tax:9606"},{"id":"A2032","pred":"tao:has_database_id","subj":"2032","obj":"Tax:9606"},{"id":"A2033","pred":"tao:has_database_id","subj":"2033","obj":"Tax:9606"},{"id":"A2034","pred":"tao:has_database_id","subj":"2034","obj":"Tax:2697049"},{"id":"A2035","pred":"tao:has_database_id","subj":"2035","obj":"Tax:2697049"},{"id":"A2036","pred":"tao:has_database_id","subj":"2036","obj":"Tax:9606"},{"id":"A2037","pred":"tao:has_database_id","subj":"2037","obj":"Tax:9606"},{"id":"A2038","pred":"tao:has_database_id","subj":"2038","obj":"Tax:2697049"},{"id":"A2039","pred":"tao:has_database_id","subj":"2039","obj":"Tax:2697049"},{"id":"A2040","pred":"tao:has_database_id","subj":"2040","obj":"Tax:2697049"},{"id":"A2041","pred":"tao:has_database_id","subj":"2041","obj":"Tax:9606"},{"id":"A2042","pred":"tao:has_database_id","subj":"2042","obj":"Tax:9606"},{"id":"A2043","pred":"tao:has_database_id","subj":"2043","obj":"Tax:2697049"},{"id":"A2044","pred":"tao:has_database_id","subj":"2044","obj":"Tax:11120"},{"id":"A2045","pred":"tao:has_database_id","subj":"2045","obj":"Tax:11120"},{"id":"A2046","pred":"tao:has_database_id","subj":"2046","obj":"Tax:9606"},{"id":"A2047","pred":"tao:has_database_id","subj":"2047","obj":"Tax:9606"},{"id":"A2048","pred":"tao:has_database_id","subj":"2048","obj":"Tax:9606"},{"id":"A2049","pred":"tao:has_database_id","subj":"2049","obj":"Gene:5366"},{"id":"A2050","pred":"tao:has_database_id","subj":"2050","obj":"Gene:6622"},{"id":"A2051","pred":"tao:has_database_id","subj":"2051","obj":"Gene:6622"},{"id":"A2052","pred":"tao:has_database_id","subj":"2052","obj":"Gene:6622"},{"id":"A2053","pred":"tao:has_database_id","subj":"2053","obj":"Gene:43740568"},{"id":"A2054","pred":"tao:has_database_id","subj":"2054","obj":"MESH:D006886"},{"id":"A2055","pred":"tao:has_database_id","subj":"2055","obj":"MESH:C558899"},{"id":"A2056","pred":"tao:has_database_id","subj":"2056","obj":"MESH:C558899"},{"id":"A2057","pred":"tao:has_database_id","subj":"2057","obj":"MESH:C558899"},{"id":"A2058","pred":"tao:has_database_id","subj":"2058","obj":"MESH:C558899"},{"id":"A2059","pred":"tao:has_database_id","subj":"2059","obj":"MESH:C558899"},{"id":"A2060","pred":"tao:has_database_id","subj":"2060","obj":"MESH:C558899"},{"id":"A2061","pred":"tao:has_database_id","subj":"2061","obj":"MESH:C000606551"},{"id":"A2062","pred":"tao:has_database_id","subj":"2062","obj":"MESH:C000606551"},{"id":"A2063","pred":"tao:has_database_id","subj":"2063","obj":"MESH:C000606551"},{"id":"A2064","pred":"tao:has_database_id","subj":"2064","obj":"MESH:C000606551"},{"id":"A2065","pred":"tao:has_database_id","subj":"2065","obj":"MESH:C000606551"},{"id":"A2066","pred":"tao:has_database_id","subj":"2066","obj":"MESH:C000606551"},{"id":"A2067","pred":"tao:has_database_id","subj":"2067","obj":"MESH:C000606551"},{"id":"A2068","pred":"tao:has_database_id","subj":"2068","obj":"MESH:D014867"},{"id":"A2069","pred":"tao:has_database_id","subj":"2069","obj":"MESH:D013792"},{"id":"A2070","pred":"tao:has_database_id","subj":"2070","obj":"MESH:D014867"},{"id":"A2072","pred":"tao:has_database_id","subj":"2072","obj":"MESH:D008775"},{"id":"A2073","pred":"tao:has_database_id","subj":"2073","obj":"MESH:C558899"},{"id":"A2074","pred":"tao:has_database_id","subj":"2074","obj":"MESH:C558899"},{"id":"A2075","pred":"tao:has_database_id","subj":"2075","obj":"MESH:C558899"},{"id":"A2076","pred":"tao:has_database_id","subj":"2076","obj":"MESH:D003404"},{"id":"A2077","pred":"tao:has_database_id","subj":"2077","obj":"MESH:C502936"},{"id":"A2078","pred":"tao:has_database_id","subj":"2078","obj":"MESH:C462182"},{"id":"A2079","pred":"tao:has_database_id","subj":"2079","obj":"MESH:C502936"},{"id":"A2080","pred":"tao:has_database_id","subj":"2080","obj":"MESH:C558899"},{"id":"A2081","pred":"tao:has_database_id","subj":"2081","obj":"MESH:C558899"},{"id":"A2082","pred":"tao:has_database_id","subj":"2082","obj":"MESH:D061466"},{"id":"A2083","pred":"tao:has_database_id","subj":"2083","obj":"MESH:C558899"},{"id":"A2084","pred":"tao:has_database_id","subj":"2084","obj":"MESH:D061466"},{"id":"A2087","pred":"tao:has_database_id","subj":"2087","obj":"MESH:D061466"},{"id":"A2088","pred":"tao:has_database_id","subj":"2088","obj":"MESH:D061466"},{"id":"A2089","pred":"tao:has_database_id","subj":"2089","obj":"MESH:D061466"},{"id":"A2090","pred":"tao:has_database_id","subj":"2090","obj":"MESH:C558899"},{"id":"A2091","pred":"tao:has_database_id","subj":"2091","obj":"MESH:D006493"},{"id":"A2092","pred":"tao:has_database_id","subj":"2092","obj":"MESH:C502936"},{"id":"A2093","pred":"tao:has_database_id","subj":"2093","obj":"MESH:C000657245"},{"id":"A2094","pred":"tao:has_database_id","subj":"2094","obj":"MESH:C000657245"},{"id":"A2095","pred":"tao:has_database_id","subj":"2095","obj":"MESH:C000657245"},{"id":"A2096","pred":"tao:has_database_id","subj":"2096","obj":"MESH:C000657245"},{"id":"A2097","pred":"tao:has_database_id","subj":"2097","obj":"MESH:C000657245"},{"id":"A2098","pred":"tao:has_database_id","subj":"2098","obj":"MESH:C000657245"},{"id":"A2099","pred":"tao:has_database_id","subj":"2099","obj":"MESH:D009102"},{"id":"A2100","pred":"tao:has_database_id","subj":"2100","obj":"MESH:D016638"},{"id":"A2101","pred":"tao:has_database_id","subj":"2101","obj":"MESH:D003643"},{"id":"A2102","pred":"tao:has_database_id","subj":"2102","obj":"MESH:D011014"},{"id":"A2103","pred":"tao:has_database_id","subj":"2103","obj":"MESH:D014842"},{"id":"A2104","pred":"tao:has_database_id","subj":"2104","obj":"MESH:C000657245"},{"id":"A2105","pred":"tao:has_database_id","subj":"2105","obj":"MESH:C000657245"},{"id":"A2106","pred":"tao:has_database_id","subj":"2106","obj":"MESH:C000657245"},{"id":"A2107","pred":"tao:has_database_id","subj":"2107","obj":"MESH:C000657245"},{"id":"A2108","pred":"tao:has_database_id","subj":"2108","obj":"MESH:C000657245"},{"id":"A2109","pred":"tao:has_database_id","subj":"2109","obj":"MESH:C000657245"},{"id":"A2110","pred":"tao:has_database_id","subj":"2110","obj":"MESH:C000657245"},{"id":"A2111","pred":"tao:has_database_id","subj":"2111","obj":"MESH:D005334"},{"id":"A2112","pred":"tao:has_database_id","subj":"2112","obj":"MESH:D016638"},{"id":"A2113","pred":"tao:has_database_id","subj":"2113","obj":"MESH:C000657245"},{"id":"A2114","pred":"tao:has_database_id","subj":"2114","obj":"MESH:C000657245"},{"id":"A2115","pred":"tao:has_database_id","subj":"2115","obj":"MESH:D012131"},{"id":"A2116","pred":"tao:has_database_id","subj":"2116","obj":"MESH:D003643"},{"id":"A2117","pred":"tao:has_database_id","subj":"2117","obj":"MESH:C000657245"},{"id":"A2118","pred":"tao:has_database_id","subj":"2118","obj":"MESH:C000657245"},{"id":"A2119","pred":"tao:has_database_id","subj":"2119","obj":"MESH:C000657245"},{"id":"A2120","pred":"tao:has_database_id","subj":"2120","obj":"MESH:D003643"},{"id":"A2121","pred":"tao:has_database_id","subj":"2121","obj":"MESH:D018352"},{"id":"A2122","pred":"tao:has_database_id","subj":"2122","obj":"MESH:C000657245"},{"id":"A2123","pred":"tao:has_database_id","subj":"2123","obj":"MESH:C000657245"},{"id":"A2124","pred":"tao:has_database_id","subj":"2124","obj":"MESH:D003643"},{"id":"A2125","pred":"tao:has_database_id","subj":"2125","obj":"MESH:D018352"},{"id":"A2126","pred":"tao:has_database_id","subj":"2126","obj":"MESH:C000657245"},{"id":"A2127","pred":"tao:has_database_id","subj":"2127","obj":"MESH:C000657245"},{"id":"A2128","pred":"tao:has_database_id","subj":"2128","obj":"MESH:D005334"},{"id":"A2129","pred":"tao:has_database_id","subj":"2129","obj":"MESH:D018352"},{"id":"A2130","pred":"tao:has_database_id","subj":"2130","obj":"MESH:C000657245"},{"id":"A2131","pred":"tao:has_database_id","subj":"2131","obj":"MESH:C000657245"},{"id":"A2132","pred":"tao:has_database_id","subj":"2132","obj":"MESH:C000657245"},{"id":"A2133","pred":"tao:has_database_id","subj":"2133","obj":"MESH:C000657245"},{"id":"A2134","pred":"tao:has_database_id","subj":"2134","obj":"MESH:D011014"},{"id":"A2135","pred":"tao:has_database_id","subj":"2135","obj":"MESH:C000657245"},{"id":"A2138","pred":"tao:has_database_id","subj":"2138","obj":"Tax:2697049"},{"id":"A2139","pred":"tao:has_database_id","subj":"2139","obj":"MESH:C000657245"},{"id":"A2141","pred":"tao:has_database_id","subj":"2141","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2\nStudy title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date\nThe efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)\nControl group: standard therapy II, III Primary (up to 28 days): all cause mortality\nSecondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care\nControl group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time\nSecondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020\nThe COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19\nValidation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020\nA Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020\nCritically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection\n30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality\nSecondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020\nTreatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures\nActive comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020\nComparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020\nStudy to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020\nBevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020\nThe efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days\nExperimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)\nSecondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence\nOthers(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020\nThe efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days\nExperimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020\nTetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020\nFingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days\nNo Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020\nTherapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)\nPlacebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation\nSecondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021\nThe Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10\nPlacebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020\nTreatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.\nWJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results\nSecondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020\nMyocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital\nDead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death\nSecondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020\nTreatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)\nPlacebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group\nSecondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021\nThe clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin\nActive comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021\nEfficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days\nNo intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days\nSecondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020\nEvaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191\nExperimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191\nPlacebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)\nSecondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \u003c2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \u003e24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021\nWashed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy\nPlacebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020\nSafety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response\nSecondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024\nSafety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:\nSuccess rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)\nSecondary:\nExtubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020\nImmunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I\nII Primary:\nClinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)\nSecondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024\nPhase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group\nSubjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions\nSecondary (Day 14, 28, Month 3, 6 postvaccination):\nSafety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune\nOther (day、14,28, Month3,6 postvaccination):\nConsistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022\nDevelopment and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform\nWe use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:\nSensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020\nHydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment\nHydroxychloroquine tablet 200 mg every 12 hr for 10 days\nPlacebo comparator: placebo\nidentical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):\nAll‐cause hospital mortality\nSecondary (up to120 days):\nLength of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012\nTocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection\nTocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022\nMesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:\nAll patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):\nDisappear time of ground‐glass shadow in the lungs\nSecondary:\nRate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020\nCD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment\nSingle dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min\nPlacebo comparator: placebo\nSingle dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):\nImprovement of COVID‐19 disease status secondary (14 days):\nConversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022\nAcute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:\nCOVID‐19 patients with acute kidney injury\nnonacute kidney injury:\nCOVID‐19 patients without acute kidney injury –\nRate of death, the length of hospital stay Primary (up to 60 days):\nRate of acute kidney injury\nSecondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020\nPhase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)\nExperimental: low‐dose group\nSubjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old\nExperimental: middle‐dose group\nSubjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old\nExperimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):\nSafety indexes of adverse reactions\nSecondary (0–28 days postvaccination, within 6 mouths postvaccination):\nSafety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)\nOther (Day 14,28, Month 6 postvaccination):\nConsistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021\nFavipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020\nNovel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):\nDisppear time of ground‐glass shadow in the lungs\nSecondary:\nAbsorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021\nMulticenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,\nActive comparator: control group of ordinary COVID‐19:\nLopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization\nExperimental: experimental group of severe COVID‐19:\nXiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:\nClinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021\nPrognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):\nall‐cause mortality\nSecondary (15 days):\nall‐cause mortality,\nSevere state NCT04292964/Completed Mar1‐Mar13 2020\nChloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022\nYinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group\nBased on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.\nDrug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nPlacebo comparator: Yinhu Qingwen decoction low‐dose group\nBased on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days\nDrug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days\nOther: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China\nActive comparator: integrated Chinese and western medicine group\nBased on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days\nOther: Chinese medicine treatment\nThis intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days\nOther: standard western medicine treatment\nStandard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II\nIII Primary (up to 28 days):\nMean clinical recovery time\nSecondary (up to 28 days):\nTime to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)\nFrequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020\nPrognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment\nhypertension patients with ACEI treatment when suffered with novel coronavirus infection in China\nControl\nhypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):\nOccupancy rate in the intensive care unit, mechanical ventilation, death\nSecondary (up to 28 days):\nAll cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020\nEvaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020\nVarious combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020\nYinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:\nYinhu Qingwen granula group:\nDrug: Yinhu Qingwen Granula\nYinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.\nPlacebo comparator: Yinhu Qingwen granula low‐dose group:\nDrug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).\nOther: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):\nchanges in the ratio of PaO2 to FiO2 from baseline\nSecondary (up to 30 days):\nPaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021\nClinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group\nChildren hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group\nControl group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):\nThe cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes\nSecondary (2 weeks):\nDuration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020\nThe effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)\nNo intervention: the blank control group\nAll subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)\nSecondary (Day −1 to 10):\nThe degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020\nImmunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group\nAnti‐PD‐1 antibody, 200 mg, IV, one time\nExperimental: thymosin group\nThymosin, 1.6 mg sc qd, last for 5 days\nPlacebo comparator: control group stand treatment II Primary (7 days):\nlung injury score\nSecondary:\nAbsolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020\nTocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab\nSubjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \u003c60 min. Tocilizumab was administered according—continuous renal replacement therapy\nFemoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label\nStandard care\nStandard of care therapy per local written policies or guidelines – Primary (up to 14 days):\nProportion of participants with normalization of fever and oxygen saturation\nSecondary:\nDuration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020\nSars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver\ncaregivers from emergency, ICU, virology and infectious disease services:\nTwo blood samples at T0 and 3 months Not applicable Primary (3 months):\nQuantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff\nSecondary (3 months):\nIdentification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020\nJohn Wiley \u0026 Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency."}